See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus

Ülo Langel

https://www.etis.ee/CV/Ülo_Langel/est
2.03.1951
ulo.langel@dbb.su.se

Teenistuskäik

Töökohad ja ametid
01.09.2018–...   
Tartu Ülikool, Loodus- ja täppisteaduste valdkond, tehnoloogiainstituut, molekulaarse biotehnoloogia professor (0,50)
2007–...   
Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli Tehnoloogiainstituut, Professor (1,00)
01.01.2003–...   
Stockholmi Ülikool, Neurokeemia teaduskond, Neurokeemia ja Molekulaarse neurobioloogia professor, Rootsi
01.01.2002–...   
Ljubljana Ülikool, Arstiteaduskond, aukülalisprofessor, Sloveenia
01.01.2001–...   
Scripps Uurimisinstituut, külalisprofessor, La Jolla, CA, USA,
01.01.1997–...   
Tartu Ülikool, Arstiteaduskond, külalisprofessor, Tartu, Eesti
01.01.2016–31.08.2018   
Tartu Ülikool, Loodus- ja täppisteaduste valdkond, tehnoloogiainstituut, molekulaarse biotehnoloogia professor (0,50)
01.09.2013–31.12.2015   
Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli Tehnoloogiainstituut, molekulaarse biotehnoloogia professor (0,50)
01.05.2013–31.08.2013   
Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli Tehnoloogiainstituut, professor (1,00)
01.09.2010–30.04.2013   
Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli Tehnoloogiainstituut, professor (1,00)
01.01.2008–30.04.2010   
Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli Tehnoloogiainstituut, molekulaarse biotehnoloogia professor (1,00)
01.06.2007–31.12.2007   
Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli Tehnoloogiainstituut, molekulaarse biotehnoloogia erakorraline professor (1,00)
01.05.2007–31.05.2007   
Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli Tehnoloogiainstituut, molekulaarse biotehnoloogia erakorraline professor (0,80)
01.10.2006–30.09.2009   
Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli Tehnoloogiainstituut, biokeemia erakorraline vanemteadur (0,20)
01.01.2005–2012   
Cepep Eesti OÜ, CePeP III AB, direktorite kolleegiumi juhataja, Stockholm, Rootsi (0,10)
01.01.2005–2013   
Stockholmi Ulikool, Stockholmi Ülikool, Neurokeemia teaduskond, juhataja, Rootsi (1,00)
01.01.2003–31.12.2004   
Orexo AB, direktorite kolleegiumi liige, Uppsala, Rootsi
01.01.2003–31.12.2004   
Stockholmi Ülikool, Neurokeemia ja Neurotoksikoloogia teaduskond, juhataja asetäitja, Stockholm, Rootsi
01.01.2001–31.12.2003   
CePeP AB, direktorite kolleegiumi juhataja, Stockholm, Rootsi
01.01.2001–31.12.2003   
Stockholmi Ülikool, Neurokeemia ja Neurotoksikoloogia teaduskond, Neurokeemia ja Neurotoksikoloogia professor, Stockholm, Rootsi
01.01.2000–31.12.2001   
The Harold L. Dorris Neuroloogia uurimiskeskus, Neurofarmakoloogia teaduskond, dotsent,The Scripps Research Institute, La Jolla, CA, USA
01.01.1997–31.12.1999   
Projektijuht (biosensorid miinide otsimiseks), Bofors, Rootsi
01.01.1997–31.12.2002   
Stockholmi Ülikool, Neurokeemia ja Neurotoksikoloogia teaduskond, õppeprorektor, Rootsi
01.01.1992–31.12.2001   
Stockholmi Ülikool, Neurokeemia ja Neurotoksikoloogia, lektor ja dotsent, Stockholm, Rootsi
01.01.1987–31.12.1991   
Stockholmi Ülikool, Biokeemiateaduskond, külalisteadur, Stockholm, Rootsi
1980–1989   
Tartu Ülikool, Arstiteaduskond, Dotsent (1,00)
1974–1980   
Tartu Ülikool, Füüsika-keemiateaduskond, Orgaanilise ja bioorgaanilise keemia instituut, Teadur (1,00)
 
 
Haridustee
1974–1980   
Tartu Ülikool, Doktoriõpe, bioorgaanilises keemias, PhD
1969–1974   
Tartu Ülikool, Keemiaosakond, bioorgaanilises keemias, BcS
 
 
Teadusorganisatsiooniline ja -administratiivne tegevus
1996−...   
Neuroteaduste Ühing, Rahvusvaheline Neurokeemia Ühing, Euroopa Peptiidie Ühing, Rootsi Biokeemia Ühing, Eesti Biokeemia Ühing
1996−...   
teaduslik retsensent NIH, wellcome trust, INSERM etc.
1995−...   
Rahvusvaheline Neuropeptiidide Ühingu liige
2005−2005   
Külaliseditor, Current Pharmaceutical Design
2003−2005   
Ajakirja "Drug Design Reviews-Online” toimetuse liige
2000−2000   
Eesti Biomeditsiini keskuse rahvusvahelise ekspertkomisjoni liige
 
 
Lisainfo
Külalisloengud : rohkem kui 100 ajavhemikul 1995-2019
Teaduslike konverentside organiseerija: Neuropeptiid -galaniin, San Diego 2004, koos T Yaksh, T. Bartfai, and T. Hökfelt.
Rakku tungivad peptiidid, Stockholm, 2005, Wenner-Gren Conference
Põhijuhendaja 51 edukalt kaitsnud PhD tudengil. Umbes 50 järeldoktorantuuri granti aastast 1997 kuni tänaseni.

Kvalifikatsioon

Teaduskraadid
Ülo Langel, doktorikraad, 1993, (juh) -, Galanin and galanin antagonists, Tartu Ülikool, Arstiteaduskond.
Ülo Langel, doktorikraad, 1980, (juh) Jaak Järv, Butyrüülkolinesteraasi struktuur-aktiivsussõltuvused, Tartu Ülikool, Füüsika-keemiateaduskond.
 
 
Teaduspreemiad ja tunnustused
2009, Ülo Langel, Eesti riiklik teaduspreemia
2001, Ülo Langel, White Star Order, 4th class, from Estonian Republic,
 
 
Teadustöö põhisuunad
ETIS KLASSIFIKAATOR: 1. Bio- ja keskkonnateadused; 1.1. Biokeemia; TÄPSUSTUS: Rakku tungivad peptiidid

Jooksvad projektid

Lõppenud projektid

Juhendamisel väitekirjad

Juhendatud väitekirjad

Publikatsioonid

Klass
Aasta
Publikatsioon
 
1.1.
2020
Gestin, Maxime; Helmfors, Henrik; Falato, Luca; Lorenzon, Nicola; Michalakis, Filip Ilias; Langel, Ülo (2020). Effect of small molecule signaling in PepFect14 transfection. PLoS ONE, 15 (1), e0228189−e0228189. DOI: 10.1371/journal.pone.0228189.
1.1.
2019
Porosk, Ly; Arukuusk, Piret; Põhako, Kaisa; Kurrikoff, Kaido; Kiisholts, Kristina; Padari, Kärt; Pooga, Margus; Langel, Ülo (2019). Enhancement of siRNA transfection by the optimization of fatty acid length and histidine content in the CPP. Biomaterials Science. DOI: 10.1039/C9BM00688E.
1.1.
2019
Kurrikoff, Kaido; Aphkhazava, David; Langel, Ülo (2019). The future of peptides in cancer treatment. Current Opinion in Pharmacology, 47, 27−32.10.1016/j.coph.2019.01.008.
1.1.
2018
Lorents, Annely; Säälik, Pille; Langel, Ülo; Pooga, Margus (2018). Arginine-Rich Cell-Penetrating Peptides Require Nucleolin and Cholesterol-Poor Subdomains for Translocation across Membranes. Bioconjugate Chemistry, 29 (4), 1168−1177. DOI: 10.1021/acs.bioconjchem.7b00805.
1.1.
2018
Freimann, Krista; Arukuusk, Piret; Kurrikoff, Kaido; Pärnaste, Ly; Raid, Raivo; Piirsoo, Andres; Pooga, Margus; Lange, Ülo (2018). Formulation of stable and homogenous cell penetrating peptide NF55 nanoparticles for efficient gene delivery in vivo. Molecular Therapy — Nucleic Acids, 10, 28−35. DOI: 10.1016/j.omtn.2017.10.011.
1.1.
2018
Srimanee, Artita; Arvanitidou, Maria; Kim, Kumjee; Hällbrink, Mattias; Langel, Ülo (2018). Cell-penetrating peptides for siRNA delivery to glioblastomas. Peptides, 104, 62−69.10.1016/j.peptides.2018.04.015.
1.1.
2018
Dowaidar, Moataz; Nasser Abdelhamid, Hani; Hällbrink, Mattias; Langel, Ülo; Zou, Xiaodong (2018). Chitosan enhances gene delivery of oligonucleotide complexes with magnetic nanoparticles-cell-penetrating peptide. Journal of Biomaterials Applications, 33 (3), 392−401.10.1177/0885328218796623.
1.1.
2018
Alvarez, Mariano J; Subramaniam, Prem S; Tang, Laura H; Grunn, Adina; Aburi, Mahalaxmi; Rieckhof, Gabrielle; Komissarova, Elena V; Hagan, Elizabeth A; Bodei, Lisa; Clemons, Paul A; Dela Cruz, Filemon S; Dhall, Deepti; Diolaiti, Daniel; Fraker, Douglas A; Ghavami, Afshin; Kaemmerer, Daniel; Karan, Charles; Kidd, Mark; Kim, Kyoung M; Kim, Hee C ... Califano, Andrea (2018). A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nature Genetics, 50 (7), 979−989.10.1038/s41588-018-0138-4.
1.1.
2018
Vasconcelos, Luís; Lehto, Tõnis; Madani, Fatemeh; Radoi, Vlad; Hällbrink, Mattias; Vukojević, Vladana; Langel, Ülo (2018). Simultaneous membrane interaction of amphipathic peptide monomers, self-aggregates and cargo complexes detected by fluorescence correlation spectroscopy. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1860 (2), 491−504.10.1016/j.bbamem.2017.09.024.
1.2.
2018
Künnapuu, K.; Veiman, K.-L.; Porosk, L.; Rammul, E.; Kiisholts, K.; Langel, Ü.; Kurrikoff, K. (2018). Tumor gene therapy by systemic delivery of plasmid DNA with cell‐penetrating peptides. FASEB BioAdvances, 1 (2), 105−114. DOI: 10.1096/fba.1026.
1.1.
2017
Pärnaste, Ly; Arukuusk, Piret; Langel, Kent; Tenson, Tanel; Langel, Ülo (2017). The formation of nanoparticles between small interfering RNA and amphipathic cell-penetrating peptides. Molecular Therapy — Nucleic Acids, 7, 1−10.10.1016/j.omtn.2017.02.003.
1.1.
2017
Juks, C.; Lorents, A.; Arukuusk, P.; Langel, Ü.; Pooga, M. (2017). Cell-penetrating peptides recruit type A scavenger receptors to the plasma membrane for cellular delivery of nucleic acids. The FASEB Journal, 31 (3), 975−988. DOI: 10.1096/fj.201600811r.
1.1.
2017
Cerrato, Carmine Pasquale; Künnapuu, Kadri; Langel, Ülo (2017). Cell-penetrating peptides with intracellular organelle targeting. Expert Opinion on Drug Delivery, 14 (2), 245−255.10.1080/17425247.2016.1213237.
1.1.
2017
Jevtuševskaja, Jekaterina; Krõlov, Katrin; Tulp, Indrek; Langel, Ülo (2017). The effect of main urine inhibitors on the activity of different DNA polymerases in loop-mediated isothermal amplification. Expert Review of Molecular Diagnostics, 17 (4), 403−410.10.1080/14737159.2017.1283218.
1.1.
2017
Kurrikoff, Kaido; Veiman, Kadi-Liis; Künnapuu, Kadri; Peets, Elin Madli; Lehto, Tõnis; Pärnaste, Ly; Arukuusk, Piret; Langel, Ülo (2017). Effective in vivo gene delivery with reduced toxicity, achieved by charge and fatty acid -modified cell penetrating peptide. Scientific Reports, 7 (1), 17056−17056.10.1038/s41598-017-17316-y.
1.1.
2017
Cerrato, Carmine Pasquale; Langel, Ülo (2017). Effect of a Fusion Peptide by Covalent Conjugation of a Mitochondrial Cell-Penetrating Peptide and a Glutathione Analog Peptide. Molecular Therapy — Methods & Clinical Development, 5, 221−231.10.1016/j.omtm.2017.04.010.
1.1.
2017
Krõlov, Katrin; Uusna, Julia; Grellier, Tiia; Andresen, Liis; Jevtuševskaja, Jekaterina; Tulp, Indrek; Langel, Ülo (2017). Implementation of antimicrobial peptides for sample preparation prior to nucleic acid amplification in point-of-care settings. Expert Review of Molecular Diagnostics, 17 (12), 1117−1125.10.1080/14737159.2017.1386557.
1.1.
2017
Dowaidar, Moataz; Abdelhamid, Hani Nasser; Hällbrink, Mattias; Zou, Xiaodong; Langel, Ülo (2017). Graphene oxide nanosheets in complex with cell penetrating peptides for oligonucleotides delivery. Biochimica et Biophysica Acta (BBA) - General Subjects, 1861 (9), 2334−2341.10.1016/j.bbagen.2017.07.002.
1.1.
2017
Dowaidar, Moataz; Regberg, Jakob; Dobchev, Dimitar A.; Lehto, Tonis; Hallbrink, Mattias; Karelson, Mati; Langel, Ülo (2017). Refinement of a Quantitative Structure-Activity Relationship Model for Prediction of Cell-Penetrating Peptide Based Transfection Systems. International Journal of Peptide Research and Therapeutics, 23 (1), 91−100.10.1007/s10989-016-9542-8.
1.1.
2017
Lehto, T., Vasconcelos, L., Margus, H., Figueroa, R., Pooga, M., Hällbrink, M., Langel, Ü. (2017). Saturated Fatty Acid Analogues of Cell-Penetrating Peptide PepFect14: Role of Fatty Acid Modification in Complexation and Delivery of Splice-Correcting Oligonucleotides. Bioconjugate Chemistry, 28 (3), 782−792. DOI: 10.1021/acs.bioconjchem.6b00680.
1.1.
2017
Urgard, Egon; Brjalin, Aleksei; Langel, Ulo; Pooga, Margus; Rebane, Ana; Annilo, Tarmo (2017). Comparison of Peptide- and Lipid-Based Delivery of miR-34a-5p Mimic into PPC-1 Cells. Nucleic Acid Therapeutics, 27 (5), 295−302. DOI: 10.1089/nat.2017.0670.
1.1.
2017
Dowaidar, Moataz; Gestin, Maxime; Cerrato, Carmine Pasquale; Jafferali, Mohammed Hakim; Margus, Helerin; Kivistik, Paula Ann; Ezzat, Kariem; Hallberg, Einar; Pooga, Margus; Hällbrink, Mattias; Langel, Ülo (2017). Role of autophagy in cell-penetrating peptide transfection model. Scientific Reports, 7 (1), 12635−12635. DOI: 10.1038/s41598-017-12747-z.
1.1.
2017
Dowaidar, Moataz; Abdelhamid, Hani Nasser; Hallbrink, Mattias; Freimann, Krista; Kurrikoff, Kaido; Zou, Xiaodong; Langel, Ülo (2017). Magnetic Nanoparticle Assisted Self-assembly of Cell Penetrating Peptides-Oligonucleotides Complexes for Gene Delivery. Scientific Reports, 7, ARTN 9159.10.1038/s41598-017-09803-z.
3.1.
2017
Gestin, Maxime; Dowaidar, Moataz; Langel, Ülo (2017). Uptake Mechanism of Cell-Penetrating Peptides. Advances in Experimental Medicine and Biology, 1030, 255−264.10.1007/978-3-319-66095-0_11.
1.1.
2016
Urgard, Egon; Lorents, Annely; Klaas, Mariliis; Padari, Kärt; Viil, Janeli; Runnel, Toomas; Langel, Kent; Kingo, Külli; Tkaczyk, Eric; Langel, Ülo; Maimets, Toivo; Jaks, Viljar; Pooga, Margus; Rebane, Ana (2016). Pre-administration of PepFect6-microRNA-146a nanocomplexes inhibits inflammatory responses in keratinocytes and in a mouse model of irritant contact dermatitis. Journal of Controlled Release, 235, 195−2014. DOI: 10.1016/j.jconrel.2016.06.006.
1.1.
2016
Freimann, Krista; Arukuusk, Piret; Kurrikoff, Kaido; Vasconcelos, Luís Daniel Ferreira; Veiman, Kadi-Liis; Uusna, Julia; Margus, Helerin; Garcia-Sosa, Alfonso T; Pooga, Margus; Langel, Ülo (2016). Optimization of in vivo DNA delivery with NickFect peptide vectors. Journal of controlled release : official journal of the Controlled Release Society, 241, 135−143. DOI: 10.1016/j.jconrel.2016.09.022.
1.1.
2016
Jevtuševskaja J, Uusna J, Andresen L, Krõlov K, Laanpere M, Grellier T, Tulp I, Langel Ü. (2016). Combination with antimicrobial peptide lyses improves loop-mediated isothermal amplification based method for Chlamydia trachomatis detection directly in urine sample. BMC Infectious Disease, 16 (329), 329.10.1186/s12879-016-1674-0.
1.1.
2016
Pärnaste, Ly; Arukuusk, Piret; Zagato, Elisa; Braeckmans, Kevin; Langel, Ülo (2016). Methods to follow intracellular trafficking of cell-penetrating peptides. Journal of Drug Targeting, 24 (6), 508−519.10.3109/1061186X.2015.1095194.
1.1.
2016
Margus, Helerin; Arukuusk, Piret; Langel, Ülo; Pooga, Margus (2016). Characteristics of Cell-Penetrating Peptide/Nucleic Acid Nanoparticles. Molecular Pharmaceutics, 13 (1), 172−179. DOI: 10.1021/acs.molpharmaceut.5b00598.
1.1.
2016
Pae, J.; Liivamägi, L.; Etverk, I.; Lubenets, D.; Arukuusk, P.; Langel, Ü.; Pooga, M. (2016). Glycosaminoglycans are required for translocation of amphipathic cell-penetrating peptides across membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1858 (8), 1860−1867. DOI: 10.1016/j.bbamem.2016.04.010.
1.1.
2016
Srimanee, Artita; Regberg, Jakob; Hällbrink, Mattias; Vajragupta, Opa; Langel, Ülo (2016). Role of scavenger receptors in peptide-based delivery of plasmid DNA across a blood-brain barrier model. International Journal of Pharmaceutics, 500, 128−135.10.1016/j.ijpharm.2016.01.014.
1.1.
2016
Kurrikof, Kaido; Gestin, Maxime; Langel, ܜlo (2016). Recent in vivo advances in cell-penetrating peptide-assisted drug delivery. Expert Opinion on Drug Delivery, 0 (0), 373−387.10.1517/17425247.2016.1125879.
1.1.
2016
Jones, Sarah; Uusna, Julia; Langel, Uelo; Howl, John (2016). Intracellular Target-Specific Accretion of Cell Penetrating Peptides and Bioportides: Ultrastructural and Biological Correlates. Bioconjugate Chemistry, 27 (1), 121−129.10.1021/acs.bioconjchem.5b00529.
1.1.
2016
Regberg, Jakob; Vasconcelos, Luis; Madani, Fatemeh; Langel, Ülo; Hallbrink, Mattias (2016). pH-responsive PepFect cell-penetrating peptides. International Journal of Pharmaceutics, 501 (1-2), 32−38.10.1016/j.ijpharm.2016.01.055.
5.1.
2016
Urgard, E.; Lorents, A.; Klaas, M.; Padarik, K.; Viil, J.; Runnel, T.; Ü Langel; Jaks, V.; Pooga, M.; Rebane, A. (2016). PepFect6-miRNA-146a nanocomplexes inhibit inflammatory responses in keratinocytes and in a mouse model of irritant contact dermatitis. Journal of Investigative Dermatology, 136 (9), S214−S214. DOI: 10.1016/j.jid.2016.06.334.
1.1.
2015
Juks, C.; Padari, K.; Margus, H.; Kriiska, A.; Etverk, I.; Arukuusk, P.; Koppel, K.; Ezzat, K.; Langel, Ü.; Pooga, M. (2015). The role of endocytosis in the uptake and intracellular trafficking of PepFect14-nucleic acid nanocomplexes via class A scavenger receptors. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1848 (12), 3205−3216. DOI: 10.1016/j.bbamem.2015.09.019.
1.1.
2015
Freimann, Krista; Kurrikoff, Kaido; Langel, Ülo (2015). Galanin receptors as a potential target for neurological disease. Expert Opinion on Therapeutic Targets, 19 (12), 1−12.
1.1.
2015
Veiman, Kadi-Liis; Künnapuu, Kadri; Lehto, Tõnis; Kiisholts, Kristina; Pärn, Kalle; Langel, Ülo; Kurrikoff, Kaido (2015). PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo. Journal of Controlled Release, 209, 238−247.10.1016/j.jconrel.2015.04.038.
1.1.
2015
Arukuusk, P.; Pärnaste, L.; Hällbrink, M.; Langel, Ü. (2015). Pepfects and nickfects for the intracellular delivery of nucleic acids (Methods in Molecular Biology). Methods in molecular biology, 1324, 303−315.10.1007/978-1-4939-2806-4_19.
1.1.
2015
Guipponi, Michel; Chentouf, Amina; Webling, Kristin E B; Freimann, Krista; Crespel, Arielle; Nobile, Carlo; Lemke, Johannes R; Hansen, Jörg; Dorn, Thomas; Lesca, Gaetan; Ryvlin, Philippe; Hirsch, Edouard; Rudolf, Gabrielle; Rosenberg, Dominique Sarah; Weber, Yvonne; Becker, Felicitas; Helbig, Ingo; Muhle, Hiltrud; Salzmann, Annick; Chaouch, Malika ... Antonarakis, Stylianos E (2015). Galanin pathogenic mutations in temporal lobe epilepsy. Human Molecular Genetics, 24 (11), 3082−3091.10.1093/hmg/ddv060.
1.1.
2015
Uusna, J.; Langel, K.; Langel, Ü. (2015). Toxicity, immunogenicity, uptake, and kinetics methods for CPPs (Methods in Molecular Biology). Methods in molecular biology, 1324, 133−148.10.1007/978-1-4939-2806-4_9.
1.1.
2015
Kurrikoff, K.; Veiman, K.-L.; Langel, Ü. (2015). CPP-based delivery system for in vivo gene delivery (Methods in Molecular Biology). Methods in molecular biology, 1324, 339−347.10.1007/978-1-4939-2806-4_22.
1.2.
2015
Cerrato, Carmine; Veiman, Kadi-Liis; Langel, Ülo (2015). Advances in peptide delivery. In: Advances in the Discovery and Development of Peptide Therapeutics (160−171). Future Science Group. DOI: 10.4155/fseb2013.14.23.
3.1.
2015
Pooga, Margus; Langel, Ülo (2015). Classes of cell-penetrating peptides. In: Ü. Langel (Ed.). Methods in Molecular Biology (3−28). Springer. DOI: 10.1007/978-1-4939-2806-4_1.
3.1.
2015
Pärn, K.; Eriste, E.; Langel, Ü. (2015). The Antimicrobial and Antiviral Applications of Cell-Penetrating Peptides. Methods in molecular biology, 1324, 223−245. DOI: 10.1007/978-1-4939-2806-4_15.
1.1.
2014
Pae, J.; Säälik, P.; Liivamägi, L.; Lubenets, D.; Arukuusk, P.; Langel, Ü.; Pooga, M. (2014). Translocation of cell-penetrating peptides across the plasma membrane is controlled by cholesterol and microenvironment created by membranous proteins. Journal of Controlled Release, 192, 103−113. DOI: 10.1016/j.jconrel.2014.07.002.
1.1.
2014
Vasconcelos, Luis; Madani, Fatemeh; Arukuusk, Piret; Pärnaste, Ly; Gräslund, Astrid, Langel, Ülo (2014). Effects of cargo molecules on membrane perturbation caused by transportan10 based cell-penetrating peptides. Biochimica et Biophysica Acta, 1838 (12), 3118−3129.10.1016/j.bbamem.2014.08.011.
1.1.
2014
Garcia-Sosa, Alfonso T.; Tulp, Indrek; Langel, Kent; Langel, Ülo (2014). Peptide-ligand binding modeling of siRNA with cell-penetrating peptides. BioMed Research International, 257040. DOI: 10.1155/2014/257040.
1.1.
2014
Krõlov, Katrin; Frolova, Jekaterina; Tudoran, Oana; Suhorutšenko, Julia; Lehto, Taavi; Sibul, Hiljar; Mäger, Imre; Laanpere, Made; Tulp, Indrek; Langel, Ülo (2014). Sensitive and Rapid Detection of Chlamydia trachomatis by Recombinase Polymerase Amplification Directly from Urine Samples. Journal of Molecular Diagnostics, 16 (1), 127−135. DOI: 10.1016/j.jmoldx.2013.08.003.
1.1.
2014
Copolovici, D; Langel, K; Eriste, E; Langel, Ü (2014). Cell-Penetrating Peptides: Design, Synthesis, and Applications. ACS Nano, 8 (3), 1972−1994.10.1021/nn4057269.
1.1.
2014
Srimanee, Artita; Regberg, Jakob; Hallbrink, Mattias; Kurrikoff, Kaido; Veiman, Kadi-Liis; Vajragupta, Opa; Langel, Ülo (2014). Peptide-Based Delivery of Oligonucleotides Across Blood–Brain Barrier Model. International Journal of Peptide Research and Therapeutics, 20 (2), 169−178.10.1007/s10989-013-9378-4.
1.1.
2014
Rytkönen, Jussi; Arukuusk, Piret; Xu, Wujun; Kurrikoff, Kaido; Langel, Ülo; Lehto, Vesa-Pekka; Närvänen, Ale (2014). Porous Silicon–Cell Penetrating Peptide Hybrid Nanocarrier for Intracellular Delivery of Oligonucleotides. Molecular Pharmaceutics, 11 (2), 382−390.10.1021/mp4002624.
1.1.
2014
Regberg, Jakob; Srimanee, Artita; Erlandsson, Mikael; Sillard, Rannar; Dobchev, Dimitar; Karelson, Mati; Langel, Ülo (2014). Rational design of a series of novel amphipathic cell-penetrating peptides. International Journal of Pharmaceutics, 464 (1-2), 111−116. DOI: 10.1016/j.ijpharm.2014.01.018.
5.1.
2014
Lorents, Annely; Urgard, E.; Runnel, T.; Wawrzyniak, P.; Langel, Ü.; Pooga, M.; Rebane, A. (2014). Functional delivery of miR-146a to human primary keratinocytes and skin equivalents with cell-penetrating peptides. ALLERGY, 69: European-Academy-of-Allergy-and-Clinical-Immunology Congress; Copenhagen, Denmark; JUN 07-11, 2014. Wiley-Blackwell, 618−618.
5.1.
2014
Margus, H.; Arukuusk, P.; Langel, Ü.; Pooga, M. (2014). Morphology of cell-penetrating peptide-nucleic acid nanoparticles and their intracellular trafficking. FEBS JOURNAL, 281, SI: FEBS EMBO 2014, Paris. Wiley-Blackwell, 413−414.
1.1.
2013
Madani, F.; Abdo, R.; Lindberg, S.; Hirose, H.; Futaki, S.; Langel, Ü.; Gräslund, A. (2013). Modeling the endosomal escape of cell-penetrating peptides using a transmembrane pH gradient. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1828 (4), 1198−1204.10.1016/j.bbamem.2012.12.008.
1.1.
2013
Lindberg, S.; Muñoz-Alarcón, A.; Helmfors, H.; Mosqueira, D.; Gyllborg, D.; Tudoran, O.; Langel, Ü. (2013). PepFect15, a novel endosomolytic cell-penetrating peptide for oligonucleotide delivery via scavenger receptors. International Journal of Pharmaceutics, 441, 242−247.10.1016/j.ijpharm.2012.11.037.
1.1.
2013
Arukuusk, P.; Pärnaste, L.; Oskolkov, N.; Copolovici, D. M.; Margus, H.; Padari, K.; Möll, K.; Maslovskaja, J.; Tegova, R.; Kivi, G.; Tover, A.; Pooga, M.; Ustav, M.; Langel, Ü. (2013). New generation of efficient peptide-based vectors, NickFects, for the delivery of nucleic acids. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1828 (5), 1365−1373. DOI: 10.1016/j.bbamem.2013.01.011.
1.1.
2013
Jones, S; Lukanowska, M; Suhorutšenko, J; Oxenham, S; Barratt, C; Publicover, S; Copolovici, D. M; Langel, Ü; Howl, J. (2013). Intracellular translocation and differential accumulation of cell-penetrating peptides in bovine spermatozoa: evaluation of efficient delivery vectors that do not compromise human sperm motility. Human Reproduction, 28 (7), 1874−1889.10.1093/humrep/det064.
1.1.
2013
Saar, I.; Runesson, J.; Järv, J.; Kurrikoff, K.; Langel, Ü. (2013). Novel galanin receptor subtype specific ligand in depression like behavior. Neurochemical Research, 38 (2), 398−404.10.1007/s11064-012-0933-8.
1.1.
2013
Eriste, Elo; Kurrikoff, Kaido; Suhorutšenko, Julia; Oskolkov, Nikita; Copolovici, Dana Maria; Jones, Sarah; Howl, John; Laakkonen, Pirjo; Langel, Ülo (2013). Peptide-based glioma-targeted drug delivery vector gHoPe2. Bioconjugate Chemistry, 24 (3), 305−313.10.1021/bc300370w.
1.1.
2013
Anderson, M.E.; Runesson, J.; Saar, I.; Langel, Ü.; Robinson, J. (2013). Galanin, through GalR1 but not GalR2 receptors, decreases motivation at times of high appetitive behavior. Behavioural Brain Research, 239, 90−93.10.1016/j.bbr.2012.10.045.
1.1.
2013
Saar, Indrek; Lahe, Jaanus; Langel, Kent; Runesson, Johan; Webling, Kristin; Järv, Jaak; Rytkönen, Jussi; Närvänen, Ale; Bartfai, Tamas; Kurrikoff, Kaido; Langel, Ülo (2013). Novel systemically active galanin receptor 2 ligands in depression-like behavior. Journal of Neurochemistry, 127 (1), 114−123.10.1111/jnc.12274.
1.1.
2013
Yu, X.; Muñoz Alarcón, A.; Ajayi, A.; Webling, K.; Steinhof, A.; Langel, Ü.; Ström, A.-L. (2013). Inhibition of autophagy via p53-mediated disruption of ULK1 in a SCA7 polyglutamine disease model. Journal of Molecular Neuroscience, 50 (3), 586−599.10.1007/s12031-013-0012-x.
1.1.
2013
Vasconselos, L.; Pärn, K.; Langel, Ü. (2013). Therapeutic potential of cell-penetrating peptides. Therapeutic Delivery, 4 (5), 573−591.10.4155/tde.13.22.
1.1.
2013
Veiman, K.L.; Mäger, I.; Ezzat, K.; Margus, H.; Lehto, T.; Langel, K.; Kurrikoff, K.; Arukuusk, P.; Suhorutšenko, J.; Padari, K.; Pooga, M.; Lehto, T.; Langel, Ü. (2013). PepFect14 peptide vector for efficient gene delivery in cell cultures. Molecular Pharmaceutics, 10 (1), 199−210. DOI: 10.1021/mp3003557.
1.1.
2013
Arukuusk, P; Pärnaste, L.; Margus, H.; Eriksson, J.; Vasconcelos, L.;.Padari, K.; Pooga, M.; Langel, Ü. (2013). Differential endosomal pathways for radically modified peptide vectors. Bioconjugate Chemistry, 24 (10), 1721−1732. DOI: 10.1021/bc4002757.
1.1.
2013
Räägel, H.; Hein, M.; Kriiska, A.; Säälik, P.; Floren, A.; Langel, Ü.; Pooga, M. (2013). Cell-penetrating peptide secures an efficient endosomal escape of an intact cargo upon a brief photo-induction. Cellular and Molecular Life Sciences, 70, 4825−4839. DOI: 10.1007/s00018-013-1416-z.
1.1.
2013
Pärn, K.; Viru, L.; Lehto, T.; Oskolkov, N.; Langel, Ü.; Merits, A. (2013). Transfection of Infectious RNA and DNA/RNA Layered Vectors of Semliki Forest Virus by the Cell-Penetrating Peptide Based Reagent PepFect6. PLoS ONE, 8 (7), e69659.10.1371/journal.pone.0069659.
1.2.
2013
Regberg, J.; Eriksson, J. N.; Langel, Ü. (2013). Cell-penetrating peptides: from cell cultures to in vivo applications. Frontiers in Bioscience, 5, 509−516.
3.1.
2013
Muñoz-Alarcón, A.; Helmfors, H; Karlsson, K.; Langel, Ü. (2013). Cell-Penetrating Peptide Fusion Proteins. In: Stefan R. Schmidt (_EditorsAbbr). Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges (397−411).. John Wiley & Sons Ltd.
3.2.
2013
Zirk, Katrin; Langel, Ülo (2013). Vectorization of splice-correcting oligonucleotides with cell-penetrating peptides. Tecno Scienze Publisher.
1.1.
2012
Dash-Wagh, S.; Jacob, S.; Lindberg, S.; Friedberger, A.; Langel, Ü.; Ulfendahl, M. (2012). Intracellular Delivery of Short Interfering RNA in Rat Organ of Corti Using a Cell-penetrating Peptide PepFect6. Molecular theraphy-Nucleic acids, 1, e61−e61.10.1038/mtna.2012.50.
1.1.
2012
Nakase, I.; Akita, H.; Kogure, K.; Gräslund, A.; Langel, Ü.; Harashima, H.; Futaki, S. (2012). Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides. Accounts of Chemical Research, 45 (7), 1132−1139.
1.1.
2012
Mäe, M.; Rautsi, O.; Enbäck, J.; Hällbrink, M.; Rosenthal Aizman, K.; Lindgren, M.; Laakonen, P.; Langel, Ü. (2012). Tumour Targeting with Rationally Modified Cell-Penetrating Peptides. International Journal of Peptide Research and Therapeutics, 18 (4), 361−371.10.1007/s10989-012-9312-1.
1.1.
2012
Webling, K.E.B.; Runesson, J.; Bartfai, T.; Langel, Ü. (2012). Galanin receptors and ligands. Front Endocrinol (Lausanne), 3, 1−14.10.3389/fendo.2012.00146.
1.1.
2012
Tanaka, G.; Nakase, I.; Fukuda, Y.; Masuda, R.; Oishi, S.; Shimura, K.; Kawaguchi, Y.; Takatani-Nakase, T.; langel, Ü.; Gräslund, A.; Okawa, K.; Matsuoka, M.; Tsujimoto, G.; Fujii, N.; Hatanaka, Y.; Futaki, S. (2012). CXCR4 stimulates macropinocytosis: implicatins for cellular uptake of arginine-rich cell-penetrating peptides and HIV. Chemistry & Biology, 19 (11), 1437−1446.10.1016/j.chembiol.2012.09.011.
1.1.
2012
Anko, M; Majhenc, J; Kogej, K; Sillard, R; Langel, Ü; Anderluh, G; Zorko, M (2012). Influence of stearyl and trifluoromethylquinoline modifications of the cell penetrating peptide TP10 on its interaction with a lipid membrane. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1818 (3), 915−924.10.1016/j.bbamem.2011.12.028.
1.1.
2012
Ajayi, A; Yu, X; Lindberg, S; Langel, Ü and Ström, A-L. (2012). Expanded ataxin-7 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible Spinocerebellar ataxia type 7 (SCAT7) model. BMC Neuroscience, 13, 86.10.1186/1471-2202-13-86.
1.1.
2012
Lorents, A.; Oskolkov, N.; Langel, Ü.; Hällbrink, M.; Pooga, M. (2012). Cell-penetrating peptides split into two groups based on the modulation of the intracellular calcium concentration. Journal of Biological Chemistry, 287 (20), 16880−16889. DOI: 10.1074/jbc.M111.318063.
1.1.
2012
Suhorutsenko, J.; Eriste, E.; Copolovici, D. M.; Langel, Ü. (2012). Human Protein 53-Derived Cell-Penetrating Peptides. International Journal of Peptide Research and Therapeutics, 18 (4), 291−297.10.1007/s10989-012-9302-3.
1.1.
2012
Mäger, Imre; Langel, Kent; Lehto, Taavi; Eiriksdottir, Emelia; Langel, Ülo (2012). The role of endocytosis on the uptake kinetics of luciferin-conjugated cell-penetrating peptides. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1818 (3), 502−511.10.1016/j.bbamem.2011.11.020.
1.1.
2012
Ezzat, K.; Helmfors, H.; Tudoran, O.; Juks, C.; Lindberg, S.; Padari, K.; El-Andaloussi, S.; Pooga, M.; Langel, Ü. (2012). Scavenger receptor-mediated uptake of cell-penetrating peptide nanocomplexes with oligonucleotides. The FASEB Journal, 26 (3), 1172−1180. DOI: 10.1096/fj.11-191536.
1.1.
2012
Lehto, T; Kurrikoff, K; Langel, Ü. (2012). Cell-penetrating peptides for the delivery of nucleic acids. Expert Opinion on Drug Delivery, 9 (7), 823−836.10.1517/17425247.2012.689285.
1.1.
2012
Laffray, S.; Bouali-Benazzouz, R.; Papon, M.-A.; Favereaux, A.; Jiang, Y.; Holm, T.; Spriet, C.; Desbarats, P.; Fossat, P.; Le Feuvre, Y.; Decossas, M.; Héliot, L.; Langel, Ü.; Nagy, F.; Landry, M. (2012). Impairment of GABAB receptor dimer by endogeneous 14-3-3ζ in chronic pain conditions. The EMBO Journal, 31 (15), 3239−3251.10.1038/emboj.2012.161.
1.1.
2012
Howl, J.; Matou-Nasri, S.; West, D.C.; Farquhar, M.; Slaninova, J.; Östenson, C-G., Zorko, m.; Östlund, P., Kumar, S.; Langel, Ü.; McKeating, J.; Jones, S. (2012). Bioportide:An Emergent Concept of Bioactive Cell-Penetrating Peptide. Cellular and Molecular Life Sciences, 69 (17), 2951−2966.
1.1.
2012
Holm, T.; Bruchmann, J.; Johansson, C.; Scheynius, A.; and Langel, Ü. (2012). Malassezia sympodialis. Letters in Applied Microbiology, 54 (1), 39−44.10.1111/j.1472-765X.2011.03168.x.
1.1.
2012
Helmfors, H.; Langel, Ü. (2012). Recent developments in applications of cell-penetrating peptides. Chimica Oggi-Chemistry Today, 30 (2), 10−12.
1.1.
2012
Regberg, J.; Srimanee, A.; Langel, Ü. (2012). Applications of Cell-Penetrating Peptides for tumor Targeting and Future Cancer Therapies. Pharmaceuticals, 5 (9), 991−1007.10.3390/ph5090991.
1.2.
2012
Ezzat, K.; Zaghloul, E. M.; EL-Andaloussi, S.; Lehto, T.; EL-Sayed, R.; Magdy, T.; Smith, C.I.E., Langel, Ü. (2012). Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions. The Journal of Control Release, 162, 1−8.
1.2.
2012
Langel, Ü.; Erlandsson, M. (2012). Recent Developments in Applications of Cell-penetrating Peptides. International Drug Discovery, 1−4.
1.2.
2012
Muńoz-Alarcón, A.; Guterstam, P.; Romero, C.; Behlke, M. A.; Lennox, K.; Wengel, J.; EL Andaloussi, S.; and Langel, Ü. (2012). Modulating anti-microRNA21 activity and specificity using oligonucleotide derivatives and length optimization. ISRN Pharmaceutics, 2012, 2012:407154. DOI: 10.5402/2012/407154.
3.1.
2012
Kurrikoff, K.; Suhorutsenko, J.; Langel, Ü. (2012). Cell-Penetrating Peptides in Cancer Targeting. In: Felix Kratz, Peter Senter, Henning Steinhagen (Ed.). Drug Delivery in Oncology: From Basic Research to Cancer Therapy (1189−1217).. Wiley-V C H Verlag Gmbh.
1.1.
2011
Said, H. S.; Abes, R., El Andaloussi, S.; Lehto, T.; Sillard, R.; Langel, Ü.; Lebleu, B. (2011). Insights into the cellular trafficking of spice redirecting oligonucleotides complexed with chemically modified cell-penetrating peptides. Journal of Controlled Release, 153, 163−172.10.1016/j.jconrel.2011.04.013.
1.1.
2011
Öjemalm, K.; Higuchi, T.; Jiang, Y.; Langel, Ü., Nilsson, I.; White, S. H.; Suga, H.; von Heijne, G. (2011). Apolar surface area determines the efficiency of translocon-medaited membrane protein insertion into the endoplasmic reticulum. Proceedings of the National Academy of Sciences, 108 (31), E359−E364.10.1073/pnas.1100120108.
1.1.
2011
Mann, A.; Thakur, G.; Shukla, V.; Singh, A. K.; Khanduri, R.; Naik, R.; Jiang, Y.; Kalra, N.; Dwarakanath, B. S.; Langel, Ü.; Ganguli, M. (2011). Differences in DNA condensation and release by lysine and arginine homopeptides govern their DNA delivery efficiencies. Molecular Pharmaceutics, 8 (5), 1729−1741.10.1021/mp2000814.
1.1.
2011
Viru, L.; Heller, G.; Lehto, T.; Pärn, K.; El Andaloussi, S.; Langel, Ü.; Merits, A. (2011). Novel viral vectors utilizing intron splice-switch to activate genome rescue, expression and replication in targeted cells. Virology Journal, 8 (1), 243.
1.1.
2011
Oskolkov, N.; Arukuusk, P.; Copolovici, D.-M.; Lindberg, S.; Margus, H.; Padari, K.; Pooga, M.; Langel, Ü. (2011). NickFects, Phosphorylated Derivatives of Transportan 10 for Cellular Delivery of Oligonucleotides. International Journal of Peptide Research and Therapeutics, 17 (2), 147−157. DOI: 10.1007/s10989-011-9252-1.
1.1.
2011
Saar, I., Runesson, J., McNamara, I., Järv, J., Robinson, J.K., Langel, U. (2011). Novel galanin receptor subtype specific ligands in feeding regulation. Neurochemistry International, 714−720.10.1016/j.neuint.2011.02.012.
1.1.
2011
Ezzat, K.; EL Andaloussi, S.; Zaghloul, EM.; Lehto, T.; Lindberg, S.; Moreno, P. M. D.; Viola, J.; Magdy, T.; Abdo, R.; Guterstam, P.; Sillard, R.; Hammond, S. M.; Wood, MJA.; Arzumanov, AA.; Gait, MJ.; Smith, CIE.; Hällbrink, M.; Langel, Ü. (2011). PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Research, 39 (12), 5284−5298.
1.1.
2011
Säälik, P.; Niinep, A.; Pae, J.; Hansen, M.; Lubenets, D.; Langel, Ü.; Pooga, M. (2011). Penetration without cells: membrane translocation of cell-penetrating peptides in the model giant plasma membrane vesicles. Journal of Controlled Release, 153 (2), 117−125.
1.1.
2011
El Andaloussi, S; Lehto, T; Mager, I; Rosenthal-Aizman, K; Oprea, I.I; Simonson, O.E; Sork, H; Ezzat, K; Copolovici, D.M; Kurrikoff, K; Viola, J.R; Zaghloul, E.M; Sillard, R; Johansson, H. J; Hassane, F.S; Guterstam, P.; Suhorutsenko, J.; Moreno, P. M. D.; Oskolkov, N; Halldin, J ... Langel, U. (2011). Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Research, 39 (9), 3972−3987. DOI: 10.1093/nar/gkq1299.
1.1.
2011
Holm, T.; Räägel, H.; El Andaloussi, S.; Hein, M.; Mäe, M.; Pooga, M.; Langel, Ü. (2011). Retro-inversion of certain cell-penetrating peptides causes severe cellular toxicity. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1808 (6), 1544−1551. DOI: 10.1016/j.bbamem.2010.10.019.
1.1.
2011
Lehto, T.; Ezzat, K.; Langel, Ü. (2011). Peptide nanoparticles for oligonucleotide delivery. In: Villaverde, A. (Ed.). Nanoparticles in Translational Science and Medicine; Progress in Molecular Biology and Translation Science (397−426).. Elsevier.10.1016/B978-0-12-416020-0.00010-3.
1.1.
2011
Suhorutšenko, J.; Oskolkov, N.; Arukuusk, P.; Kurrikoff, K.; Eriste, E.; Copolovici, D.-M.; Langel, Ü. (2011). Cell-Penetrating Peptides, PepFects, Show No Evidence of Toxicity and Immunogenicity In Vitro and In Vivo. Bioconjugate Chemistry, 22 (11), 2255−2262.10.1021/bc200293d.
1.2.
2011
Lindberg, S.; Copolovici, D.M.; Langel, Ü. (2011). Therapeutic delivery opportunities, obstacles and applications for cell-penetrating peptides. Therapeutic Delivery, 2, 71−82.
1.2.
2011
Madani, F.; Lindberg, S.; Langel, Ü.; Futaki, S.; Gräslund, A. (2011). Mechanisms of cellular uptake of cell penetrating peptides. Journal of Biophysics, 1−10. DOI: 10.1155/2011/414729.
3.1.
2011
El Andaloussi, S; Said, H. F; Boisguerin, P.; Sillard, R.; Langel, Ü.; Lebleu, B. (2011). Cell-penetrating peptides-based strategies for the delivery of splice redirecting antisense oligonucleotides. In: Methods in Molecular Biology (75−89).. Springer.
3.1.
2011
Johansson, H, J; EL Andaloussi, S; Langel, Ü. (2011). Mimicry of protein function with cell-penetrating peptides. In: Langel Ülo (_EditorsAbbr). Cell-Penetrating Peptides. Methods in Molecular Biology. (233−247).. Humana Press. (4).
3.1.
2011
Bell, T.J.; Eiriksdottir, E.; Langel, Ü.; Eberwine, J. (2011). PAIR technology: exon-specific RNA binding protein isolation in live cells. In: Langel, Ülo (_EditorsAbbr). Cell-Penetrating Peptides. Methods and Protocols. Methods in Molecular Biology. (473−486).. Humana Press.
3.1.
2011
EL Andaloussi, S.; Lehto, T.; Lundin, P.; Langel, Ü. (2011). Application of PepFect peptides for the delivery of splice-correcting oligonucleotides. In: Langel, Ü. (Ed.). Cell-Penetrating Peptides. Methods adn Protocols. Methods in Molecular Biology (361−374).. Humana Press. (4).
3.1.
2011
Guterstam, P.; EL Andaloussi, S.; Langel, Ü. (2011). Charaterization of cellular internalization pathways for CPP-mediated oligonucleotide delivery. In: Langel, Ü. (_EditorsAbbr). Cell-Penetrating Peptides. Methods and Protocols. Methods in Molecular Biology (219−230).. Humana Press. (4).
3.1.
2011
Holm, T.; EL Andaloussi, S.; Langel, Ü. (2011). Comparison of CPP uptake methods. In: Langel, Ülo (_EditorsAbbr). Cell-Penetrating Peptides. Methods and Protocols. Methods in Molecular Biology. (207−217).. Humana Press. (4).
3.1.
2011
Lundin, P.; EL Andaloussi, S.; Langel, Ü. (2011). Toxicity methods for CPPs. In: Langel, Ülo (_EditorsAbbr). Cell-Penetrating Peptides. Methods and Protocols. Methods in Molecular Biology (195−205).. Humana Press. (4).
3.1.
2011
Floren, A.; Mäger, I.; Langel, Ü. (2011). Uptake kinetics of cell-penetrating peptides. In: Langel, Ü. (_EditorsAbbr). Cell-Penetrating Peptides. Methods and Protocols. Methods in Molecular Biology (117−128).. Humana Press. (4).
3.1.
2011
Lindgren, M.; Langel, Ü. (2011). Classes and prediction of cell-penetrating peptides. In: Langel, Ülo (_EditorsAbbr). Cell-Penetrating Peptides. Methods and Protocols. Methods in Molecular Biology (3−19).. Humana Press.
3.1.
2011
Langel, Ü. (2011). Cell-Penetrating Peptides (eessõna). In: Langel, Ü. (_EditorsAbbr). Methods and Protocols. Methods in Molecular Biology (5−6).. Humana Press. (4).
3.1.
2011
Räägel, Helin; Säälik, Pille; Langel, Ülo; Pooga, Margus (2011). Mapping of Protein Transduction Pathways with Fluorescent Microscopy. In: Langel, Ülo (Ed.). Cell-Penetrating Peptides: Methods and Protocols, Methods in Molecular Biology (165−179). . Springer. DOI: 10.1007/978-1-60761-919-2_12.
5.2.
2011
Part, Kristin; Rosenthal-Aizman, Katri; Oskolkov, Nikita; Land, Tiit; Langel, Ülo; Z. Fernaeus, Sandra. (2011). Co-transfection of siRNA and plasmid DNA using the cell-penetrating peptide PepFect6 in cell-culture. Peptide Vectors and Delivery of Therapeutics Tallinn, Estonia, May 19th - 21st 2011. -, 44−44.
1.1.
2010
Langel, K; Lindberg, S; Copolovici, D; Arukuusk, P; Sillard, R; Langel, Ü. (2010). Novel fatty acid modifications of transportan 10. International Journal of Peptide Research and Therapeutics, 16 (4), 247−255.10.1007/s10989-010-9224-x.
1.1.
2010
Jones, S.; Holm, T.; Mäger, I.;, Langel, Ü.; Howl, J. (2010). Characterization of bioactive cell penetrating peptides from human cytochrome c: protein mimicry and the development of a novel apoptogenic agent. Chemistry & Biology, 17 (7), 735−744.
1.1.
2010
Eiriksdottir, E.; Mäger, I.; Lehto, T.; EL Andaloussi, S.; Langel, Ü. (2010). Cellular Internalization Kinetics of Luciferin-Cell-Penetrating Peptide Conjugates. Bioconjugate Chemistry, 21 (9), 1662−1672.10.1021/bc100174y.
1.1.
2010
Runesson, J.; Sollenberg, U.E.; Jurkowski, W.; Yazdi, S.; Eriksson, E.E.; Elofsson, A.; Langel, Ü. (2010). Determining receptor-ligand interaction of human galanin receptor type 3. Neurochemistry International, 57 (7), 804−811.
1.1.
2010
Dobchev, D. A.; Mäger, I.; Tulp, I.; Karelson, G.; Tamm, T.; Tämm, T.; Jänes, J.; Langel, Ü.; Karelson, M. (2010). Prediction of Cell-Penetrating Peptides Using Artificial Neural Networks. Current Computer - Aided Drug Design, 6 (2), 79−89.
1.1.
2010
Sollenberg, U. E.; Runesson, J,: Sillard, R.; Langel, Ü. (2010). Binding of chimeric peptides M617 and M871 to galanin receptor type 3 reveals characteristics of galanin receptor-ligand interaction. International Journal of Peptide Research and Therapeutics, 16 (1), 17−22.10.1007/s10989-009-9197-9.
1.1.
2010
Ezzat, K.; El-Andaloussi, S.; Abdo, R.; Langel, Ü. (2010). Peptide-Based Matrices as Drug Delivery Vehicles. Current Pharmaceutical Design, 16 (9), 1167−1178.
1.1.
2010
Fossat, P.; Dobremez, E.; Bouali-Benazzouz, R.; Favereaux, A.; Bertrand, SS.; Kilk, K.; Léger, C.; Cazalets, JR.; Langel, Ü.; Landry, M.; Nagy, F. (2010). Knockdown of L calcium channel subtypes: differential effects in neuropathic pain. Journal of Neuroscience, 30, 3, 1073−1085.
1.1.
2010
Lehto, Taavi; Abes, Rachida; Oskolkov, Nikita; Suhorutsenko, Julia; Copolovici, Dana-Maria; Mager, Imre; Viola, Joana R.; Simonson, Oscar E.; Ezzat, Kariem; Guterstam, Peter; Eriste, Elo; Smith, C. I. Edvard; Lebleu, Bernard; El Andaloussi, Samir; Langel, Ulo (2010).

Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy

. Journal of Controlled Release, 141 (1), 42−51. DOI: 10.1016/j.jconrel.2009.08.028.
1.1.
2010
Järver, P.; Mäger, I.; Langel, Ü. (2010). In vivo biodistribution and efficacy of peptide mediated delivery. Trends in Pharmacological Sciences, 31 (11), 528−535.10.1016/j.tips.2010.07.006.
1.1.
2010
Mäger, I.; Eiríksdóttir, E.; Langel, K.; Andalouss, S.E.; Langel, Ü. (2010). Assessing the uptake kinetics and internalization mechanisms of cell-penetrating peptides using a quenched fluorescence assay. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1798 (3), 338−343.10.1016/j.bbamem.2009.11.001.
1.2.
2010
Saar, K.; Saar, H.; Hansen, M.; Langel, Ü.; Pooga, M. (2010). Distribution of CPP-Protein Complexes in Freshly Resected Human Tissue Material. Pharmaceuticals, 3 (3), 621−635. DOI: 10.3390/ph3030621.
3.4.
2010
Säälik, P.; Niinep, A.; Pae, J.; Hansen, M.; Langel, Ü.; Pooga, M. (2010). Interaction of cell-penetrating peptides in the model of giant plasma membrane vesicles. Peptides 2010: The 31st European Peptide Symposium; Copenhagen; September 5-9 2010. Ed. Lebl, M.; Meldal, M.; Jensen, K.J.; Hoeg-Jensen, T. European Peptide Society, 410−411.
5.1.
2010
Lorents, A.; Oskolkov, N.; Tõnissoo, T.; Langel, Ü.; Hällbrink, M.; Pooga, M. (2010). Amphipathic CPPs upregulate Ca in cells’ cytosol and induce lysosomal exocytosis. In: (A34). . DOI: 10.1016/j.drudis.2010.09.385.
5.1.
2010
Suhorutsenko, J.; Copolovici, D. M.; Eriste, E.; Oskolkov, N.; Arukuusk, P.; Langel, Ü. (2010). New cell-penetrating peptides induce no inflammatory response in antigen-presenting cell lines. Scandinavian Journal of Immunology, 71, 508−509.
5.1.
2010
Padari, K.; Juks, C.; Oskolkov, N.; Raid, R.; Langel, Ü.; Pooga, M. (2010). Cellular delivery of oligonucleotides by PepFect. In: (1092−1093). . DOI: 10.1016/j.drudis.2010.09.386.
5.1.
2010
Pooga, M.; Säälik, P.; Niinep, A.; Pae, J.; Lubenets, D.; Hansen, M.; Langel, Ü. (2010). Interaction of cell-penetrating peptides with giant plasma membrane vesicles. JOURNAL OF PEPTIDE SCIENCE, 16: The 31st European Peptide Symposium; Copenhagen; September 5-9 2010. , 150. (Suppl 1).
1.1.
2009
Guterstam, P.; Madani, F.; Hirose, H.; Takeuchi, T.; Futaki, S.; El-Andaloussi, S.; Gräslund, A.; Langel, Ü. (2009). Elucidating cell-penetrating peptide mechanisms of action for membrane interaction, cellular uptake, and translocation utilizing the hydrophobic counter-anion pyrenebutyrate. Biochimica et Biophysica Acta, 12 (1788), 2509−2517. DOI: 10.1016/j.bbamem.2009.09.014.
1.1.
2009
Kilk, K.; Mahlapuu, R.; Soomets, U.; Langel, Ü. (2009). Analysis of in vitro toxicity of five cell-penetrating peptides by metabolic profiling. Toxicology, 265 (3), 87−95.
1.1.
2009
Mäe, M.; El-Andaloussi, S.; Lundin, P.; Oskolkov, N.; Johansson, H.J.; Guterstam, P.; Langel, Ü. (2009). A stearylated CPP for delivery of splice correcting oligonucleotides using a noncovalent co-incubation strategy. Journal of Controlled Release, 134 (3), 221−227.
1.1.
2009
Mäe, M.; Myberg, H.; El-Andaloussi, S.; Langel, Ü. (2009). Design at a tumour harving cell-penetrating peptides for drug delivery. International Journal of Peptide Research and Therapeutics, 15, 11−15.
1.1.
2009
Mäe, M.; El-Andaloussi, S.; Lehto, T.; Langel, Ü. (2009). Chemically modified cell-penetrating peptides for the delivery of nucleic acids. Expert Opinion on Drug Delivery, 6 (11), 1195−1205. DOI: 10.1517/17425240903213688.
1.1.
2009
Eiriksdóttir, E.; Langel, Ü.; Rosenthal-Aizman, K. (2009). An improved synthesis of releasable luciferin-CPP conjugates. Tetrahedron Letters, 50, 4731−4733.
1.1.
2009
Räägel, H.; Säälik, P.; Hansen, M., Langel, Ü.; Pooga, M. (2009). Cell-penetrating peptides-protein constructs induce a population of non-acidic vesicles during trafficking through the endolysosomal pathway. Journal of Controlled Release, 139 (2), 108−117. DOI: 10.1016/j.jconrel.2009.06.028.
1.1.
2009
Runesson, J.; Saar, I.; Lundström, L.; Järv, J.; and Langel, Ü. (2009). A novel GalR2-specific peptide agonist. Neuropeptides, 43 (3), 187−192.
1.1.
2009
Säälik, P.; Padari, K.; Niinep, A.; Lorents, A.; Hansen, M.; Jokitalo, E.; Langel, Ü.; Pooga, M. (2009). Protein delivery with transportans is mediated by caveolae rather than flotillin-dependent pathways. Bioconjugate Chemistry, 20 (5), 877−887. DOI: 10.1021/bc800416f.
3.1.
2009
Runesson, J.; Robinson, J.; Sollenberg, U.; Langel, Ü. (2009). Twenty-five years of galanin research. In: J. Howl (_EditorsAbbr). Bioactive peptides (237−260).. Boca Raton: CRC Press Inc.. (CRC Handbook).
3.1.
2009
Langel, Ü.; Cravatt, B.; Gräslund, A.; von Heijne, G.; Land, T.; Niessen, S.; Zorko, M. (2009). Introduction to peptides and proteins. In: Introduction to peptides and proteins (x−x).. London, New York: Taylor & Francis Inc.
3.1.
2009
Hansen, M.; Eriste, E. Langel Ü. (2009). The Internalization mechanisms and Bioactivity of the Cell-Penetrating Peptides. In: Gröner, B. (Ed.). Peptides as Drugs: Discovery and Development, (125−143).. John Wiley & Sons Ltd.
3.4.
2009
Säälik, P.; Räägel, H.; Hansen, M.; Langel, Ü.; Pooga, M. (2009). Protein delivery with transportans avoids recycling endosomal route and is not potentiated by EGF. In: Lankinen, H. (Ed.). Peptides 2008 (390−391). . University of Helsinki.
5.1.
2009
Runesson, J.; Saar, I.; Järv, J.; Langel, Ü. (2009). Novel peptide agonists, favoring galanin receptor type 2 over galanin receptor type 1 and 3. FEBS JOURNAL, 276: 34th Congress of the Federation-of-European-Biochemical-Societies; Prague, CZECH REPUBLIC; JUL 04-09, 2009. 164. (Suppl. 1).
5.2.
2009
Laur, Kristi; Langel, Ülo; Kogerman, Priit; Valkna, Andres (2009). Regulation of transcription factor Gli activity using oligodeoxynucleotide decoy bound to Transportan 10. Spetsai Summer School: Proteins and their Networks - from specific to global analysis; Spetsese saar, Kreeka; 7.09.2009-17.09.2009.
5.2.
2009
Laur, Kristi; Langel, Ülo; Kogerman, Priit; Valkna, Andres. (2009). Regulation of transcription factor GLI activity using oligodeoxynucleotide decoy with Transportan. 3rd Intracellular Delivery of Therapeutic Molecules: From Bench to Bedside. 15 years of cell-penetrating peptides: from molecular mechanisms to the clinic: 3rd Intracellular Delivery of Therapeutic Molecules: From Bench to Bedside; Montpellier, France; 31.08.2009-2.09.2009. 42−42.
6.3.
2009
Pooga, M.; Langel, Ü.; Hansen, M., Soomets, U.; Kilk, K. (2009). Rakusisesed märklauad. Villems, R. (Toim.). Eesti Vabariigi Teaduspreemiad (72−85). . Tallinn: Eesti Teaduste Akadeemia.
1.1.
2008
Järver, P.; Fernaeus, S.; El-Andaloussi, S.; Tjörnhammar, M.-L.; Langel, Ü. (2008). Co-Transduction of Sleeping Beauty Transposase and donor Plasmid via a Cell-penetrating Peptide. A simple one step method. International Journal of Peptide Research and Therapeutics, 14 (1), 58−63. DOI: 10.1007/s10989-007-9114-z.
1.1.
2008
Lundin, P.; Johansson, H.; Guterstam, P.; Holm, T.; Hansen, M.; Langel, Ü.; EL Andaloussi, S. (2008). Distinct Uptake Routes of Cell-Penetrating Peptide Conjugates. Bioconjugate Chemistry, 19 (12), 2535−2542. DOI: 10.1021/bc800212j.
1.1.
2008
Arsov, Z.; Nemec, M.; Schara, M.; Johansson, H.; Langel, Ü.; and Zorko, M. (2008). Cholesterol prevents interaction of the cell-penetrating peptide transportan with model lipid membranes. Journal of Peptide Science, 14 (12), 1303−1308.
1.1.
2008
Arrighi, R.; Ebikeme, C.; Jiang, Y.; Ranford-Cartwright, L.; Barrett, M.; Langel, U.; Faye, I. (2008). Cell-penetrating peptide TP10 shows broad-spectrum activity against both Plasmodium falciparum and Trypanosoma brucei brucei. Antimicrobial Agents and Chemotherapy, 52 (9), 3414−3417.
1.1.
2008
Vukojević, V.; Ming, Y.; D`Addario, C.; Hansen, M.; Langel, Ü.; Schultz, R.,Johansson, B.; Rigler, R.; Terenius, L. (2008). µ-Opioid receptor activation in live cells. The FASEB Journal, 22 (10), 3537−3548. DOI: 10.1096/fj.08-108894.
1.1.
2008
Oglecka, K.; Lundberg, P.; Magzoub, M.; Eriksson, L. E. G.; Langel, Ü.; Gräslund, A. (2008). Relevance of the N-terminal NLS-like Sequence of the Prion Protein for Membrane Perturbation Effects. Biochimica et Biophysica Acta, 1778 (1), 206−213. DOI: 10.1016/j.bbamem.2007.09.034.
1.1.
2008
Myrberg, H.; Zhang, L.; Mäe, M.; Langel, Ü. (2008). Design of a tumor-homing cell-penetrating peptide. Bioconjugate Chemistry, 19 (1), 70−75. DOI: 10.1021/bc0701139.
1.1.
2008
Löfgren, K.; Wahlström, A.; Lundberg, P.; Langel, Ü.; Gräslund, A. (2008). Antiprion properties of prion protein-derived cell-penetrating peptides. The FASEB Journal, 22 (7), 2177−2184. DOI: 10.1096/fj.07-099549.
1.1.
2008
Kuteeva, E.; Wardi, T.; Lundström, L.; Sollenberg, U.; Langel, Ü.; Hökfelt, T.; Ögren, S.- O. (2008). Differential Role of Galanin Receptors in the Regulation of Depression-like Behavior and Monoamine/Stress-Related Genes at the Cell Body Level. Neuropsychopharmacology, 33 (11), 2573−2585. DOI: 10.1038/sj.npp.1301660.
1.1.
2008
Holmström, T.; Mialon, A.; Kallio, M.; Nymalm, Y.; Mannermaa, L.; Holm, T.; Johansson, H.; Black, E.; Gillespie, D.; Salminen, T. A.; Langel, Ü.; Valdez, B.; Westermarck, J. (2008). c-Jun Supports Ribosomal RNA processing and nucleolar localization of RNA Helicase DDX21. Journal of Biological Chemistry, 283 (11), 7046−7053. DOI: 10.1074/jbc.M709613200.
1.1.
2008
Hawes, J. J.; Brunzell, D.; Narasimhaiah, R., Langel, Ü.; Wynick, D.; Picciotto, M. (2008). Galanin protects against behavioral and neurochemical correlates of opiate reward. Neuropsychopharmacology, 33 (8), 1864−1873. DOI: 10.1038/sj.npp.1301579.
1.1.
2008
Guterstam, P.; Lindgren, M.; Johansson, H.; Tederbark, U.; Wengel, J.; El-Andaloussi, S.; Langel, Ü. (2008). Splice switching efficiency and specificity for locked nucleic acids. Biochemical Journal, 412 (2), 307−312.
1.1.
2008
Fuxe, K.; Marcellino, D.; Rivera, A.; Diaz-Cabiale, Z.; Filip, M.; Gago, B.; Roberts, D. C.; Langel, Ü.; Genedani, S.; Ferraro, L.; de la Calle, A.; Narvaez, J.; Tanganelli, S.; Woods, A.; Agnati, L. F. (2008). Receptor- receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Research Reviews, 58, 2, 415−452. DOI: 10.1016/j.brainresrev.2007.11.007.
1.1.
2008
Alier, K. A.; Chen, Y., Sollenberg, U. E.; Langel, Ü.; Smith, P. A. (2008). Selective stimulation of GalR1 and GalR2 in rat in rat substantia gelatinosa reveals a cellular basis for the anti- and pronociceptive actions of galanin. Pain, 137 (1), 138−146. DOI: 10.1016/j.pain.2007.08.030.
1.1.
2008
Hansen, M.; Kilk, K.; Langel, Ü. (2008). Predicting cell-penetrating peptides. Advanced Drug Delivery Reviews, 60, 572−579. DOI: 10.1016/j.addr.2007.09.003.
1.1.
2008
Johansson, H.J.; El-Andaloussi, S.; Holm, T.; Mäe, M.; Jänes, J.; Maimets, T.; Langel, Ü. (2008). Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein. Molecular therapy, 16 (1), 115−123.
1.1.
2007
Yandek, L.E.; Pokorny, A.; Floren, A.; Knoelke, K.; Langel, Ü.; Almeida, P.F.F. (2007). Mechanism Cell-Penetrating Peptide Tp10 Permeation of Lipid Bilayers. Biophysical Journal, 92 (7), 2434−2444.
1.1.
2007
Myrberg, H.; Lindgren, M.; Langel, Ü. (2007). Protein Delivery by the Cell-penetrating Peptide YTA2. Bioconjugate Chemistry, 18 (1), 170−174.
1.1.
2007
Lundström, L.; Sollenberg, U.; Langel, Ü. (2007). Molecular characterization of the ligand binding site of the human galanin receptor type 2, identifying subtype selective interactions. Journal of Neurochemistry, 103 (5), 1774−1784.
1.1.
2007
Fisher, L.; Samuelsson, M.; Jiang, Y., Ramberg, V.; Figuero, R.; Hallberg, E.; Langel, Ü.; Iverfeldt, K. (2007). Targeting cytokine expression in glial cells by cellular delivery of an NF-kB decoy. Journal of Molecular Neuroscience , 31 (3), 209−219.
1.1.
2007
El-Andaloussi, S.; Johansson, H.; Holm, T.; Langel, Ü. (2007). A novel cell-penetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids. Molecular Therapy, 15 (10), 1820−1826. DOI: 10.1038/sj.mt.6300255.
1.1.
2007
El-Andaloussi, S.; Guterstam, P.; Langel, Ü. (2007). Assessing the delivery efficacy and internalization route of cell-penetrating peptides. Nature Protocols, 2 (8), 2043−2047. DOI: 10.1038/nprot.2007.302.
1.1.
2007
Bodor, N.; Toth-Sarudy, É.; Holm, T.; Pallagi, I.; Vass, E. P.; Buchwald, P.T.; Langel, Ü. (2007). Novel, cell-penetrating molecular transporters with flexible backbones and permanently charged side chains. Journal of Pharmacy and Pharmacology, 59 (8), 1065−1076.
1.1.
2007
Blackshear, A.; Yamamoto, M.; Anderson, B.J.; Holmes, P.V.; Lundström, L.; Langel, Ü.; Robinson, J.K. (2007). Intracerebroventricular administration of galanin or galanin receptor subtype 1 agonist M617 induces c-Fos activation in a central amygdala and dorsomedial hypothalamus. Peptides, 28 (5), 1120−1124.
1.1.
2007
Barany-Wallje, E.; Gaur, J.; Lundberg, P.; Langel, Ü.; Gräslund, A. (2007). Cell-penetrating peptides: membrane perturbation effects caused by Tp10 attached to bioactive cargoes. FEBS Letters, 581 (13), 2389−2393.
1.1.
2007
Bavec, A.; Jiang, Y.; Langel, Ü.; Zorko, M. (2007). Role of cysteine 341 and arginine 348 of GLP-1 receptor in G-protein coupling. Molecular Biology Reports, 34 (1), 53−60.
1.1.
2007
El-Andaloussi, S.; Järver, P.; Johansson, H.J.; Langel, Ü. (2007). Cargo dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochemical Journal, 407 (2), 285−292. DOI: 10.1042/BJ20070507.
1.1.
2007
Ehrlich, K.; Viirlaid, S.; Mahlapuu, R.; Saar, K.; Kullisaar, T.; Zilmer, M.; Langel, Ü.; Soomets, U. (2007). Design, synthesis and properties of novel powerful antioxidants, glutathione analogues. Free Radical Research, 41 (7), 779−787.
1.1.
2007
Fuxe, K.; Canals, M.; Torvinen, M.; Marcellino, D.; Terasmaa, A.; Genedani, S.; Leo, G.; Guidolin, G.; Diaz-Cabiale, Z.; Rivera, A.; Lundström, L.; Langel, Ü.; Narvaez, J.; Tanganelli, S.; Lluis, C.; Ferre, S.; Woods, A.; Franco, R.; Agnati, LF. (2007). Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. Journal of Neural Transmission, 114 (1), 49−75. DOI: 10.1007/s00702-006-0589-0.
1.1.
2007
Lundberg, P.; El -Andaloussi, S.; Sütlü, T.; Johansson, H.; Langel, Ü. (2007). Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. The FASEB Journal, 21 (11), 2664−2671. DOI: 10.1096/fj.06-6502com.
1.2.
2007
Järver, P.; Langel, K.; El-Andaloussi, S.; Langel, Ü. (2007). Applications of cell-penetrating peptides in regulation of gene expression. Biochemical Society Transactions, 35 (4), 770−774.
3.1.
2007
Jones, S.; Östlund, P.; Langel, Ü.; Zorko, M.; Nicholl, I.; Howl, J. (2007). A rhegnylogic strategy for the synthesis of signal transduction modulatory, cell penetrating peptides. In: Rolka, K.; Rekovski, P.; Silberring, J. (_EditorsAbbr). Peptides 2006 (430−443).. Kenes International: Geneva University Press.
3.1.
2007
Lundberg, P.; Kilk, K.; Langel, Ü. (2007). Cell-penetrating peptide mediated delivery of peptide nucleic acid oligomers. In: Friedmann, T.; Rossi, J. (Ed.). Gene Transfer. Delivery And Expression of DNA And RNA (581−586).. New York: Cold Spring Harbor Laboratories Press.
5.1.
2007
Lorents, A.; Padari, K.; Hansen, M.; Langel, Ü.; Pooga, M. (2007). Biogenesis of VGF secretory granules in epithelial thyroid cells. FEBS Journal, 274. , 97.
1.1.
2006
Mäe, M.; Langel, Ü. (2006). Cell-penetrating peptides as vectors for peptide protein and oligonucleotide delivery. Current Opinion in Pharmacology, 6 (5), 509−514.
1.1.
2006
Mazarati, A.; Sollenberg, UE.; Lundström, L.; Shin, D.; Langel, Ü.; Sankar, R. (2006). Regulation of kindling epileptogenesis by hippocampal galanin type 1 and type 2 receptors: the effects of subtype selective ligands and the role of G-protein mediated signaling. Journal of Pharmacology and Experimental Therapeutics, 318 (2), 700−708.
1.1.
2006
Jimenez-Andrade, J.M.; Lundström, L.; Sollenberg, U.; Langel, Ü.; Castaneda-Hernandez, G.; Carlton, S.M. (2006). Activation of peripheral galanin receptors: Differential effects on nociception. Pharmacology Biochemistry and Behavior, 85 (1), 273−280.
1.1.
2006
Järver, P.; Langel, Ü. (2006). Cell-penetrating peptides. A brief introduction. Biochimica et Biophysica Acta - Biomembranes, 1758 (3), 260−263.
1.1.
2006
Lundberg, P.; Langel, Ü. (2006). Uptake mechanism of novel cell-penetrating peptides derived from the Alzheimer´s disease associated gamma-secretase complex. International Journal of Peptide Research and Therapeutics, 12 (2), 105−114.
1.1.
2006
EL-Andaloussi, S.; Johansson, H.; Lundberg, P.; Langel, Ü. (2006). Induction of splice correction by cell-penetrating nucleic acids. Journal of Gene Medicine, 8 (10), 1262−1273.
1.1.
2006
Elmquist, A.; Hansen, M.; Langel, Ü. (2006). Structure-activity relationship study of the cell-penetrating peptide pVEC. Biochimica et Biophysica Acta - Biomembranes, 1758 (6), 721−729.
1.1.
2006
Zeng, F.; Peritz, T.; Kannanayakal, TJ.; Kilk, K.; Eiríksdóttir, E.; Langel, Ü.; Eberwine, J. (2006). A protocol for PAIR: PNA-assisted identification of RNA binding proteins in living cells. Nature Protocols, 1 (2), 920−927. DOI: 10.1038/nprot.2006.81.
1.1.
2006
Peritz, T.; Zeng, F.; Kannanayakal, TJ.; Kilk, K.; Eiríksdóttir, E.; Langel, Ü.; Eberwine, J. (2006). Immunoprecipitation of mRNA-protein complexes. Nature Protocols, 1 (2), 577−580. DOI: 10.1038/nprot.2006.82.
1.1.
2006
Zielinski, J.; Kilk, K.; Peritz, T.; Kannanayakal, T.; Miyashiro, KY.; Eiriksdottir, E.; Jochems, J.; Langel, Ü.; Eberwine, J. (2006). In vivo identification of ribonucleoprotein-RNA interactions. Proceedings of the National Academy of Sciences, 5, 1557−1562.
1.1.
2006
Holm, T.; Johansson, H.; Lundberg, P.; Lindgren, M.; Pooga, M.; Langel, Ü. (2006). Studying the uptake of cell-penetrating peptides. Nature Protocols, 1 (2), 1001−1005. DOI: 10.1038/nprot.2006.174.
1.1.
2006
Lindgren, M.; Rosenthal-Aizman, K.; Saar, K.; Eiriksdottir, E.; Jiang, Y.; Sassian, M.; Ostlund, P.; Hällbrink, M.; Langel, U. (2006). Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochemical Pharmacology, 71 (4), 416−425.
1.2.
2006
Robinson, JK.; Bartfai, T.; Langel, Ü. (2006). Galanin/GALP Receptors and CNS Homeostatic Processes. CNS & Neurological Disorders - Drug Targets, 5 (3), 327−334.
1.2.
2006
Sollenberg, U.E.; Lundström, L.; Bartfai, T.; Langel, Ü. (2006). M871 - a novel peptide antagonist selectively recognizing the galanin receptor type 2. International Journal of Peptide Research and Therapeutics, 12 (2), 115−119. DOI: 10.1007/s10989-005-9008-x.
3.1.
2006
Jiang, Y.; Soomets, U.; Langel, Ü. (2006). Design and synthesis of CPPs. In: Langel, Ü (Ed.). Handbook of Cell-Penetrating Peptides, 2nd Edition (537−551).. CRC Press Inc.
3.1.
2006
Hällbrink, M.; Langel, Ü. (2006). Prediction of cell-penetrating peptides and prodrug approach. In: Langel, Ü. (_EditorsAbbr). Handbook of Cell-Penetrating Peptides, 2nd edition (77−85).. CRC Press Inc.
3.1.
2006
Ganyu, A.; Langel, Ü.; Good, L. (2006). Microbial Membrane Penetrating Peptides and Their Applications. In: Langel, Ü (_EditorsAbbr). Handbook of Cell-Penetrating Peptides, 2nd Edition (515−533).. CRC Press Inc.
3.1.
2006
Lindgren, M., Pooga, M., Langel, Ü. (2006). Methods to Study the Translocation of Cell-Penetrating Peptides. In: Langel, Ü. (Ed.). Handbook of Cell-Penetrating Peptides, Second Edition (567−587). . Boca Raton: CRC Press Inc. (CRC Handbook).
3.1.
2006
Pooga, M., Padari, K., Langel, Ü. (2006). Mechanisms of cargo delivery by transportans. In: Langel, Ü. (Ed.). Handbook of Cell-Penetrating Peptides, Second Edition (183−199). . Boca Raton: CRC Press Inc. (CRC Handbook).
3.1.
2006
EL-Andaloussi, S.; Johansson, H.; Lundberg, P.; Langel, Ü. (2006). Cell-penetrating short interfering RNAs and decoy oligonucleotides. In: Langel, Ü. (_EditorsAbbr). Handbook for cell-penetrating peptides (375−386).. CRC Press Inc.
3.1.
2006
Saar, K.; Langel, Ü. (2006). Toxicity methods for cell-penetrating peptides. In: Langel, Ü. (_EditorsAbbr). Handbook of Cell-Penetrating Peptides, Second Edition (553−565).. CRC Press Inc.
3.1.
2006
El-Andaloussi, S.; Johansson, H.; Lundberg, P.; Langel, Ü. (2006). Decoy and siRNA oligonucleotide as cargo. In: Langel, Ü (_EditorsAbbr). Handbook of Cell-Penetrating Peptides, 2nd Edition (375−386).. CRC Press Inc.
3.1.
2006
Langel, Ü. (2006). Classes and prediction of cell-penetrating peptides. In: Langel, Ü (_EditorsAbbr). Handbook of Cell-Penetrating Peptides, 2nd Edition (1−3).. CRC Press Inc.
5.1.
2006
Säälik, P.; Hansen, M.; Langel, Ü.; Pooga, M. (2006). Actin-dependent CPP-mediated protein cellular delivery takes place via induced endocytosis. Journal of Peptide Science, 12, 236.
5.1.
2006
Padari, K.; Koppel, K.; Hansen, M.; Langel, Ü.; Pooga, M. (2006). Endocytic pathways of transportan-mediated protein cellular delivery. Journal of Peptide Science, 12, 236.
6.7.
2006
Langel, Ü. (2006). Preface. In: Langel, Ü. (_EditorsAbbr). Handbook of Cell-Penetrating Peptides, 2nd Edition (1).. CRC Press Inc.
1.1.
2005
Langel, Ü. (2005). Cell-penetrating peptides, mechanisms and applications. Current Pharmaceutical Design, 11 (28), 3595−3596.
1.1.
2005
Magzoub, M.; Sandgren, S.; Lundberg, P.; Oglecka, K.; Lilja, J.; Wittrup, A.; Eriksson, GLE.; Langel, Ü.; Belting, M.; Gräslund, A. (2005). N-terminal peptides from unprocessed prion proteins enter cells by macropinocytosis. Biochemical and Biophysical Research Communications, 348 (2), 379−385.
1.1.
2005
Brever, A.; Langel, Ü.; Robinson, JK. (2005). Intracerebroventricular administration of galanin decreases free water intake and operant water reinforcer efficacy in water-restricted rats. Neuropeptides, 39 (2), 117−124.
1.1.
2005
Brever, A.; Echevarria, DJ.; Langel, Ü.; Robinson, JK. (2005). Assessment of new functional roles for galanin in the CNS. Neuropeptides, 39 (3), 320−323.
1.1.
2005
Marinova, Z.; Vukojevic, V.; Surcheva, S.; Yakovleva, T.; Cebers, G.; Pasikova, N.; Usynin, I.; Hugonin, L.; Fang, W.; Hallberg, M.; Hirschberg, D.; Bergman, T.; Langel, Ü.; Hauser, KF.; Pramanik, A.; Aldrich, JV.; Gräslund, A.; Terenius, L.; Bakalkin, G. (2005). Translocation of dynorphin neuropeptides across the plasma membrane: a putative mechanism of signal transmission. Journal of Biological Chemistry, 280 (28), 26360−26370.
1.1.
2005
Echevarria, D.J.; Brewer, A.; Bushell, G.; Manuzon, H.; Langel, Ü.; Robinson, J.K. (2005). Galanin and perseveration. Brain Research, 1041 (2), 143−148.
1.1.
2005
Zorko, M.; Langel, Ü. (2005). Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Advanced Drug Delivery Reviews, 57 (4), 529−545.
1.1.
2005
Parenteau, J.; Klinck, R.; Good, L.; Langel, Ü.; Wellinger, R.J.; Elela, S.A. (2005). Free uptake of cell-penetrating peptides in fission yeast. FEBS Letters, 579 (21), 4873−4878.
1.1.
2005
Stahl, A.; Nilsson, S.; Lundberg, P.; Bhushan, S.; Biverstahl, H.; Moberg, P.; Morisset, M.; Vener, A.; Mäler, L.; Langel, Ü. (2005). Two novel targeting peptide degrading proteases, PrePs, in mitochondria and chloropast: so similar and still different. Journal of Molecular Biology, 349 (4), 847−860.
1.1.
2005
Sollenberg, U.; Bartfai, T.; Langel, Ü. (2005). Galnon - a low-molecular weight ligand of the galanin receptors. Neuropeptides, 39 (3), 161−163.
1.1.
2005
Sato, M.; Hutchinson, DS.; Bengtsson, T.; Floren, A.; Langel, Ü.; Horinouchi, T.; Evans, B.A:; Summers, R. (2005). Functional domains of the mouse beta3-adrenoceptor associated with differential G protein coupling. Journal of Pharmacology and Experimental Therapeutics, 315 (3), 1354−1361.
1.1.
2005
EL-Andaloussi, S.; Johansson, H.; Magnusdottir, A.; Järver, P.; Lundberg, P.; Langel, Ü. (2005). TP10, a delivery vector for decoy oligonucleotides targeting the Myc protein. Journal of Controlled Release, 110 (1), 189−201.
1.1.
2005
EL-Andaloussi, S.; Holm, T.; Langel, Ü. (2005). Cell-penetrating peptides: Mechanisms and Applications. Current Pharmaceutical Design, 11 (28), 3597−3611.
1.1.
2005
Lundström, L.;Sollenberg, U.; Brewer, A.; Kouya, PF.; Zheng, K.; Xu, XJ.; Xia, S.; Robinson, JK.; Wiesenfeld-Hallin, Z.; Xu, ZQ.; Hökfelt, T.; Bartfai, T.; Langel, Ü. (2005). A Galanin Receptor Subtype 1 Specific Agonist. International Journal of Peptide Research and Therapeutics, 11 (1), 17−27.
1.1.
2005
Lu, X.; Lundström, L.; Langel, Ü.; Bartfai, T. (2005). Galanin Receptor Ligands. Neuropeptides, 39 (3), 165−167.
1.1.
2005
Lundström, L.; Elmquist, A.; Bartfai, T.; Langel, Ü. (2005). Galanin and its receptors in neurological disorders. NeuroMolecular Medicine, 7, 157−180.
1.1.
2005
Lundström, L.; Lu, X.; Langel, Ü.; Bartfai, T. (2005). Important pharmacophores for binding to galanin receptor 2. Neuropeptides, 39 (3), 169−171.
1.1.
2005
Holm, T.; Netzereab, S.; Hansen, M.; Langel, Ü.; Hällbrink, M. (2005). Uptake of cell-penetrating peptides in yeasts. FEBS Letters, 579 (23), 5217−5222.
1.1.
2005
Ostlund, P.; Kilk, K.; Lindgren, M.; Hallbrink, M.; Jiang, Y.; Budihna, M.; Cerne, K.; Bavec, A.; Ostenson, CG.; Zorko, M.; Langel, U. (2005). Cell-penetrating mimics of agonist-activated G-protein coupled receptors. International Journal of Peptide Research and Therapeutics, 11 (4), 237−247.
1.1.
2005
Kilk, K.; El-Andaloussi, S.; Jarver, P.; Meikas, A.; Valkna, A.; Bartfai, T.; Kogerman, P.; Metsis, M.; Langel, U. (2005). Evaluation of transportan 10 in PEI mediated plasmid delivery assay. Journal of Controlled Release, 103 (2), 511−523. DOI: 10.1016/j.jconrel.2004.12.006.
1.1.
2005
Mae, M.; Myrberg, H.; Jiang, Y.; Paves, H.; Valkna, A.; Langel, U. (2005). Internalisation of cell-penetrating peptides into tobacco protoplasts. Biochimica et Biophysica Acta - Biomembranes, 1669 (2), 101−107.
1.1.
2005
Saar, K.; Lindgren, M.; Hansen, M.; Eiriksdottir, E.; Jiang, Y.; Rosenthal-Aizman, K.; Sassian, M.; Langel, U. (2005). Cell-penetrating peptides: A comparative membrane toxicity study. Analytical Biochemistry, 345 (1), 55−65.
1.1.
2005
Hallbrink, M.; Kilk, K.; Elmquist, A.; Lundberg, P.; Lindgren, M.; Jiang, Y.; Pooga, M.; Soomets, U.; Langel, U. (2005). Prediction of cell-penetrating peptides. International Journal of Peptide Research and Therapeutics, 11 (4), 249−259.
1.1.
2005
Floren, A.; Sollenberg, U.; Lundstrom, L.; Zorko, M.; Stojan, J.; Budihna, M.; Wheatley, M.; Martin, NP.; Kilk, K.; Mazarati, A.; Bartfai, T.; Lindgren, M.; Langel, U. (2005). Multiple interaction sites of galnon trigger its biological effects. Neuropeptides, 39 (6), 547−558.
1.1.
2005
Padari, K.; Saalik, P.; Hansen, M.; Koppel, K.; Raid, R.; Langel, Ü.; Pooga, M. (2005). Cell transduction pathways of transportans. Bioconjugate Chemistry, 16 (6), 1399−1410.
1.2.
2005
Zilmer, M.; Soomets, U.; Rehema, A.; Langel, Ü. (2005). The glutathione system as an attractive therapeutic target. Drug Design Reviews - Online, 2 (2), 121−127.
1.2.
2005
Soomets, U.; Zilmer, M.; Langel, Ü. (2005). Manual solid-phase synthesis of glutathione analogs: a laboratory-based short course. Methods in molecular biology, 298, 241−257.
1.2.
2005
Kilk, K.; Langel, U. (2005). Cellular delivery of peptide nucleic acid by cell-penetrating peptides. Methods in molecular biology, 298, 131−141.
3.1.
2005
Pooga, M.; Langel, Ü. (2005). Synthesis of cell penetrating peptides for cargo delivery. In: Howl, John (Ed.). Peptide Synthesis and Applications (77−90). . Totowa, NJ: Humana Press. (Methods in Molecular Biology; 298).
5.1.
2005
Pooga, M., Padari, K., Säälik, P., Koppel, K., Hansen, M., Raid, R., Langel, Ü. (2005). Mechanisms of protein cellular delivery with transportans. FEBS Journal, 272 (Suppl. 1), 525.
5.2.
2005
Ehrlich, K.; Mahlapuu, R.; Viirlaid, S.; Zilmer, M.; Langel, Ü.; Soomets, U. (2005). Antioxidative properties of novel antioxidant UPF1 and its analogues. 1st BBBB Conference on Pharmaceutical Sciences, Siofok, Hungary,September 26-28. 132−133.
1.1.
2004
Nekhotiaeva, N.; Elmquist, A.; Rajarao, GK.; Hällbrink, M.; Langel, Ü.; Good, L. (2004). Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. The FASEB Journal, 18 (2), 394−396.
1.1.
2004
Lindgren, M.; Hällbrink, M.; Elmquist, A.; Langel, Ü. (2004). Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. Biochemical Journal, 377 (1), 69−76.
1.1.
2004
Brever, A.; Langel, Ü.; Robinson, JK. (2004). Intracerebroventricularly administered galanin does not alter operant reaction time of differentially reinforced high rate schedule operant responding in rats. Neuroscience Letters, 369 (3), 245−249.
1.1.
2004
Järver, P.; Langel, Ü. (2004). The use of cell-penetrating peptides in gene regulation. Drug Discovery Today, 9 (9), 395−402.
1.1.
2004
Jiang, Y.; Sassian, M.; Langel, Ü. (2004). Synthesis and applications of cell-penetrating peptide-PNA conjucate. Chimica Oggi-Chemistry Today, 22, 36−39.
1.1.
2004
Poder, P.; Zilmer, M.; Starkopf, J.; Kals, J.; Talonpoika, A.; Pulges, A.; Langel, U.; Kullisaar, T.; Viirlaid, S.; Mahlapuu, R.; Zarkovski, A.; Arend, A.; Soomets, U. (2004). An antioxidant tetrapeptide UPF1 in rats has a neuroprotective effect in transient global brain ischemia. Neuroscience Letters, 370 (1), 45−50.
1.1.
2004
Saalik, P.; Elmquist, A.; Hansen, M.; Padari, K.; Saar, K.; Viht, K.; Langel, V.; Pooga, M. (2004). Protein cargo delivery properties of cell-penetrating peptides. A comparative study. Bioconjugate Chemistry, 15 (6), 1246−1253.
1.1.
2004
Kilk, K.; Elmquist, A.; Saar, K.; Pooga, M.; Land, T.; Bartfai, T.; Soomets, U.; Langel, U. (2004). Targeting of antisense PNA oligomers to human galanin receptor type 1 mRNA. Neuropeptides, 38 (5), 316−324.
1.1.
2004
Fisher, L.; Soomets, U.; Toro, V.C.; Chilton, L.; Jiang, Y.; Langel, U.; Iverfeldt, K. (2004). Cellular delivery of a double-stranded oligonucleotide NF kappa B decoy by hybridization to complementary PNA linked to a cell-penetrating peptide. Gene Therapy, 11 (16), 1264−1272.
1.1.
2004
Mazarati, A.; Lu, X.; Kilk, K.; Langel, U.; Wasterlain, C.; Bartfai, T. (2004). Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. European Journal of Neuroscience, 19 (12), 3235−3244.
1.1.
2004
Hua, X.Y.; Hayes, C.S.; Hofer, A.; Fitzsimmons, B.; Kilk, K.; Langel, U.; Bartfai, T.; Yaksh, T.L. (2004). Galanin acts at GalR1 receptors in spinal antinociception: synergy with morphine and AP-5. Journal of Pharmacology and Experimental Therapeutics, 308 (2), 574−582.
1.2.
2004
Eiríksdottir, E.; Myrberg, H.; Hansen, M.; Langel, Ü. (2004). Cellular Uptake of Cell-Penetrating Peptides. Drug Design Reviews - Online, 1 (2), 161−173.
3.2.
2004
Johansson, H.J.; Järver, P.; Langel, U. (2004). Cell penetrating peptides and their application in gene regulation. In: Epton, R. (_EditorsAbbr). Innovation and Perspectives in Solid Phase Synthesis & Combinatorial Chemical Libraries. Proceedings of the 8th International Symposium (123−128).. London, England, UK: Mayflower Worldwide.
5.1.
2004
Fisher, L.; Samuelsson, M.; Toro, V. C.; Soomets, U.; Yang, J.; Langel, Ü.; Iverfeldt, K. (2004). Downregulation of Abeta-induced cytokine expression in glial cells using NFkappaB decoy. Journal of Neuroimmunology, 154, 31−31.
5.2.
2004
Mahlapuu, R.; Soomets, U.; Bogdanovic, N.; Zilmer, M.; Karelson, E.; Langel, Ü. (2004). Modulating G-proteins and adenylate cyclase activity by amyloid precursor protein carboxy-terminal fragments and amyloid b-peptide. 34th Ann Meeting Soc Neurosci.. San Diego.
6.6.
2004
Mahlapuu, R., Soomets, U., Zilmer, M., Langel, Ü. (2004). Alzheimeri tõve molekulaarsed alused: osalevad valgud ja peptiidid: uued ravistrateegiad. Lege Artis, 8 (32), 10−14.
1.1.
2003
Zachariou, V.; Brunzell, DH.; Hawes, J.; Stedman, DB.; Bartfai, T.; Bartfai, T.; Steiner, R.; Wynick, D.; Langel, Ü. (2003). The neuropeptide galanin modulates behavioral and neurochemical signs of opiate withdrawal. Proceedings of the National Academy of Sciences of the United States of America, 100 (15), 9028−9033.
1.1.
2003
Wu, WP.; Hao, JX.; Lundström, L.; Wiesenfeld-Hallin, ZS.; Langel, Ü.; Bartfai, T.; Xu, XJ. (2003). Systemic galnon, a low-molecular weight galanin agonist, reduces heat hyperalgesia in rats with nerve injury. European Journal of Pharmacology, 482, 133−137.
1.1.
2003
Elmquist, A.; Langel, Ü. (2003). In vitro uptake and stability study of pVEC and its all-D-analoque. Biological Chemistry, 384 (3), 387−393.
1.1.
2003
Bavec, J.; Hällbrink, M.; Olsson, M.; Langel, Ü.; Zorko, M. (2003). Different role of intracellular loops of glucagon-like peptide-1 receptor in G-protein coupling. Regulatory Peptides, 111, 137−144.
1.1.
2003
Lundberg, P.; Langel, Ü. (2003). A brief introduction to cell-penetrating peptides. Journal of Molecular Recognition, 16 (5), 227−233.
1.1.
2003
Howitt, S. G.; Kilk, K.; Wang, Y.; Smith, D. M.; Langel, U.; Poyner, D. R. (2003). The role of the 8-18 helix of CGRP8-37 in mediating high affinity binding to CGRP receptors; coulombic and steric interactions. British Journal of Pharmacology, 138 (2), 325−332.
1.1.
2003
Adlerz, L.; Soomets, U.; Holmlund, L.; Viirlaid, S.; Langel, U.; Iverfeldt, K. (2003). Down-regulation of amyloid precursor protein by peptide nucleic acid oligomer in cultured rat primary neurons and astrocytes. Neuroscience Letters, 336 (1), 55−59.
1.1.
2003
Mahlapuu, R.; Viht, K.; Balaspiri, L.; Bogdanovic, N.; Saar, K.; Soomets, U.; Land, T.; Zilmer, M.; Karelson, E.; Langel, U. (2003). Amyloid precursor protein carboxy-terminal fragments modulate G-proteins and adenylate cyclase activity in Alzheimer's disease brain. Molecular Brain Research, 117 (1), 73−82.
1.1.
2002
Conner, A. C.; Hay, D. L.; Howitt, S. G.; Kilk, K.; Langel, U.; Wheatley, M.; Smith, D. M.; Poyner, D. R. (2002). Interaction of calcitonin-gene-related peptide with its receptors. Biochemical Society Transactions, 30 (4), 451−455.
1.1.
2002
Lundberg, P.; Magzoub, M.; Lindberg, M.; Hällbrink, M.; Jarvet, J.; Eriksson, L.E.G.; Langel, Ü.; Gräslund, A. (2002). Cell membrane translocation of the N-terminal (1–28) part of the prion protein. Biochemical and Biophysical Research Communications, 299 (1), 85−90.
1.1.
2002
Karelson, E.; Mahlapuu, R.; Zilmer, M.; Soomets, U.; Bogdanovic, N.; Langel, U. (2002). Possible signaling by glutathione and its novel analogue through potent stimulation of frontocortical G proteins in normal aging and in Alzheimer's disease. Annals of the New York Academy of Sciences, 973, 537−540.
1.1.
2002
Östenson, CG.; Sandberg-Nordquist, AC.; Chen, J.; Hällbrink, M.; Rotin, D.; Langel, Ü.; Efendic, S. (2002). Overexpression of protein-tyrosine phosphotase PTPo is linked to impaired glucose-induced insulin secretion in hereditary diabetic Goto-Kakizaki rats. Biochemical and Biophysical Research Communications, 291 (4), 945−950.
1.1.
2002
Suzuki, H.; iwanaga, T.; Yoshie, H.; Yamabe, K.; Yanaihara, N., Langel, Ü.; Maeda, T. (2002). Expression of galanin receptor 1 (GALR1) in the rat trigeminal ganglia and molar teeth. Neuroscience Research, 42 (3), 197−207.
1.1.
2002
Farquhar, M.; Soomets, U.; Bates, R.L.; Martin, A.; Langel, Ü.; Howl, J. (2002). Novel mastoparan analogs induce differential secretion from mast cells. Chemistry & Biology, 9 (1), 63−70.
3.1.
2002
Valkna, A.; Soomets, U.; Langel, Ü. (2002). Transport peptides as carriers of oligonucleotides. In: Langel, Ü. (_EditorsAbbr). Cell penetrating peptides: processes an applications (347−363).. Boca Raton, FL: CRC Press Inc. (Pharmacology & Toxicology Series).
3.1.
2002
Pooga, M.; Elmquist, A.; Langel, Ü. (2002). Toxicity and biological effects of CPP. In: Langel, Ü. (Ed.). Cell penetrating peptides : processes and applications (245−262). . Boca Raton, FL: CRC Press Inc.
3.1.
2002
Pooga, M.; Hällbrink, M.; Langel, Ü. (2002). Transportans. In: Langel, Ü. (Ed.). Cell penetrating peptides : processes and applications (53−70). . Boca Raton, FL: CRC Press Inc.
3.1.
2002
Hällbrink, M.; Langel, Ü. (2002). Comparison of gargo delivery efficiency of cell-penetrating peptides. In: Epton, R. (_EditorsAbbr). Innovation and Perspectives in Solid phase Synthesis and Combinatorial Libraries (165−168).. Southampton: Mayflower Worldwide.
3.1.
2002
Kahl, U.; Langel, Ü.; Bartfai, T. (2002). Galanin Receptors. In: Pangalos, MN.; Davies, CH. (_EditorsAbbr). Understanding G-protein receptors and their role in the CNS (286−306).. Oxford Univ Press.
3.1.
2002
Lindgren, M.; Hällbrink, M.; Langel, Ü. (2002). Quantification of cell-penetrating peptides and their cargoes. In: Langel, Ü. (_EditorsAbbr). Cell penetrating Peptides. Processes and Applications (263−275).. CRC Press Inc.
3.1.
2002
Zorko, M.; Hällbrink, M.; Langel, Ü. (2002). Kinetics of uptake of cell-penetrating peptides. In: Langel, Ü (_EditorsAbbr). Cell Penetrating Peptides. Processes and Applications (277−293).. CRC Press Inc.
3.1.
2002
Valkna, A.; Soomets, U.; Langel, Ü. (2002). Cell-penetrating peptides as vectors for delivery of nucleic acids. In: Langel, Ü. (Ed.). Cell Penetrating Peptides. Processes and Applications (347−363).. New York: CRC Press Inc.
3.1.
2002
Pooga, M.; Soomets, U.; Bartfai, T.; Langel, Ü. (2002). Synthesis of cell-Penetrating peptide-PNA constructs. In: Nielsen, P. (Ed.). Peptide nucleic acids: methods and protocols (225−236). . Totowa, NJ: Human Press. (Methods in molecular biology; 208).
3.1.
2002
Langel, Ü. (2002). Preface, in Cell Penetrating Peptides. Processes and Applications. Cell Penetrating Peptides. Processes and Applications (x−x).. CRC Press Inc.
1.1.
2001
Hällbrink, M.; Floren, A.; Elmquist, A.; Pooga, M.; Bartfai, T.; Langel, Ü. (2001). Cargo delivery kinetics of cell-penetrating peptides. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1515 (2), 101−109.
1.1.
2001
Lindberg, M.; Jarvet, J.; Langel, Ü.; Gräslund, A. (2001). Secondary Structure and Position of the Cell-Penetrating Peptide Transportan in SDS Micelles As Determined by NMR. Biochemistry, 40 (10), 3141−3149.
1.1.
2001
Saar, K.; Mahlapuu, R.; Laidmae, E.; Valkna, A.; Kahl, U.; Karelson, E.; Langel, U. (2001). Characterisation of a new chimeric ligand for galanin receptors: galanin(1-13)-[D-Trp(32)]-neuropeptide Y(25-36) amide. Regulatory Peptides, 102 (1), 15−19.
1.1.
2001
Toro, VC.; Tehranian, R.; Zetterström, M.; Eriksson, G.; Langel, Ü.; Bartfai, T.; Iverfeldt, K. (2001). Increased gene expression of interleukin-1alfa and interleukin-6 in rat primary glial cells induced by b-amyloid fragment. Journal of Molecular Neuroscience , 17 (3), 341−350.
1.1.
2001
Hällbrink, M.; Holmqvist, T.; Olsson, M.; Östenson, CG.; Efendic, S.; Langel, Ü. (2001). Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Galfas and Galfai/Galfao activation. Biochimica et Biophysica Acta, 1546 (1), 79−86.
1.1.
2001
Elmquist, A.; Lindgren, M.; Bartfai, T.; Langel, Ü. (2001). VE-cadherin derived cell-penetrating peptide, pVEC, with carrier function. Experimental Cell Research, 269, 237−244.
1.1.
2001
Balaspiri, L.; Langel, Ü. (2001). Synthesis of b-amyloid precursor peptide and presenilin segments. Journal of Peptide Science, 7 (1), 58−60.
1.1.
2001
Mazarati, A.; Langel, Ü.; Bartfai, T. (2001). Galanin: an endogenous anticonvulsant? Neuroscientist, 7 (6), 506−517.
1.1.
2001
Pramanik, A.; Olsson, M.; Langel, Ü.; Bartfai, T. (2001). Fluorescence correlation spectroscopydetects galanin receptor diversity on insulinoma cells. Biochemistry, 40 (36), 10839−10845.
1.1.
2001
Yakovleva, T.; Pramanik, A.; kawasaki, T.; Tan-No, K.; Gileva, I.; Lindegren, H.; Langel, Ü.; Ekström, TJ.; Rigler, R.; Terenius, L.; Bakalkin, G. (2001). p53 Latency: C-terminal domain prevents binding of p53 core to target but not to nonspecific DNA sequence. Journal of Biological Chemistry, 276 (19), 15650−15658.
1.1.
2001
Berglund, M.M; Saar, K.; Lundell, I.; Langel, U.; Larhammar, D. (2001). Binding of chimeric NPY/galanin peptides M32 and M242 to cloned neuropeptide Y receptor subtypes Y1, Y2, Y4 and Y5. Neuropeptides, 35, 148−153.
1.2.
2001
Pooga, M.; Langel, Ü. (2001). Targeting of cancer-related proteins with PNA oligomers. Current Cancer Drug Targets, 1 (3), 231−239.
1.3.
2001
Magzoub, M.; Kilk, K.; Eriksson, G.; Langel, Ü.; Gräslund, A. (2001). Interaction and structure induction of cell-penetrating peptides in the presence of phospholipid vesicles. Biochimica et Biophysica Acta, 1512(1) (2), 77−89.
3.4.
2001
Brown, J.; Howl, J.; Martin, A.; Soomets, U.; Langel, Ü.; Brown, C. (2001). Single amino-acid substitutions in a mimetic tetradecapeptide agonist of the human P2Y2 receptor prevent second messenger activation. Peptides 2000: European Peptide Symposium; Montpellier, France; 10.-15.09.2000. Ed. Martinez, J.; Fehrentz, J.A. Paris: EDK, 913−914.
3.4.
2001
Farquhar, M.; Soomets, U.; Brown, C.; Martin, A.; Bates, R.; Langel, Ü.; Howl, J. (2001). Venomous chimeric secretagogues. Peptides 2000: European Peptide Symposium; Montpellier, France; 10.-15.09.2000. Ed. Martinez, J.; Fehrentz, J.A. Paris: EDK, 633−634.
5.1.
2001
Lindner, AB.; Danon, T.; Sanden, B.; mansson, P.; langel, Ü.; berkovich, E.; Sheradsky, T.; Willner, I.; Eshhar, Z. (2001). High affinity metamphetamine antibodies for sensitive detection of amphetamine type substances. Proceedings, 2001 ONDCP International Technology Symposium: ONDCP International Technology Symposium, San Diego, June 25-28, 2001. San Diego State University Press, 504−510.
1.1.
2000
Lindgren, M.; Hällbrink, M.; Prochiantz, A.; Langel, Ü. (2000). Cell penetrating peptides. Trends in Pharmacological Sciences, 21 (3), 99−103.
1.1.
2000
Floren, A.; Land, T.; Langel, Ü. (2000). Galanin receptor subtypes and ligand binding. Neuropeptides, 34 (6), 331−337.
1.1.
2000
Rezaei, K.; Saar, K.; Soomets, U.; Valkna, A.; Nasman, J.; Zorko, M.; Akerman, K.; Schroeder, T.; Bartfai, T.; Langel, U. (2000). Role of third intracellular loop of galanin receptor type 1 in signal transduction. Neuropeptides, 34 (1), 25−31.
3.1.
2000
Poyner, D.; Howitt, S.; Soomets, U.; Langel, Ü. (2000). Structure activity relationship for CGRP receptor ligands. In: The CGRP family: Calcitonin Gene-related peptide (CGRP) , amylin and adrenomedullin. In: Poyner, D.; Marshall, SD.; Brain, SD. (_EditorsAbbr). Molecular Biology Intelligence Unit 10 (25−32).. Texas, USA: Landes Bioscience.
3.2.
2000
Poyner, D.R.; Howitt, S.; Soomets, U.; Langel, Ü. (2000). Structure activity relationship for CGRP receptor ligands. In: Poyner, D.; Marshall, I.; Brain, S.D. (Ed.). The CGRP family: Calcitonin Gene-Related Peptide (Cgrp), Amylin, & Adrenomedullin (25−32).. Georgetown: Landes Bioscience.
3.2.
2000
Soomets, U.; Kilk, K.; Land, T.; Langel, Ü. (2000). Transportan, its analogues and their applications. Innovation and Perspectives in Solid Phase Synthesis and Combinatorial Libraries: Peptides, Proteins and Nucleic Acids. Proceedings of the 5th International Symposium, London. Ed. Epton, R. Kingswinford, England: Mayflower Worldwide, 131−136.
1.1.
1999
Bavec, B.; Jureus, A.; Cigic, B.; Langel, Ü.; Zorko, M. (1999). Peptitergent PD1 affects the GTPase activity of rat brain cortical membranes. Peptides, 20 (2), 177−184.
1.1.
1999
Hallbrink, M.; Saar, K.; Ostenson, CG.; Soomets, U.; Efendic, S.; Howl, J.; Wheatley, M.; Zorko, M.; Langel, U. (1999). Effects of vasopressin-mastoparan chimeric peptides on insulin release and G-protein activity. Regulatory Peptides, 82, 45−51.
1.1.
1999
Xu, ZQD.; Ma, XS.; Soomets, U.; Langel, U.; Hokfelt, T. (1999). Electrophysiological evidence for a hyperpolarizing, galanin (1-15)-selective receptor on hippocampal CA3 pyramidal neurons. Proceedings of the National Academy of Sciences of the United States of America, 96 (25), 14583−14587.
1.1.
1999
Soomets, U.; Mahlapuu, R.; Tehranian, R.; Jarvet, J.; Karelson, E.; Zilmer, M.; Iverfeldt, K.; Zorko, M.; Graslund, A.; Langel, U. (1999). Regulation of GTPase and adenylate cyclase activity by amyloid beta-peptide and its fragments in rat brain tissue. Brain Research, 850, 179−188.
1.2.
1999
Pramanik, A.; Jureus, A.; Langel, Ü.; Bartfai, T.; Rigler, R. (1999). Galanin receptor binding studies in the membranes of cultured cells measured by florescence correlation spectroscopy. Biomed Chromatogr, 13 (2), 119−120.
1.2.
1999
Soomets, U.; Hälbrink, M; Langel, Ü. (1999). Antisence properties of peptide nucleic acids. Frontiers in Bioscience (FBS), 4, D782−D786.
3.1.
1999
Soomets, U.; Langel, Ü. (1999). Intracellular third loop of galanin receptor as G-protein interaction site. In: Tam, JP.; Kaumaya, PTP (_EditorsAbbr). Frontiers in Peptide Science (662−663).. London: Kluwer Academic Publishers.
3.1.
1999
Soomets, U.; Langel, Ü. (1999). Intracellular third loop of galanin receptor as G-protein interaction site. Peptides. Frontiers of Peptide Science: 15th American Peptide Symposium; Nashville, Tennessee; 14.-19.06.1997. Ed. Tam, J.P.; Kauyama, P.T.P. Dodrecht: Kluwer Academic Publishers, 662−663.
6.2.
1999
Soomets, U.; Zilmer, M.; Starkopf, J.; Karelson, E.-R.; Vihalemm, T.; Zilmer, K.; Sillard, R.; Bourne, J; Langel, Ü. (1999). Selected knowledge for medical biochemistry. Tartu: Tartu Ülikooli Kirjastus.
1.1.
1998
Klimenko, VM.; Lioudyno, VI.; Langel, Ü.; Krasnova, IN.; Abdurasulova, IN. (1998). Contribution of galaninergic structures of the brain to reaction to lipopolysaccharide. Bull Exp Biol Med (Moscow), 125 (4), 380−383.
1.1.
1998
Öhman, A.; Lycksell, PO.; Jureus, A.; Langel, Ü.; Bartfai, T.; Gräslund, A. (1998). NMR study of the conformation and localisation of porcine galanin in SDS micelles. Biochemistry, 37 (25), 9169−9178.
1.1.
1998
Parker, D.; Söderberg, C.; Zotova, E.; Shupliakov, O.; Langel, Ü.; Bartfai, T.; larhammar, D.; Brodin, L.; Grillner, S. (1998). Co-localized neuropeptide Y and GABA have complementary presynaptic effects on sensory synaptic transmission. European Journal of Neuroscience, 10 (9), 2856−2870.
1.1.
1998
Jureus, A.; Lindgren, M.; Langel, Ü.; Bartfai, T. (1998). Purification of a galanin degrading 70 kDa metallopeptidase from bovine spinal cord. Neuropeptides, 32 (5), 453−460.
1.1.
1998
Pooga, M.; Lindgren, M.; Hällbrink, M.; Bråkenhielm, E.; Langel, Ü. (1998). Galanin-Based Peptides, Galparan and Transportan, with Receptor-Dependent and Independent Activities. Annals of New York Academy of Sciences, 863, 450−453.
1.1.
1998
Pooga, M.; Hällbrink, M.; Zorko, M.; Langel, Ü. (1998). Cell penetration by transportan. The FASEB Journal, 12 (1), 67−77.
1.1.
1998
Bavec, A.; Soomets, U.; Langel, U.; Zorko, M. (1998). Structural features of amphipathic peptides required for the activation of G-proteins. Acta Chimica Slovenica, 45 (1), 27−34.
1.1.
1998
Karelson, E.; Langel, U. (1998). Galaninergic signalling and adenylate cyclase. Neuropeptides, 32 (3), 197−210.
1.1.
1998
Mazarati, AM.; Liu, HT.; Soomets, U.; Sankar, R.; Shin, D.; Katsumori, H.; Langel, U.; Wasterlain, CG. (1998). Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. Journal of Neuroscience, 18 (23), 10070−10077.
1.1.
1998
Poyner, DR.; Soomets, U.; Howitt, SG.; Langel, U. (1998). Structural determinants for binding to CGRP receptors expressed by human SK-N-MC and Col 29 cells: studies with chimeric and other peptides. British Journal of Pharmacology, 124 (8), 1659−1666.
1.1.
1998
Pooga, M.; Soomets, U.; Hallbrink, M.; Valkna, A.; Saar, K.; Rezaei, K.; Kahl, U.; Hao, JX.; Xu, XJ.; Wiesenfeld-Hallin, Z.; Hokfelt, T.; Bartfai, A.; Langel, U. (1998). Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nature Biotechnology, 16 (9), 857−861.
1.2.
1998
Soomets, U.; Mahlapuu, R.; Karelson, E.; Zilmer, M.; Zorko, M.; Langel, Ü. (1998). Regulation of activity of GTPase and adenylate cyclase in the rat ventral hippocampus by fragments of b-amyloid. Clinical Neuroscience, 51 (1), 59−60.
1.2.
1998
Soomets, U.; Hällbrink, M.; Zorko, M.; Langel, Ü. (1998). From galanin and mastoparan to galparan and transportan. Current Topics in Peptide and Protein Research, 2, 83−113.
1.2.
1998
Longland, C.; Mezna, M.; Langel, Ü.; Hällbrink, M.; Soomets, U.; Wheatley, M.; Michelangeli, F.; Howl, J. (1998). Biochemical mechanisms of calcium mobilisation induced by mastoparan and chimeric hormone-mastoparan constructs. Cell Calcium, 24 (1), 27−34.
1.2.
1998
Langel, Ü.; Bartfai, T. (1998). Chemistry and molecularbiology of galanin receptor ligands. Annals of New York Academy of Sciences, 863, 86−93.
1.2.
1998
Kask, K.; Berthold, M.; Kahl, U.; Jureus, A.; Nordvall, G.; Langel, Ü.; Bartfai, T. (1998). Mutagenesis study of human galanin receptor GalR1 reveals domains involved in ligand binding. Annals of New York Academy of Sciences, 863, 78−85.
1.2.
1998
Xu, Z.Q.D.; Bartfai, T.; Langel, Ü.; Hökfelt, T. (1998). Effects of three galanin analogues on the outward current evoked by galanin in locus coeruleus. Annals of New York Academy of Sciences, 863, 459−465.
5.2.
1998
Langel, Ü.; Soomets, U.; Mahlapuu, R.; Karelson, E.; Zilmer, M.; Zorko, M. (1998). Regulation of GTPase and adenylate cyclase by amyloid-peptides. The 6th International Conference on Alzheimer's Disease and Related Disorders. Neurobiology of Aging, 19, S48.
6.2.
1998
Soomets, U.; Karlström, A.; Zilmer, M.; Langel, Ü. (1998). Solid phase peptide synthesis of glutathione and its analogs by Fmoc- and tert-Boc-Chemistry (second edition). In: .. Tartu : Tartu University Press.
6.2.
1998
Soomets, U.; Karlström, A.; Zilmer, M.; Langel, Ü. (1998). Solid phase peptide synthesis of glutathione and its analogs by Fmoc- and tert-Boc-chemistry. Manual for laboratory course. Tartu: Tartu University Press.
1.1.
1997
Östenson, CG.; Zaitsev, S.; Berggren, PO.; Efendic, S.; Langel, Ü.; Bartfai, T. (1997). Galparan: a powerfulinsulin releasing chimeric peptide acting at novel site. Endocrinology, 138 (8), 3308−3313.
1.1.
1997
Hianik, T.; Kaatze, U.; Sargent, DF.; Krivanek, R.; Halstenberg, S.; Pieper, W.; Gaburjakova, J.; Gaburjakova, M.; Pooga, M.; Langel, Ü. (1997). A study of interaction of some neuropeptides and their analogs with bilayer lipid membranes and liposomes. Bioelectrochemistry and Bioenergetics, 42 (2), 123−132.
1.1.
1997
Berthold, M.; Kahl, U.; Jureus, A.; kask, K.; Langel, Ü.; Nordvall, G.; Bartfai, T. (1997). Mutagenesis and ligand modification study on galanin binding to its GTP-binding-protein-coupled receptor GalR1. European Journal of Biochemistry, 249 (2), 601−606.
1.1.
1997
Kulinski, T.; Wennerberg, AB.; Rigler, R.; Provencher, SW.; Pooga, M.; Langel, Ü.; Bartfai, T. (1997). Conformational analysis of galanin using end to end distance distribution observed by Forster resonance energy transfer. European Biophysics Journal with Biophysics Letters, 26 (2), 145−154.
1.1.
1997
Jureus, A.; Langel, Ü.; Bartfay, T. (1997). L-Ala substituted rat galanin receptor subtypes. Journal of Peptide Research, 49 (3), 195−200.
1.1.
1997
Howl, J.; Langel, Ü.; Wheatley, M. (1997). Chimeric hormones and neuropeptides. Clinical Science, 93 (6), 605−606.
1.1.
1997
Consolo, S.; Baldi, G.; Nannini, L.; Uboldi, M.C.; Pooga, M.; Langel, Ü.; Bartfai, T. (1997). Galparan induces in vivo acetylcholine release in the frontal cortex. Brain Research, 756, 174−178.
1.1.
1997
Howl, J.; Langel, U.; Hawtin, S.R.; Valkna, A.; Yarwood, N.J.; Saar, K.; Wheatley, M. (1997). Chimeric strategies for the rational design of bioactive analogs of small peptide hormones. The FASEB Journal, 11 (7), 582−590.
1.1.
1997
Soomets, U.; Kairane, C.; Zilmer, M.; Langel, U. (1997). Attempt to solubilize Na+/K+-exchanging ATPase with amphiphilic peptide PD1. Acta Chemica Scandinavica, 51 (3), 403−406.
1.1.
1997
Saar, K.; Valkna, A.; Soomets, U.; Rezaei, K.; Zorko, M.; Zilmer, M.; Langel, U. (1997). Role of the third cytoplasmic loop in signal transduction by galanin receptors. Biochemical Society Transactions, 25 (3), 1036−1040.
1.2.
1997
Soomets, U.; Hällbrink, M.; Zorko, M.; Langel, Ü. (1997). From galanin and mastoparan to galparan and transportan. Current Topics in Peptide and Protein Research, 2, 83−113.
1.2.
1997
Mezna, M.; Langel, Ü.; Hällbrink, M.; Wheatley, M.; Michelangeli, M.; Howl, J. (1997). Calcium-mobilizing actions of chimeric hormone-mastoparan peptides. Biochemical Society Transactions, 25 (2), 450S.
1.1.
1996
Öhman, A.; Davydov, R.; Backlund, BM.; Langel, Ü.; Gräslund, A. (1996). A study of melittin, motilin and galanin in reversed micellar environments, using circular dichroism spectroscopy. Biophysical Chemistry, 59, 185−192.
1.1.
1996
Grundemar, L.; Kahl, U.; Callreus, T.; langel, Ü.; Bienert, M.; Beyermann, M. (1996). Ligand binding and functional effects of systematic double D-amino acid residue substituted neuropeptide Y analogs of Y1 and Y2 receptor types. Regulatory Peptides, 62, 131−136.
1.1.
1996
Carlsson, PO.; Östenson, CG.; Efendic, S.; langel, Ü.; Jansson, L. (1996). Pituitary adenylate cyclase activating polypeptide (PACAP) redistributes the blood within the pancreas of anesthetized rats. Regulatory Peptides, 63, 123−128.
1.1.
1996
Langel, Ü.; Pooga, M.; Kairane, C.; Zilmer, M.; Bartfay, T. (1996). Effects of chimeric galanin-mastoparan analogues on rat cerebral cortical Na+,K+-ATP-ase and galanin receptors. Regulatory Peptides, 62 (1), 47−52.
1.2.
1996
Kairane, C.; Tähepõld, L.; Langel, Ü.; Sillard, R.; Zilmer, M. (1996). Investigation of some natural peptides and their synthetic derivatives using brain Na,K-ATPase. Neurochemistry (Russian), 13 (4), 265−269.
1.2.
1996
Jureus, A.; Langel, Ü. (1996). Galanin and galanin antagonists. Acta Chimica Slovenica, 43 (1), 51−60.
2.2.
1996
Soomets, U; Starkopf, J; Zilmer, Mihkel; Karelson, Ello-Rahel; Vihalemm, Tiiu; Zilmer, K; Valkna, A; Sillard, R; Langel, Ü (1996). Bioorganic chemistry for medical students. Tartu: Tartu University.
1.1.
1995
Valkna, A.; Laidmäe, E.; Karelson, E.; Zilmer, M.; Jureus, A.; Langel, Ü. (1995). Effects of chimeric galanin receptors ligands on basal adenylate cyclase activity in rat ventral hippocampal membranes. Protein and Peptide Letters, 2 (1), 267−274.
1.1.
1995
Kask, K.; Berthold, M.; Bourne, J.; Andell, S.; Langel, Ü.; Bartfai, T. (1995). Binding and agonist/antagonist actions of M35, galanin(1-13)-bradykinin(2-9) amide chimeric peptide, in rin m5F insulinoma cells. Regulatory Peptides, 59 (3), 341−348.
1.1.
1995
Zetterström, M.; Trogen, L.; Hammarström, LG.; Juhlin, L.; Nilsson, B.; Damberg, C.; Bartfai, T.; Langel, Ü. (1995). Synthesis of N-methyl-dehydroalanine containing analogue of misrocystin by combination of solid phase peptide synthesis and b-elimination in solution. Acta Chemica Scandinavica, 49 (9), 696−700.
1.1.
1995
Kask, K.; Langel, Ü.; Bartfay, T. (1995). Galanin - a neuropeptide with inhibitory actions. Cellular and Molecular Neurobiology, 15 (6), 653−673.
1.1.
1995
Xu, X.J.; Wiesenfeldt-Hallin, Z.; Langel, Ü.; Bedecs, K.; Bartfay, T. (1995). New high affinity peptide antagoniosts to the spinal galanin receptor. British Journal of Pharmacology, 116 (3), 2076−2080.
1.1.
1995
Xu, X.J.; Andell, S.; Zhang, X.; Wiesenfeldt-Hallin, Z.; Langel, Ü.; Bedecs, K.; Hökfelt, T.; Bartfay, T. (1995). Peripheral axotomy increases the expression of galanin message associated peptide (GMAP) in dorsal root ganglion cells and alters the effects of intrathecal GMAP on the flexor reflex in the rat. Neuropeptides, 28 (5), 299−307.
1.1.
1995
Bedecs, K.; Langel, Ü.; Bartfay, T. (1995). Metabolism of galanin and galanin(1-16) in isolated cerebrospinal fluid and spinal cord membranes from rat. Neuropeptides, 29 (3), 137−143.
1.1.
1995
Bartfay, T.; Langel, Ü. (1995). Galanin receptor ligands as potential therapeutic agents in depression and neurodegeneration. European Journal of Medical Genetics, 30, 163−174.
1.1.
1995
Valkna, A.; Laidmae, E.; Karelson, E.; Zilmer, M.; Jureus, A.; Langel, Ü. (1995). Effects of chimeric galanin receptor ligands on basal adenylate-cyclase activity in rat ventral hippocampal membranes. Protein and Peptide Letters, 2 (1), 267−274.
1.1.
1995
Heinsoo, A.; Raidaru, G.; Linask, K.; Järv, J.; Zetterstrom, M.; Langel, Ü. (1995). Synthesis of n-protected erythro-phenylalanylepoxides. Tetrahedron-Asymmetry, 6 (9), 2245−2247.
1.1.
1995
Valkna, A.; Jureus, A.; Karelson, E.; Zilmer, M.; Bartfai, T.; Langel, U. (1995). Differential regulation of adenylate-cyclase activity in rat ventral and dorsal hippocampus by rat galanin. Neuroscience Letters, 187 (2), 75−78.
1.2.
1995
Öhman, A.; Lycksell, P.O.; Andell, S.; Langel, Ü.; Bartfai, T.; Gräslund, A. (1995). Solvent stabilized solution structures of galanin and galanin analogs, studied by CD spectroscopy. Biochimica et Biophysica Acta, 1236 (2), 259−265.
1.1.
1994
Wennerberg, ABA.; Jackson, M.; Öhman, A.; Gräslund, A.; Langel, Ü.; Rigler, R.; Mantsch, HH. (1994). The structure of the rodent and porcine neuropeptide galanin and antagonists as determined by FT-IR spectroscopy an CD spectroscopy. Canadian Journal of Chemistry, 72 (6), 1495−1499.
1.1.
1994
Bedecs, K.; langel, Ü.; Xu, XJ.; Wiesenfeld-Hallin, Z.; Bartfai, T. (1994). Biological activities of two endogeneously occuring N-terminally extended forms of galanin in the rat spinal cord. European Journal of Pharmacology, 259 (2), 151−156.
1.1.
1994
Rivera Baeza, C.; Kask, K.; Langel, Ü.; Unden, A.; Bartfai, T. (1994). Analogs of galanin(1-16) modified in positions 1-3 as ligands to rat hypothalamic galanin receptors. Acta Chemica Scandinavica, 48 (5), 434−438.
1.1.
1994
Kahl, U.; Langel, Ü.; Bartfai, T.; Grundemar, L. (1994). Functional effects and ligands binding of chimeric galanin-neuropeptide Y (NPY) peptides on NPY and galanin receptor types. British Journal of Pharmacology, 111 (4), 1129−1134.
1.1.
1994
Gregersen, S.; Langel, Ü.; Bartfai, T.; Ahren, B. (1994). Galanin message-assotiated polypeptide (GMAP) does not affect insulin secretion from isolated islets. European Journal of Pharmacology, 259 (1), 79−82.
1.1.
1994
Arvidsson, K.; Langel, Ü.; Ehrenberg, A. (1994). Comparison of the solution structures of the chimeric peptides galanin(1-12)-Ala-neuropeptide Y(25-36) amide and galanin(1-12) Pro-neuropeptide Y(25-36)amide. European Journal of Biochemistry, 222 (2), 573−581.
1.1.
1994
Gregersen, S.; Langel, Ü.; Bartfay, T.; Ahren, B (1994). N-Terminally elongated fragments of galanin(1-16) inhibit insulin secretion from isolated mouse islets. Regulatory Peptides, 53 (1), 31−38.
1.1.
1994
Gregersen, S.; Langel, Ü.; Bartfay, T.; Ahren, B. (1994). Galanin message-associated polypeptide (GMAP) does not affect insulin secretion from isolated islets. European Journal of Pharmacology, 259 (1), 79−82.
1.1.
1993
Crowley, JM.; Robinson, JK.; Langel, Ü.; Bartfai, T. (1993). Galanin receptor antagonists M40 and C7 block galanin induced feeding. Brain Research, 600 (2), 268−272.
1.1.
1993
Zini, S.; Roisin, MP.; Langel, Ü.; Bartfai, T.; Ben-Ari, Y. (1993). Galanin reduces release of excitatory amino acids but not GABA in the rat hippocampus. European Journal of Pharmacology-Molecular Pharmacology Section, 245 (1), 1−7.
1.1.
1993
Bartfai, T.; Hökfelt, T.; Langel, Ü. (1993). Galanin - a neuro-endocrine peptide. Critical Reviews in Neurobiology, 7, 229−274.
1.1.
1993
Gregersen, S.; Lindskog, S.; Land, T.; Langel, U.; Bartfai, T.; Ahren, B. (1993). Blockade of galanin-induced inhibition of insulin secretion from isolated mouse islets by the nonmethionine containing antagonist M35. European Journal of Pharmacology, 232 (1), 35−39.
1.1.
1993
Girotti, P.; Bertorelli, R.; Fisone, G.; Land, T.; Langel, U.; Consolo, S.; Bartfai, T. (1993). N-terminal galanin fragments inhibit the hippocampal release of acetylcholine in vivo. Brain Research, 612, 258−262.
1.1.
1993
Arvidsson, K.; Land, T.; Langel, U.; Bartfai, T.; Ehrenberg, A. (1993). Solution structure by 2D 1H-NMR of a chimeric peptide recognized by galanin and neuropeptide Y receptors. Biochemistry, 32 (30), 7787−7798.
1.1.
1993
Ogren, S.O.; Pramanik, A.; Land, T.; Langel, U. (1993). Differential effects of the putative galanin receptor antagonists M15 and M35 on striatal acetylcholine release. European Journal of Pharmacology, 242 (1), 59−64.
1.1.
1993
Hulting, A.L.; Land, T.; Berthold, N.; Langel, U.; Hokfelt, T.; Bartfai, T. (1993). Galanin receptors from human pituitary-tumors assayed with human galanin as ligand. Brain Research, 625, 173−176.
1.1.
1993
Bartfai, T.; Langel, U.; Bedecs, K.; Andell, S.; Land, T.; Gregersen, S.; Ahren, B.; Girotti, P.; Consolo, S.; Corwin, R.; Crawley, J.; Xu, X.J.; Wiesenfeld-Hallin, Z.; Hokfelt, T. (1993). Galanin-receptor ligand M40 peptide distinguishes between putative galanin-receptor subtypes. Proceedings of the National Academy of Sciences of the United States of America, 90 (23), 11287−11291.
1.1.
1992
Verge, VMK.; Xu, XJ.; Langel, Ü.; Hökfelt, T.; Wiesenfeld-Hallin, Z.; Bartfai, T. (1992). Evidence for endogenous inhibition of autotomy by galanin in the rat after sciatic nerve section: demonstrated by chronic intrathecal infusion a high affinity galanin receptor antagonist. Neuroscience Letters, 149 (2), 193−197.
1.1.
1992
Hökfelt, T.; Aman, K.; Arvidsson, U.; Bedecs, K.; Ceccatelli, S.; Hulting, AL.; Langel, Ü.; Meister, B.; Pieribone, V.; Bartfai, T. (1992). Galanin message-associated peptide(GMAP) - and galanin-like immunoreactivities: overlapping and differential distributions in the rat. Neuroscience Letters, 142 (2), 139−142.
1.1.
1992
Hökfelt, T.; bartfai, T.; Ceccatelli, S.; Cortes, R.; Fisone, G.; hulting, AL.; Langel, Ü.; Meister, B.; Melander, T.; Pieribone, V.; Schalling, M.; Verge, VMK.; Villar, M.; Wiesenfeld-hallin, Z.; Xu, XJ.; Xu, Z. (1992). Central and Sensory galanin, neurons and functional aspects. Biomedical Research, 13, 311−317.
1.1.
1992
Bedecs, K.; Langel, Ü.; Bartfai, T.; Wiesenfeld-Hallin, Z. (1992). Galanin receptors and their second messengers in the lumbar dorsal spinal cord; the effect of GTP and sciatic nerve transection. Acta Physiologica Scandinavica, 144 (3), 213−220.
1.1.
1992
Bartfai, T.; Fisone, G.; Langel, Ü. (1992). Galanin and galanin antagonists: molecular and biochemical perspectives. Trends in Pharmacological Sciences, 13 (8), 312−317.
1.1.
1992
Wiesenfeld-Hallin, Z.; Xu, XJ.; Langel, Ü.; Bedecs, K.; Hökfelt, T.; Bartfai, T. (1992). Galanin mediated control of pain: enhanced role after nerve injury. Proceedings of the National Academy of Sciences of the United States of America, 89 (8), 3334−3337.
1.1.
1992
Ögren, SO.; Hökfelt, T.; Kask, K.; Langel, Ü.; Bartfai, T. (1992). Evidence for a role of the neuropeptide galanin in spatial learning. Neuroscience, 51 (1), 1−5.
1.1.
1992
Lindskog, S.; Ahren, B.; Land, T.; Langel, U.; Bartfai, T. (1992). The novel high-affinity antagonist, galantide, blocks the galanin-mediated inhibition of glucose-induced insulin secretion. European Journal of Pharmacology, 210 (2), 183−188.
1.1.
1992
Langel, U.; Land, T.; Bartfai, T. (1992). Design of chimeric peptide ligands to galanin receptors and substance-P receptors. International Journal of Peptide and Protein Research, 39, 516−522.
1.1.
1992
Laasik, J.; Sillard, R.; Langel, U.; Zilmer, M. (1992). Lipid-protein interactions in neurotropic na-pump regulation. Acta Physiologica Scandinavica, 146, 249−251.
1.1.
1991
Gregersen, S.; Hermansen, K.; Lindskog, S.; Langel, Ü.; Fisone, G.; Bartfai, T.; Ahren, B. (1991). Galanin-induced inhibition of insulin secretion from rat islets: effects of rat and pig galanin and galanin fragments and analogues. European Journal of Pharmacology, 203 (1), 111−114.
1.1.
1991
Sillard, R.; Langel, Ü.; Jörnvall, H. (1991). Isolation and characterization of galanin from sheep brain. Peptides, 12 (4), 855−859.
1.1.
1991
Land, T.; Langel, U.; Bartfai, T. (1991). Hypothalamic degradation of galanin(1–29) and galanin(1–16): identification and characterization of the peptidolytic products. Brain Research, 558 (2), 245−250.
1.1.
1991
Land, T.; Langel, U.; Low, M.; Berthold, M.; Unden, A.; Bartfai, T. (1991). Linear and cyclic N-terminal galanin fragments and analogs as ligands at the hypothalamic galanin receptor. International Journal of Peptide and Protein Research, 38 (3), 262−272.
1.1.
1991
Bartfai, T.; Bedecs, K.; Land, T.; Langel, U.; Bertorelli, R.; Girotti, P.; Consolo, S.; Xu, X.J.; Wiesenfeld-Hallin, Z.; Nilsson, S.; Pieribone, V.A.; Hokfelt, T. (1991). M-15: High-affinity chimeric peptide that blocks the neuronal actions of galanin in the hippocampus, locus coeruleus, and spinal cord. Proceedings of the National Academy of Sciences of the United States of America, 88, 10961−10965.
3.1.
1991
Fisone, G.; Langel, Ü.; Land, T.; Berthold, M.; Bertorelli, R.; Girotti, P.; Consolo, S.; Crowley, JN.; Hökfelt, T.; Bartfai, T. (1991). Galanin receptor ligands in the hippocampus: galanin, N-terminal galanin fragments and analogues. In: Hokfelt, T.; Bartfai, T.; Jacobowitz, D.; Ottoson, D. (_EditorsAbbr). Galanin: A new multifunctional peptide in the neuro-endocrine system (213−220).. New York: Macmillan Press. (Wenner-Gren International Symposium Series).
3.1.
1991
Land, T.; Langel, Ü.; Fisone, G.; Bedecs, K.; Bartfai, T. (1991). Assay for galanin receptor. In: Methods in Neurosciences (225−234).. Academic Press.
3.1.
1991
Rigler, R.; Wennerberg, A.; Cooke, RM.; Elofsson, A.; Nilsson, L.; Vogel, H.; Holley, LH.; Carlquist, M.; Langel, Ü.; Bartfai, T.; Campell, ID. (1991). On the solution structure of galanin. In: Hökfelt, T.; Bartfai, T.; Jacubowitz, D.; Ottoson, D. (_EditorsAbbr). Galanin: A new multifunctional peptide in the neuro-endicrine system (17−25).. London: Macmillan Press.
1.1.
1990
Crawley, J.; Austin, MC.; Fiske, SM.; Martin, B.; Consolo, S.; Berthold, M.; Langel, Ü.; Bartfai, T. (1990). Activity of centrally administered galanin fragments on stimulation of feeding behaviour and on galanin receptor binding in the rat hypothalamus. Journal of Neuroscience, 10 (11), 3695−3700.
1.1.
1990
Zorko, M.; Langel, Ü.; Palumaa, P. (1990). Simultaneous action of quaternary ammonium ligands and alkanesulfonylchlorides on electric eel acetylcholinesterase. Periodicum Biologorum, 4, 385−391.
5.1.
1990
Langel, Ü.; Land, T.; Bartfai, T. (1990). Synthetic galanin analogs with biochemical activity. Peptides: Twenty-First European peptide Symposium; September 2-8, 1990; Platja d´Aro, Spain. _EditorsAbbr Giralt, E.; Andreu, D. 727−728.
1.1.
1989
Fisone, G.; Langel, Ü.; Carlquist, M.; Bergman, T.; Consolo, S.; Hökfelt, T.; Unden, A.; Andell, S.; Bartfai, T. (1989). Galanin receptor and its ligands in the rat hippocampus. European Journal of Biochemistry, 181 (1), 269−276.
1.1.
1989
Sepp, A.; Palumaa, P.; Langel, U.; Jarv, J.; Zorko, M. (1989). Spatial orientation of normal-alkanesulfonyl chlorides in the active-center of cholinesterases. Bioorganic Chemistry, 17 (1), 79−85.
1.2.
1987
Zharkovski, AM.; Langel, Ü.; Chereshka, KS.; Zharkovsaia, T (1987). Significance of the dopamine-blocking and m-choline-blocking components in the antiapomorphine action of neuroleptics. Biulleten eksperimental'noi biologii i meditsiny, 103 (3), 317−319.
1.2.
1987
Eller, M.; Kõiv, A.; Langel, Ü.; Rinken, A.; Tähepõld, L.; Järv, J. (1987). Quinuclidine benzilate can't be used as a ligand in equilibrium binding studies with muscarinic receptor. Neirokhimiya, 6, 605−609.
1.3.
1987
Rinken, A.; Langel, J.; Järv, J. (1987). Solubilisation of muscarinic cholinoreceptor and its complex with QNB. Biochemistry (Moscow), 52, 263−269.
1.1.
1986
Laasberg, T.; Neuman, T.; Langel, Ü. (1986). Acetylcholine receptors in the gastrulating chick embryo. Experientia, 42 (4), 439−440.
1.1.
1986
Langel, Ü.; Sillard, R.; Järv, J.; Godovikov, N.; Kardanov, N.; Trifonova, S (1986). Interaction of n-alkylcholinbenzilates with cholinesterases. Organic Reactivity, 23 (2, 82), 134−143.
1.1.
1986
Sillard, RG.; Langel, UL.; Jarv, JL.; Godovinkov, NN.; Kardanov, NA.; Trifonova, SA. (1986). Dissociation kinetics of antagonists from complex with rat-brain muscarinic receptor. Organic Reactivity, 23 (3), 370−381.
1.1.
1984
Rinken, AA.; Langel, UL.; Jarv, JL. (1984). Solubilization of muscarinic receptor and receptor-quinuclidinyl benzilate complex with digitonin. Biologicheskie Membrany, 1 (4), 341−348.
1.1.
1984
Rinken, AA.; Langel, YL.; Tyakhepyld, LY.; Yarv, YL. (1984). Kinetics of the inactivation of the muscarine cholinoreceptor, solubilized by digitonin. Biochemistry (Moscow), 49 (11), 1533−1537.
1.2.
1984
Käämbre, T. A.; Langel, Ü. L.; Rinken, A. A.; Tähepõld, L. J.; Järv, J. L. (1984). Action of proteases and phospholipase A2 on the membrane-bound muscarinic acetylcholine receptor from rat brain. Neirokhimiya, 3 (2), 107−115.
1.2.
1982
Langel, Ü.; Rinken, A.; Tähepõld, L.; Järv, J. (1982). Kinetics of the muscarinic receptor inactivation. Neirokhimiya, 1 (4), 343−351.
1.1.
1981
Jarv, JL.; Langel, UL. (1981). Substrate acyl fragment effects in butyrylcholinesterase catalyzed reaction. Bioorganicheskaya Khimiya, 7 (2), 217−227.
1.1.
1980
Langel, Ü.; Speek, M.; Järv, J. (1980). Effect of pH on the cholinesterase reaction with substrates. Biochemistry (Moscow), 45 (12), 2138−2139.
1.1.
1979
Jarv, JL.; Langel, UL. (1979). Substrate leaving group effects in the butyrylcholinesterase catalyzed reactions. Bioorganicheskaya Khimiya, 5 (5), 746−756.
1.1.
1978
Jarv, JL.; Speek, MA.; Langel, UL.; Rotanova, TV. (1978). Interaction of alkylboronic acids with cholinesterases. Bioorganicheskaya Khimiya, 4 (10), 1364−1371.
1.1.
1978
Langel, U.; Jarv, J. (1978). Dissociation-constant of butyrylcholinesterase anionic center. Bioorganicheskaya Khimiya, 4 (10), 1352−1357.
1.1.
1978
Langel, U.; Jarv, J. (1978). Influence of ph on butyrylcholinesterase reaction with organophosphorus inhibitors. Biochimica et Biophysica Acta, 526 (2), 450−456.
1.1.
1978
Langel, U.; Jarv, J. (1978). Leaving group effects in butyrylcholinesterase reaction with organophosphorus inhibitors. Biochimica et Biophysica Acta, 525 (1), 122−133.
1.1.
1978
Langel, U.; Jarv, J. (1978). Influence of ph on naphthalene binding to butyrylcholinesterase active-center. Organic Reactivity, 15 (4), 443−449.
1.1.
1976
Järv, J.; Aaviksaar, A.; Godovikov, N.; Langel, Ü.; Past, U. (1976). Cobra venom acetylcholinesterase active site titration. Biochemistry (Moscow), 41 (5), 827−835.
1.3.
1974
Langel, Ü.; Järv, J.; Aaviksaar, A. (1974). Spectrophotometric determination of the concentration of organophosphorus thioesters. Acta et commentationes Universitatis Tartuensis, 332, 172−178.

Tööstusomand

20.11.2020

Ülo Langel

https://www.etis.ee/CV/Ülo_Langel/eng
2.03.1951
ulo.langel@dbb.su.se
Scopus Author ID: 7004415478

Career

Institutions and positions
01.09.2018–...   
University of Tartu, Faculty of Science and Technology, Institute of Technology, Professor of Molecular Biotechnology (0,50)
2007–...   
University of Tartu, Faculty of Science and Technology (old), Institute of Technology, University of Tartu, Professor (1,00)
01.01.2003–...   
Professor of neurochemistry and molecular neurobiology, Dept. Neurochemistry, Stockholm University, Sweden
01.01.2002–...   
Honorary Visiting Professor, Medical Faculty, Ljubljana University, Slovenia
01.01.2001–...   
Adjunct Visiting Professor, The Scripps Research Institute, La Jolla, CA, USA
01.01.1997–...   
Visiting Professor, Faculty of Medicine, Tartu University, Tartu, Estonia
01.01.2016–31.08.2018   
University of Tartu, Faculty of Science and Technology, Institute of Technology, Professor of Molecular Biotechnology (0,50)
01.09.2013–31.12.2015   
University of Tartu, Faculty of Science and Technology (old), Institute of Technology, University of Tartu, Professor of Molecular Biotechnology (0,50)
01.05.2013–31.08.2013   
University of Tartu, Faculty of Science and Technology (old), Institute of Technology, University of Tartu, Professor (1,00)
01.09.2010–30.04.2013   
University of Tartu, Faculty of Science and Technology (old), Institute of Technology, University of Tartu, Professor (1,00)
01.01.2008–30.04.2010   
University of Tartu, Faculty of Science and Technology (old), Institute of Technology, University of Tartu, Professor of Molecular Biotechnology (1,00)
01.06.2007–31.12.2007   
University of Tartu, Faculty of Science and Technology (old), Institute of Technology, University of Tartu, Professor extraordinarius (1,00)
01.05.2007–31.05.2007   
University of Tartu, Faculty of Science and Technology (old), Institute of Technology, University of Tartu, Professor extraordinarius (0,80)
01.10.2006–30.09.2009   
University of Tartu, Faculty of Science and Technology (old), Institute of Technology, University of Tartu, Senior Research Fellow extraordinarius (0,20)
01.01.2005–2012   
Cepep Eesti OÜ, Chairman of the board of Directors of the CePeP III AB, Stockholm, Sweden (0,10)
01.01.2005–2013   
Stockholmi Ulikool, Chair, Dept. Neurochemistry, Stockholm University, Sweden (1,00)
01.01.2003–31.12.2004   
Member of the board of Directors of the Orexo AB, Uppsala, Sweden
01.01.2003–31.12.2004   
Deputy Chairman, Dept. Neurochemistry and Neurotoxicology, Stockholm University, Sweden
01.01.2001–31.12.2003   
Chairman of the board of Directors of the CePEP AB, Stcockholm, Sweden
01.01.2001–31.12.2003   
Professor of neurochemistry and neurotoxicology, Dept. Neurochemistry and Neurotoxicology, Stockholm University, Sweden
01.01.2000–31.12.2001   
Associate Professor, The Harold L. Dorris Neurological Research Center, Dept. of Neuropharmacology, The Scripps Research Institute, La Jolla, CA, USA
01.01.1997–31.12.1999   
Project leader (chemistry of biosensors for mine detection) at Bofors Sweden, part time
01.01.1997–31.12.2002   
Director of studies, Dept. Neurochemistry and Neurotoxicology, Stockholm University, Sweden
01.01.1992–31.12.2001   
Lecturer and Associate Professor, Dept. Neurochemistry and Neurotoxicology, Stockholm University, Sweden
01.01.1987–31.12.1991   
Visiting research fellow, Dept. Biochemistry, Stockholm University, Sweden
1980–1989   
University of Tartu, Faculty of Medicine, Associate Professor (1,00)
1974–1980   
University of Tartu, Faculty of Physics and Chemistry, Institute of Organic and Bioorganic Chemistry, Researcher (1,00)
 
 
Education
1974–1980   
Tartu University,Bioorganic chemistry, PhD
1969–1974   
Department of Chemistry, Tartu University, Bioorganic chemistry, BcS
 
 
R&D related managerial and administrative work
1996−...   
Society of Neuroscience, International Society for Neurochemistry, European Peptide Society, Swedish Biochemical Society, Estonian Biochemical Society
1996−...   
Scientific reviewer of: NIH, wellcome Trust, INSERM etc.
1995−...   
Fellow member of International Neuropeptide Society
2005−2005   
Guest Editor, Current Pharmaceutical Design
2003−2005   
Editorial Advisory Board Member of the journal “Drug Design Reviews-Online”
2000−2000   
Member of International review Board for the Estonian centre of Excellence in Biomedicine, Tartu
 
 
Additional information
Invited lecturer : more than 100 in 1995-2019
Organiser of scientific conferences:
Neuropeptide galanin, San Diego 2004, together with T Yaksh, T. Bartfai, and T. Hökfelt
Cell-penetrating peptides, Stockholm 2005, Wenner-Gren Conference
Frontiers in Drug Delivery, Tartu 2018
Main supervisor for 51 defended PhD students.
Post-doctoral fellows: ca 50 in 1997-...now

Qualifications

Academic degrees
Ülo Langel, Doctor's Degree, 1993, (sup) -, Galanin and galanin antagonists, University of Tartu, Faculty of Medicine.
Ülo Langel, Doctor's Degree, 1980, (sup) Jaak Järv, Butyrüülkolinesteraasi struktuur-aktiivsussõltuvused (Effects of structure and pH in reactions of cholinesterase), University of Tartu, Faculty of Physics and Chemistry.
 
 
Honours & awards
2009, Ülo Langel, The National Science Award of the Rebublic of Estonia
2001, Ülo Langel, White Star Order, 4th class, from Estonian Republic,
 
 
Fields of research
ETIS CLASSIFICATION: 1. Biosciences and Environment; 1.1. Biochemistry; SPECIFICATION: Cell penetrating peptides
 
 

Projects in progress

Completed projects

Dissertations under supervision

Supervised dissertations

Publications

Category
Year
Publication
 
1.1.
2020
Gestin, Maxime; Helmfors, Henrik; Falato, Luca; Lorenzon, Nicola; Michalakis, Filip Ilias; Langel, Ülo (2020). Effect of small molecule signaling in PepFect14 transfection. PLoS ONE, 15 (1), e0228189−e0228189. DOI: 10.1371/journal.pone.0228189.
1.1.
2019
Porosk, Ly; Arukuusk, Piret; Põhako, Kaisa; Kurrikoff, Kaido; Kiisholts, Kristina; Padari, Kärt; Pooga, Margus; Langel, Ülo (2019). Enhancement of siRNA transfection by the optimization of fatty acid length and histidine content in the CPP. Biomaterials Science. DOI: 10.1039/C9BM00688E.
1.1.
2019
Kurrikoff, Kaido; Aphkhazava, David; Langel, Ülo (2019). The future of peptides in cancer treatment. Current Opinion in Pharmacology, 47, 27−32.10.1016/j.coph.2019.01.008.
1.1.
2018
Lorents, Annely; Säälik, Pille; Langel, Ülo; Pooga, Margus (2018). Arginine-Rich Cell-Penetrating Peptides Require Nucleolin and Cholesterol-Poor Subdomains for Translocation across Membranes. Bioconjugate Chemistry, 29 (4), 1168−1177. DOI: 10.1021/acs.bioconjchem.7b00805.
1.1.
2018
Freimann, Krista; Arukuusk, Piret; Kurrikoff, Kaido; Pärnaste, Ly; Raid, Raivo; Piirsoo, Andres; Pooga, Margus; Lange, Ülo (2018). Formulation of stable and homogenous cell penetrating peptide NF55 nanoparticles for efficient gene delivery in vivo. Molecular Therapy — Nucleic Acids, 10, 28−35. DOI: 10.1016/j.omtn.2017.10.011.
1.1.
2018
Srimanee, Artita; Arvanitidou, Maria; Kim, Kumjee; Hällbrink, Mattias; Langel, Ülo (2018). Cell-penetrating peptides for siRNA delivery to glioblastomas. Peptides, 104, 62−69.10.1016/j.peptides.2018.04.015.
1.1.
2018
Dowaidar, Moataz; Nasser Abdelhamid, Hani; Hällbrink, Mattias; Langel, Ülo; Zou, Xiaodong (2018). Chitosan enhances gene delivery of oligonucleotide complexes with magnetic nanoparticles-cell-penetrating peptide. Journal of Biomaterials Applications, 33 (3), 392−401.10.1177/0885328218796623.
1.1.
2018
Alvarez, Mariano J; Subramaniam, Prem S; Tang, Laura H; Grunn, Adina; Aburi, Mahalaxmi; Rieckhof, Gabrielle; Komissarova, Elena V; Hagan, Elizabeth A; Bodei, Lisa; Clemons, Paul A; Dela Cruz, Filemon S; Dhall, Deepti; Diolaiti, Daniel; Fraker, Douglas A; Ghavami, Afshin; Kaemmerer, Daniel; Karan, Charles; Kidd, Mark; Kim, Kyoung M; Kim, Hee C ... Califano, Andrea (2018). A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nature Genetics, 50 (7), 979−989.10.1038/s41588-018-0138-4.
1.1.
2018
Vasconcelos, Luís; Lehto, Tõnis; Madani, Fatemeh; Radoi, Vlad; Hällbrink, Mattias; Vukojević, Vladana; Langel, Ülo (2018). Simultaneous membrane interaction of amphipathic peptide monomers, self-aggregates and cargo complexes detected by fluorescence correlation spectroscopy. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1860 (2), 491−504.10.1016/j.bbamem.2017.09.024.
1.2.
2018
Künnapuu, K.; Veiman, K.-L.; Porosk, L.; Rammul, E.; Kiisholts, K.; Langel, Ü.; Kurrikoff, K. (2018). Tumor gene therapy by systemic delivery of plasmid DNA with cell‐penetrating peptides. FASEB BioAdvances, 1 (2), 105−114. DOI: 10.1096/fba.1026.
1.1.
2017
Pärnaste, Ly; Arukuusk, Piret; Langel, Kent; Tenson, Tanel; Langel, Ülo (2017). The formation of nanoparticles between small interfering RNA and amphipathic cell-penetrating peptides. Molecular Therapy — Nucleic Acids, 7, 1−10.10.1016/j.omtn.2017.02.003.
1.1.
2017
Juks, C.; Lorents, A.; Arukuusk, P.; Langel, Ü.; Pooga, M. (2017). Cell-penetrating peptides recruit type A scavenger receptors to the plasma membrane for cellular delivery of nucleic acids. The FASEB Journal, 31 (3), 975−988. DOI: 10.1096/fj.201600811r.
1.1.
2017
Cerrato, Carmine Pasquale; Künnapuu, Kadri; Langel, Ülo (2017). Cell-penetrating peptides with intracellular organelle targeting. Expert Opinion on Drug Delivery, 14 (2), 245−255.10.1080/17425247.2016.1213237.
1.1.
2017
Jevtuševskaja, Jekaterina; Krõlov, Katrin; Tulp, Indrek; Langel, Ülo (2017). The effect of main urine inhibitors on the activity of different DNA polymerases in loop-mediated isothermal amplification. Expert Review of Molecular Diagnostics, 17 (4), 403−410.10.1080/14737159.2017.1283218.
1.1.
2017
Kurrikoff, Kaido; Veiman, Kadi-Liis; Künnapuu, Kadri; Peets, Elin Madli; Lehto, Tõnis; Pärnaste, Ly; Arukuusk, Piret; Langel, Ülo (2017). Effective in vivo gene delivery with reduced toxicity, achieved by charge and fatty acid -modified cell penetrating peptide. Scientific Reports, 7 (1), 17056−17056.10.1038/s41598-017-17316-y.
1.1.
2017
Cerrato, Carmine Pasquale; Langel, Ülo (2017). Effect of a Fusion Peptide by Covalent Conjugation of a Mitochondrial Cell-Penetrating Peptide and a Glutathione Analog Peptide. Molecular Therapy — Methods & Clinical Development, 5, 221−231.10.1016/j.omtm.2017.04.010.
1.1.
2017
Krõlov, Katrin; Uusna, Julia; Grellier, Tiia; Andresen, Liis; Jevtuševskaja, Jekaterina; Tulp, Indrek; Langel, Ülo (2017). Implementation of antimicrobial peptides for sample preparation prior to nucleic acid amplification in point-of-care settings. Expert Review of Molecular Diagnostics, 17 (12), 1117−1125.10.1080/14737159.2017.1386557.
1.1.
2017
Dowaidar, Moataz; Abdelhamid, Hani Nasser; Hällbrink, Mattias; Zou, Xiaodong; Langel, Ülo (2017). Graphene oxide nanosheets in complex with cell penetrating peptides for oligonucleotides delivery. Biochimica et Biophysica Acta (BBA) - General Subjects, 1861 (9), 2334−2341.10.1016/j.bbagen.2017.07.002.
1.1.
2017
Dowaidar, Moataz; Regberg, Jakob; Dobchev, Dimitar A.; Lehto, Tonis; Hallbrink, Mattias; Karelson, Mati; Langel, Ülo (2017). Refinement of a Quantitative Structure-Activity Relationship Model for Prediction of Cell-Penetrating Peptide Based Transfection Systems. International Journal of Peptide Research and Therapeutics, 23 (1), 91−100.10.1007/s10989-016-9542-8.
1.1.
2017
Lehto, T., Vasconcelos, L., Margus, H., Figueroa, R., Pooga, M., Hällbrink, M., Langel, Ü. (2017). Saturated Fatty Acid Analogues of Cell-Penetrating Peptide PepFect14: Role of Fatty Acid Modification in Complexation and Delivery of Splice-Correcting Oligonucleotides. Bioconjugate Chemistry, 28 (3), 782−792. DOI: 10.1021/acs.bioconjchem.6b00680.
1.1.
2017
Urgard, Egon; Brjalin, Aleksei; Langel, Ulo; Pooga, Margus; Rebane, Ana; Annilo, Tarmo (2017). Comparison of Peptide- and Lipid-Based Delivery of miR-34a-5p Mimic into PPC-1 Cells. Nucleic Acid Therapeutics, 27 (5), 295−302. DOI: 10.1089/nat.2017.0670.
1.1.
2017
Dowaidar, Moataz; Gestin, Maxime; Cerrato, Carmine Pasquale; Jafferali, Mohammed Hakim; Margus, Helerin; Kivistik, Paula Ann; Ezzat, Kariem; Hallberg, Einar; Pooga, Margus; Hällbrink, Mattias; Langel, Ülo (2017). Role of autophagy in cell-penetrating peptide transfection model. Scientific Reports, 7 (1), 12635−12635. DOI: 10.1038/s41598-017-12747-z.
1.1.
2017
Dowaidar, Moataz; Abdelhamid, Hani Nasser; Hallbrink, Mattias; Freimann, Krista; Kurrikoff, Kaido; Zou, Xiaodong; Langel, Ülo (2017). Magnetic Nanoparticle Assisted Self-assembly of Cell Penetrating Peptides-Oligonucleotides Complexes for Gene Delivery. Scientific Reports, 7, ARTN 9159.10.1038/s41598-017-09803-z.
3.1.
2017
Gestin, Maxime; Dowaidar, Moataz; Langel, Ülo (2017). Uptake Mechanism of Cell-Penetrating Peptides. Advances in Experimental Medicine and Biology, 1030, 255−264.10.1007/978-3-319-66095-0_11.
1.1.
2016
Urgard, Egon; Lorents, Annely; Klaas, Mariliis; Padari, Kärt; Viil, Janeli; Runnel, Toomas; Langel, Kent; Kingo, Külli; Tkaczyk, Eric; Langel, Ülo; Maimets, Toivo; Jaks, Viljar; Pooga, Margus; Rebane, Ana (2016). Pre-administration of PepFect6-microRNA-146a nanocomplexes inhibits inflammatory responses in keratinocytes and in a mouse model of irritant contact dermatitis. Journal of Controlled Release, 235, 195−2014. DOI: 10.1016/j.jconrel.2016.06.006.
1.1.
2016
Freimann, Krista; Arukuusk, Piret; Kurrikoff, Kaido; Vasconcelos, Luís Daniel Ferreira; Veiman, Kadi-Liis; Uusna, Julia; Margus, Helerin; Garcia-Sosa, Alfonso T; Pooga, Margus; Langel, Ülo (2016). Optimization of in vivo DNA delivery with NickFect peptide vectors. Journal of controlled release : official journal of the Controlled Release Society, 241, 135−143. DOI: 10.1016/j.jconrel.2016.09.022.
1.1.
2016
Jevtuševskaja J, Uusna J, Andresen L, Krõlov K, Laanpere M, Grellier T, Tulp I, Langel Ü. (2016). Combination with antimicrobial peptide lyses improves loop-mediated isothermal amplification based method for Chlamydia trachomatis detection directly in urine sample. BMC Infectious Disease, 16 (329), 329.10.1186/s12879-016-1674-0.
1.1.
2016
Pärnaste, Ly; Arukuusk, Piret; Zagato, Elisa; Braeckmans, Kevin; Langel, Ülo (2016). Methods to follow intracellular trafficking of cell-penetrating peptides. Journal of Drug Targeting, 24 (6), 508−519.10.3109/1061186X.2015.1095194.
1.1.
2016
Margus, Helerin; Arukuusk, Piret; Langel, Ülo; Pooga, Margus (2016). Characteristics of Cell-Penetrating Peptide/Nucleic Acid Nanoparticles. Molecular Pharmaceutics, 13 (1), 172−179. DOI: 10.1021/acs.molpharmaceut.5b00598.
1.1.
2016
Pae, J.; Liivamägi, L.; Etverk, I.; Lubenets, D.; Arukuusk, P.; Langel, Ü.; Pooga, M. (2016). Glycosaminoglycans are required for translocation of amphipathic cell-penetrating peptides across membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1858 (8), 1860−1867. DOI: 10.1016/j.bbamem.2016.04.010.
1.1.
2016
Srimanee, Artita; Regberg, Jakob; Hällbrink, Mattias; Vajragupta, Opa; Langel, Ülo (2016). Role of scavenger receptors in peptide-based delivery of plasmid DNA across a blood-brain barrier model. International Journal of Pharmaceutics, 500, 128−135.10.1016/j.ijpharm.2016.01.014.
1.1.
2016
Kurrikof, Kaido; Gestin, Maxime; Langel, ܜlo (2016). Recent in vivo advances in cell-penetrating peptide-assisted drug delivery. Expert Opinion on Drug Delivery, 0 (0), 373−387.10.1517/17425247.2016.1125879.
1.1.
2016
Jones, Sarah; Uusna, Julia; Langel, Uelo; Howl, John (2016). Intracellular Target-Specific Accretion of Cell Penetrating Peptides and Bioportides: Ultrastructural and Biological Correlates. Bioconjugate Chemistry, 27 (1), 121−129.10.1021/acs.bioconjchem.5b00529.
1.1.
2016
Regberg, Jakob; Vasconcelos, Luis; Madani, Fatemeh; Langel, Ülo; Hallbrink, Mattias (2016). pH-responsive PepFect cell-penetrating peptides. International Journal of Pharmaceutics, 501 (1-2), 32−38.10.1016/j.ijpharm.2016.01.055.
5.1.
2016
Urgard, E.; Lorents, A.; Klaas, M.; Padarik, K.; Viil, J.; Runnel, T.; Ü Langel; Jaks, V.; Pooga, M.; Rebane, A. (2016). PepFect6-miRNA-146a nanocomplexes inhibit inflammatory responses in keratinocytes and in a mouse model of irritant contact dermatitis. Journal of Investigative Dermatology, 136 (9), S214−S214. DOI: 10.1016/j.jid.2016.06.334.
1.1.
2015
Juks, C.; Padari, K.; Margus, H.; Kriiska, A.; Etverk, I.; Arukuusk, P.; Koppel, K.; Ezzat, K.; Langel, Ü.; Pooga, M. (2015). The role of endocytosis in the uptake and intracellular trafficking of PepFect14-nucleic acid nanocomplexes via class A scavenger receptors. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1848 (12), 3205−3216. DOI: 10.1016/j.bbamem.2015.09.019.
1.1.
2015
Freimann, Krista; Kurrikoff, Kaido; Langel, Ülo (2015). Galanin receptors as a potential target for neurological disease. Expert Opinion on Therapeutic Targets, 19 (12), 1−12.
1.1.
2015
Veiman, Kadi-Liis; Künnapuu, Kadri; Lehto, Tõnis; Kiisholts, Kristina; Pärn, Kalle; Langel, Ülo; Kurrikoff, Kaido (2015). PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo. Journal of Controlled Release, 209, 238−247.10.1016/j.jconrel.2015.04.038.
1.1.
2015
Arukuusk, P.; Pärnaste, L.; Hällbrink, M.; Langel, Ü. (2015). Pepfects and nickfects for the intracellular delivery of nucleic acids (Methods in Molecular Biology). Methods in molecular biology, 1324, 303−315.10.1007/978-1-4939-2806-4_19.
1.1.
2015
Guipponi, Michel; Chentouf, Amina; Webling, Kristin E B; Freimann, Krista; Crespel, Arielle; Nobile, Carlo; Lemke, Johannes R; Hansen, Jörg; Dorn, Thomas; Lesca, Gaetan; Ryvlin, Philippe; Hirsch, Edouard; Rudolf, Gabrielle; Rosenberg, Dominique Sarah; Weber, Yvonne; Becker, Felicitas; Helbig, Ingo; Muhle, Hiltrud; Salzmann, Annick; Chaouch, Malika ... Antonarakis, Stylianos E (2015). Galanin pathogenic mutations in temporal lobe epilepsy. Human Molecular Genetics, 24 (11), 3082−3091.10.1093/hmg/ddv060.
1.1.
2015
Uusna, J.; Langel, K.; Langel, Ü. (2015). Toxicity, immunogenicity, uptake, and kinetics methods for CPPs (Methods in Molecular Biology). Methods in molecular biology, 1324, 133−148.10.1007/978-1-4939-2806-4_9.
1.1.
2015
Kurrikoff, K.; Veiman, K.-L.; Langel, Ü. (2015). CPP-based delivery system for in vivo gene delivery (Methods in Molecular Biology). Methods in molecular biology, 1324, 339−347.10.1007/978-1-4939-2806-4_22.
1.2.
2015
Cerrato, Carmine; Veiman, Kadi-Liis; Langel, Ülo (2015). Advances in peptide delivery. In: Advances in the Discovery and Development of Peptide Therapeutics (160−171). Future Science Group. DOI: 10.4155/fseb2013.14.23.
3.1.
2015
Pooga, Margus; Langel, Ülo (2015). Classes of cell-penetrating peptides. In: Ü. Langel (Ed.). Methods in Molecular Biology (3−28). Springer. DOI: 10.1007/978-1-4939-2806-4_1.
3.1.
2015
Pärn, K.; Eriste, E.; Langel, Ü. (2015). The Antimicrobial and Antiviral Applications of Cell-Penetrating Peptides. Methods in molecular biology, 1324, 223−245. DOI: 10.1007/978-1-4939-2806-4_15.
1.1.
2014
Pae, J.; Säälik, P.; Liivamägi, L.; Lubenets, D.; Arukuusk, P.; Langel, Ü.; Pooga, M. (2014). Translocation of cell-penetrating peptides across the plasma membrane is controlled by cholesterol and microenvironment created by membranous proteins. Journal of Controlled Release, 192, 103−113. DOI: 10.1016/j.jconrel.2014.07.002.
1.1.
2014
Vasconcelos, Luis; Madani, Fatemeh; Arukuusk, Piret; Pärnaste, Ly; Gräslund, Astrid, Langel, Ülo (2014). Effects of cargo molecules on membrane perturbation caused by transportan10 based cell-penetrating peptides. Biochimica et Biophysica Acta, 1838 (12), 3118−3129.10.1016/j.bbamem.2014.08.011.
1.1.
2014
Garcia-Sosa, Alfonso T.; Tulp, Indrek; Langel, Kent; Langel, Ülo (2014). Peptide-ligand binding modeling of siRNA with cell-penetrating peptides. BioMed Research International, 257040. DOI: 10.1155/2014/257040.
1.1.
2014
Krõlov, Katrin; Frolova, Jekaterina; Tudoran, Oana; Suhorutšenko, Julia; Lehto, Taavi; Sibul, Hiljar; Mäger, Imre; Laanpere, Made; Tulp, Indrek; Langel, Ülo (2014). Sensitive and Rapid Detection of Chlamydia trachomatis by Recombinase Polymerase Amplification Directly from Urine Samples. Journal of Molecular Diagnostics, 16 (1), 127−135. DOI: 10.1016/j.jmoldx.2013.08.003.
1.1.
2014
Copolovici, D; Langel, K; Eriste, E; Langel, Ü (2014). Cell-Penetrating Peptides: Design, Synthesis, and Applications. ACS Nano, 8 (3), 1972−1994.10.1021/nn4057269.
1.1.
2014
Srimanee, Artita; Regberg, Jakob; Hallbrink, Mattias; Kurrikoff, Kaido; Veiman, Kadi-Liis; Vajragupta, Opa; Langel, Ülo (2014). Peptide-Based Delivery of Oligonucleotides Across Blood–Brain Barrier Model. International Journal of Peptide Research and Therapeutics, 20 (2), 169−178.10.1007/s10989-013-9378-4.
1.1.
2014
Rytkönen, Jussi; Arukuusk, Piret; Xu, Wujun; Kurrikoff, Kaido; Langel, Ülo; Lehto, Vesa-Pekka; Närvänen, Ale (2014). Porous Silicon–Cell Penetrating Peptide Hybrid Nanocarrier for Intracellular Delivery of Oligonucleotides. Molecular Pharmaceutics, 11 (2), 382−390.10.1021/mp4002624.
1.1.
2014
Regberg, Jakob; Srimanee, Artita; Erlandsson, Mikael; Sillard, Rannar; Dobchev, Dimitar; Karelson, Mati; Langel, Ülo (2014). Rational design of a series of novel amphipathic cell-penetrating peptides. International Journal of Pharmaceutics, 464 (1-2), 111−116. DOI: 10.1016/j.ijpharm.2014.01.018.
5.1.
2014
Lorents, Annely; Urgard, E.; Runnel, T.; Wawrzyniak, P.; Langel, Ü.; Pooga, M.; Rebane, A. (2014). Functional delivery of miR-146a to human primary keratinocytes and skin equivalents with cell-penetrating peptides. ALLERGY, 69: European-Academy-of-Allergy-and-Clinical-Immunology Congress; Copenhagen, Denmark; JUN 07-11, 2014. Wiley-Blackwell, 618−618.
5.1.
2014
Margus, H.; Arukuusk, P.; Langel, Ü.; Pooga, M. (2014). Morphology of cell-penetrating peptide-nucleic acid nanoparticles and their intracellular trafficking. FEBS JOURNAL, 281, SI: FEBS EMBO 2014, Paris. Wiley-Blackwell, 413−414.
1.1.
2013
Madani, F.; Abdo, R.; Lindberg, S.; Hirose, H.; Futaki, S.; Langel, Ü.; Gräslund, A. (2013). Modeling the endosomal escape of cell-penetrating peptides using a transmembrane pH gradient. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1828 (4), 1198−1204.10.1016/j.bbamem.2012.12.008.
1.1.
2013
Lindberg, S.; Muñoz-Alarcón, A.; Helmfors, H.; Mosqueira, D.; Gyllborg, D.; Tudoran, O.; Langel, Ü. (2013). PepFect15, a novel endosomolytic cell-penetrating peptide for oligonucleotide delivery via scavenger receptors. International Journal of Pharmaceutics, 441, 242−247.10.1016/j.ijpharm.2012.11.037.
1.1.
2013
Arukuusk, P.; Pärnaste, L.; Oskolkov, N.; Copolovici, D. M.; Margus, H.; Padari, K.; Möll, K.; Maslovskaja, J.; Tegova, R.; Kivi, G.; Tover, A.; Pooga, M.; Ustav, M.; Langel, Ü. (2013). New generation of efficient peptide-based vectors, NickFects, for the delivery of nucleic acids. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1828 (5), 1365−1373. DOI: 10.1016/j.bbamem.2013.01.011.
1.1.
2013
Jones, S; Lukanowska, M; Suhorutšenko, J; Oxenham, S; Barratt, C; Publicover, S; Copolovici, D. M; Langel, Ü; Howl, J. (2013). Intracellular translocation and differential accumulation of cell-penetrating peptides in bovine spermatozoa: evaluation of efficient delivery vectors that do not compromise human sperm motility. Human Reproduction, 28 (7), 1874−1889.10.1093/humrep/det064.
1.1.
2013
Saar, I.; Runesson, J.; Järv, J.; Kurrikoff, K.; Langel, Ü. (2013). Novel galanin receptor subtype specific ligand in depression like behavior. Neurochemical Research, 38 (2), 398−404.10.1007/s11064-012-0933-8.
1.1.
2013
Eriste, Elo; Kurrikoff, Kaido; Suhorutšenko, Julia; Oskolkov, Nikita; Copolovici, Dana Maria; Jones, Sarah; Howl, John; Laakkonen, Pirjo; Langel, Ülo (2013). Peptide-based glioma-targeted drug delivery vector gHoPe2. Bioconjugate Chemistry, 24 (3), 305−313.10.1021/bc300370w.
1.1.
2013
Anderson, M.E.; Runesson, J.; Saar, I.; Langel, Ü.; Robinson, J. (2013). Galanin, through GalR1 but not GalR2 receptors, decreases motivation at times of high appetitive behavior. Behavioural Brain Research, 239, 90−93.10.1016/j.bbr.2012.10.045.
1.1.
2013
Saar, Indrek; Lahe, Jaanus; Langel, Kent; Runesson, Johan; Webling, Kristin; Järv, Jaak; Rytkönen, Jussi; Närvänen, Ale; Bartfai, Tamas; Kurrikoff, Kaido; Langel, Ülo (2013). Novel systemically active galanin receptor 2 ligands in depression-like behavior. Journal of Neurochemistry, 127 (1), 114−123.10.1111/jnc.12274.
1.1.
2013
Yu, X.; Muñoz Alarcón, A.; Ajayi, A.; Webling, K.; Steinhof, A.; Langel, Ü.; Ström, A.-L. (2013). Inhibition of autophagy via p53-mediated disruption of ULK1 in a SCA7 polyglutamine disease model. Journal of Molecular Neuroscience, 50 (3), 586−599.10.1007/s12031-013-0012-x.
1.1.
2013
Vasconselos, L.; Pärn, K.; Langel, Ü. (2013). Therapeutic potential of cell-penetrating peptides. Therapeutic Delivery, 4 (5), 573−591.10.4155/tde.13.22.
1.1.
2013
Veiman, K.L.; Mäger, I.; Ezzat, K.; Margus, H.; Lehto, T.; Langel, K.; Kurrikoff, K.; Arukuusk, P.; Suhorutšenko, J.; Padari, K.; Pooga, M.; Lehto, T.; Langel, Ü. (2013). PepFect14 peptide vector for efficient gene delivery in cell cultures. Molecular Pharmaceutics, 10 (1), 199−210. DOI: 10.1021/mp3003557.
1.1.
2013
Arukuusk, P; Pärnaste, L.; Margus, H.; Eriksson, J.; Vasconcelos, L.;.Padari, K.; Pooga, M.; Langel, Ü. (2013). Differential endosomal pathways for radically modified peptide vectors. Bioconjugate Chemistry, 24 (10), 1721−1732. DOI: 10.1021/bc4002757.
1.1.
2013
Räägel, H.; Hein, M.; Kriiska, A.; Säälik, P.; Floren, A.; Langel, Ü.; Pooga, M. (2013). Cell-penetrating peptide secures an efficient endosomal escape of an intact cargo upon a brief photo-induction. Cellular and Molecular Life Sciences, 70, 4825−4839. DOI: 10.1007/s00018-013-1416-z.
1.1.
2013
Pärn, K.; Viru, L.; Lehto, T.; Oskolkov, N.; Langel, Ü.; Merits, A. (2013). Transfection of Infectious RNA and DNA/RNA Layered Vectors of Semliki Forest Virus by the Cell-Penetrating Peptide Based Reagent PepFect6. PLoS ONE, 8 (7), e69659.10.1371/journal.pone.0069659.
1.2.
2013
Regberg, J.; Eriksson, J. N.; Langel, Ü. (2013). Cell-penetrating peptides: from cell cultures to in vivo applications. Frontiers in Bioscience, 5, 509−516.
3.1.
2013
Muñoz-Alarcón, A.; Helmfors, H; Karlsson, K.; Langel, Ü. (2013). Cell-Penetrating Peptide Fusion Proteins. In: Stefan R. Schmidt (_EditorsAbbr). Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges (397−411).. John Wiley & Sons Ltd.
3.2.
2013
Zirk, Katrin; Langel, Ülo (2013). Vectorization of splice-correcting oligonucleotides with cell-penetrating peptides. Tecno Scienze Publisher.
1.1.
2012
Dash-Wagh, S.; Jacob, S.; Lindberg, S.; Friedberger, A.; Langel, Ü.; Ulfendahl, M. (2012). Intracellular Delivery of Short Interfering RNA in Rat Organ of Corti Using a Cell-penetrating Peptide PepFect6. Molecular theraphy-Nucleic acids, 1, e61−e61.10.1038/mtna.2012.50.
1.1.
2012
Nakase, I.; Akita, H.; Kogure, K.; Gräslund, A.; Langel, Ü.; Harashima, H.; Futaki, S. (2012). Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides. Accounts of Chemical Research, 45 (7), 1132−1139.
1.1.
2012
Mäe, M.; Rautsi, O.; Enbäck, J.; Hällbrink, M.; Rosenthal Aizman, K.; Lindgren, M.; Laakonen, P.; Langel, Ü. (2012). Tumour Targeting with Rationally Modified Cell-Penetrating Peptides. International Journal of Peptide Research and Therapeutics, 18 (4), 361−371.10.1007/s10989-012-9312-1.
1.1.
2012
Webling, K.E.B.; Runesson, J.; Bartfai, T.; Langel, Ü. (2012). Galanin receptors and ligands. Front Endocrinol (Lausanne), 3, 1−14.10.3389/fendo.2012.00146.
1.1.
2012
Tanaka, G.; Nakase, I.; Fukuda, Y.; Masuda, R.; Oishi, S.; Shimura, K.; Kawaguchi, Y.; Takatani-Nakase, T.; langel, Ü.; Gräslund, A.; Okawa, K.; Matsuoka, M.; Tsujimoto, G.; Fujii, N.; Hatanaka, Y.; Futaki, S. (2012). CXCR4 stimulates macropinocytosis: implicatins for cellular uptake of arginine-rich cell-penetrating peptides and HIV. Chemistry & Biology, 19 (11), 1437−1446.10.1016/j.chembiol.2012.09.011.
1.1.
2012
Anko, M; Majhenc, J; Kogej, K; Sillard, R; Langel, Ü; Anderluh, G; Zorko, M (2012). Influence of stearyl and trifluoromethylquinoline modifications of the cell penetrating peptide TP10 on its interaction with a lipid membrane. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1818 (3), 915−924.10.1016/j.bbamem.2011.12.028.
1.1.
2012
Ajayi, A; Yu, X; Lindberg, S; Langel, Ü and Ström, A-L. (2012). Expanded ataxin-7 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible Spinocerebellar ataxia type 7 (SCAT7) model. BMC Neuroscience, 13, 86.10.1186/1471-2202-13-86.
1.1.
2012
Lorents, A.; Oskolkov, N.; Langel, Ü.; Hällbrink, M.; Pooga, M. (2012). Cell-penetrating peptides split into two groups based on the modulation of the intracellular calcium concentration. Journal of Biological Chemistry, 287 (20), 16880−16889. DOI: 10.1074/jbc.M111.318063.
1.1.
2012
Suhorutsenko, J.; Eriste, E.; Copolovici, D. M.; Langel, Ü. (2012). Human Protein 53-Derived Cell-Penetrating Peptides. International Journal of Peptide Research and Therapeutics, 18 (4), 291−297.10.1007/s10989-012-9302-3.
1.1.
2012
Mäger, Imre; Langel, Kent; Lehto, Taavi; Eiriksdottir, Emelia; Langel, Ülo (2012). The role of endocytosis on the uptake kinetics of luciferin-conjugated cell-penetrating peptides. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1818 (3), 502−511.10.1016/j.bbamem.2011.11.020.
1.1.
2012
Ezzat, K.; Helmfors, H.; Tudoran, O.; Juks, C.; Lindberg, S.; Padari, K.; El-Andaloussi, S.; Pooga, M.; Langel, Ü. (2012). Scavenger receptor-mediated uptake of cell-penetrating peptide nanocomplexes with oligonucleotides. The FASEB Journal, 26 (3), 1172−1180. DOI: 10.1096/fj.11-191536.
1.1.
2012
Lehto, T; Kurrikoff, K; Langel, Ü. (2012). Cell-penetrating peptides for the delivery of nucleic acids. Expert Opinion on Drug Delivery, 9 (7), 823−836.10.1517/17425247.2012.689285.
1.1.
2012
Laffray, S.; Bouali-Benazzouz, R.; Papon, M.-A.; Favereaux, A.; Jiang, Y.; Holm, T.; Spriet, C.; Desbarats, P.; Fossat, P.; Le Feuvre, Y.; Decossas, M.; Héliot, L.; Langel, Ü.; Nagy, F.; Landry, M. (2012). Impairment of GABAB receptor dimer by endogeneous 14-3-3ζ in chronic pain conditions. The EMBO Journal, 31 (15), 3239−3251.10.1038/emboj.2012.161.
1.1.
2012
Howl, J.; Matou-Nasri, S.; West, D.C.; Farquhar, M.; Slaninova, J.; Östenson, C-G., Zorko, m.; Östlund, P., Kumar, S.; Langel, Ü.; McKeating, J.; Jones, S. (2012). Bioportide:An Emergent Concept of Bioactive Cell-Penetrating Peptide. Cellular and Molecular Life Sciences, 69 (17), 2951−2966.
1.1.
2012
Holm, T.; Bruchmann, J.; Johansson, C.; Scheynius, A.; and Langel, Ü. (2012). Malassezia sympodialis. Letters in Applied Microbiology, 54 (1), 39−44.10.1111/j.1472-765X.2011.03168.x.
1.1.
2012
Helmfors, H.; Langel, Ü. (2012). Recent developments in applications of cell-penetrating peptides. Chimica Oggi-Chemistry Today, 30 (2), 10−12.
1.1.
2012
Regberg, J.; Srimanee, A.; Langel, Ü. (2012). Applications of Cell-Penetrating Peptides for tumor Targeting and Future Cancer Therapies. Pharmaceuticals, 5 (9), 991−1007.10.3390/ph5090991.
1.2.
2012
Ezzat, K.; Zaghloul, E. M.; EL-Andaloussi, S.; Lehto, T.; EL-Sayed, R.; Magdy, T.; Smith, C.I.E., Langel, Ü. (2012). Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions. The Journal of Control Release, 162, 1−8.
1.2.
2012
Langel, Ü.; Erlandsson, M. (2012). Recent Developments in Applications of Cell-penetrating Peptides. International Drug Discovery, 1−4.
1.2.
2012
Muńoz-Alarcón, A.; Guterstam, P.; Romero, C.; Behlke, M. A.; Lennox, K.; Wengel, J.; EL Andaloussi, S.; and Langel, Ü. (2012). Modulating anti-microRNA21 activity and specificity using oligonucleotide derivatives and length optimization. ISRN Pharmaceutics, 2012, 2012:407154. DOI: 10.5402/2012/407154.
3.1.
2012
Kurrikoff, K.; Suhorutsenko, J.; Langel, Ü. (2012). Cell-Penetrating Peptides in Cancer Targeting. In: Felix Kratz, Peter Senter, Henning Steinhagen (Ed.). Drug Delivery in Oncology: From Basic Research to Cancer Therapy (1189−1217).. Wiley-V C H Verlag Gmbh.
1.1.
2011
Said, H. S.; Abes, R., El Andaloussi, S.; Lehto, T.; Sillard, R.; Langel, Ü.; Lebleu, B. (2011). Insights into the cellular trafficking of spice redirecting oligonucleotides complexed with chemically modified cell-penetrating peptides. Journal of Controlled Release, 153, 163−172.10.1016/j.jconrel.2011.04.013.
1.1.
2011
Öjemalm, K.; Higuchi, T.; Jiang, Y.; Langel, Ü., Nilsson, I.; White, S. H.; Suga, H.; von Heijne, G. (2011). Apolar surface area determines the efficiency of translocon-medaited membrane protein insertion into the endoplasmic reticulum. Proceedings of the National Academy of Sciences, 108 (31), E359−E364.10.1073/pnas.1100120108.
1.1.
2011
Mann, A.; Thakur, G.; Shukla, V.; Singh, A. K.; Khanduri, R.; Naik, R.; Jiang, Y.; Kalra, N.; Dwarakanath, B. S.; Langel, Ü.; Ganguli, M. (2011). Differences in DNA condensation and release by lysine and arginine homopeptides govern their DNA delivery efficiencies. Molecular Pharmaceutics, 8 (5), 1729−1741.10.1021/mp2000814.
1.1.
2011
Viru, L.; Heller, G.; Lehto, T.; Pärn, K.; El Andaloussi, S.; Langel, Ü.; Merits, A. (2011). Novel viral vectors utilizing intron splice-switch to activate genome rescue, expression and replication in targeted cells. Virology Journal, 8 (1), 243.
1.1.
2011
Oskolkov, N.; Arukuusk, P.; Copolovici, D.-M.; Lindberg, S.; Margus, H.; Padari, K.; Pooga, M.; Langel, Ü. (2011). NickFects, Phosphorylated Derivatives of Transportan 10 for Cellular Delivery of Oligonucleotides. International Journal of Peptide Research and Therapeutics, 17 (2), 147−157. DOI: 10.1007/s10989-011-9252-1.
1.1.
2011
Saar, I., Runesson, J., McNamara, I., Järv, J., Robinson, J.K., Langel, U. (2011). Novel galanin receptor subtype specific ligands in feeding regulation. Neurochemistry International, 714−720.10.1016/j.neuint.2011.02.012.
1.1.
2011
Ezzat, K.; EL Andaloussi, S.; Zaghloul, EM.; Lehto, T.; Lindberg, S.; Moreno, P. M. D.; Viola, J.; Magdy, T.; Abdo, R.; Guterstam, P.; Sillard, R.; Hammond, S. M.; Wood, MJA.; Arzumanov, AA.; Gait, MJ.; Smith, CIE.; Hällbrink, M.; Langel, Ü. (2011). PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Research, 39 (12), 5284−5298.
1.1.
2011
Säälik, P.; Niinep, A.; Pae, J.; Hansen, M.; Lubenets, D.; Langel, Ü.; Pooga, M. (2011). Penetration without cells: membrane translocation of cell-penetrating peptides in the model giant plasma membrane vesicles. Journal of Controlled Release, 153 (2), 117−125.
1.1.
2011
El Andaloussi, S; Lehto, T; Mager, I; Rosenthal-Aizman, K; Oprea, I.I; Simonson, O.E; Sork, H; Ezzat, K; Copolovici, D.M; Kurrikoff, K; Viola, J.R; Zaghloul, E.M; Sillard, R; Johansson, H. J; Hassane, F.S; Guterstam, P.; Suhorutsenko, J.; Moreno, P. M. D.; Oskolkov, N; Halldin, J ... Langel, U. (2011). Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Research, 39 (9), 3972−3987. DOI: 10.1093/nar/gkq1299.
1.1.
2011
Holm, T.; Räägel, H.; El Andaloussi, S.; Hein, M.; Mäe, M.; Pooga, M.; Langel, Ü. (2011). Retro-inversion of certain cell-penetrating peptides causes severe cellular toxicity. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1808 (6), 1544−1551. DOI: 10.1016/j.bbamem.2010.10.019.
1.1.
2011
Lehto, T.; Ezzat, K.; Langel, Ü. (2011). Peptide nanoparticles for oligonucleotide delivery. In: Villaverde, A. (Ed.). Nanoparticles in Translational Science and Medicine; Progress in Molecular Biology and Translation Science (397−426).. Elsevier.10.1016/B978-0-12-416020-0.00010-3.
1.1.
2011
Suhorutšenko, J.; Oskolkov, N.; Arukuusk, P.; Kurrikoff, K.; Eriste, E.; Copolovici, D.-M.; Langel, Ü. (2011). Cell-Penetrating Peptides, PepFects, Show No Evidence of Toxicity and Immunogenicity In Vitro and In Vivo. Bioconjugate Chemistry, 22 (11), 2255−2262.10.1021/bc200293d.
1.2.
2011
Lindberg, S.; Copolovici, D.M.; Langel, Ü. (2011). Therapeutic delivery opportunities, obstacles and applications for cell-penetrating peptides. Therapeutic Delivery, 2, 71−82.
1.2.
2011
Madani, F.; Lindberg, S.; Langel, Ü.; Futaki, S.; Gräslund, A. (2011). Mechanisms of cellular uptake of cell penetrating peptides. Journal of Biophysics, 1−10. DOI: 10.1155/2011/414729.
3.1.
2011
El Andaloussi, S; Said, H. F; Boisguerin, P.; Sillard, R.; Langel, Ü.; Lebleu, B. (2011). Cell-penetrating peptides-based strategies for the delivery of splice redirecting antisense oligonucleotides. In: Methods in Molecular Biology (75−89).. Springer.
3.1.
2011
Johansson, H, J; EL Andaloussi, S; Langel, Ü. (2011). Mimicry of protein function with cell-penetrating peptides. In: Langel Ülo (_EditorsAbbr). Cell-Penetrating Peptides. Methods in Molecular Biology. (233−247).. Humana Press. (4).
3.1.
2011
Bell, T.J.; Eiriksdottir, E.; Langel, Ü.; Eberwine, J. (2011). PAIR technology: exon-specific RNA binding protein isolation in live cells. In: Langel, Ülo (_EditorsAbbr). Cell-Penetrating Peptides. Methods and Protocols. Methods in Molecular Biology. (473−486).. Humana Press.
3.1.
2011
EL Andaloussi, S.; Lehto, T.; Lundin, P.; Langel, Ü. (2011). Application of PepFect peptides for the delivery of splice-correcting oligonucleotides. In: Langel, Ü. (Ed.). Cell-Penetrating Peptides. Methods adn Protocols. Methods in Molecular Biology (361−374).. Humana Press. (4).
3.1.
2011
Guterstam, P.; EL Andaloussi, S.; Langel, Ü. (2011). Charaterization of cellular internalization pathways for CPP-mediated oligonucleotide delivery. In: Langel, Ü. (_EditorsAbbr). Cell-Penetrating Peptides. Methods and Protocols. Methods in Molecular Biology (219−230).. Humana Press. (4).
3.1.
2011
Holm, T.; EL Andaloussi, S.; Langel, Ü. (2011). Comparison of CPP uptake methods. In: Langel, Ülo (_EditorsAbbr). Cell-Penetrating Peptides. Methods and Protocols. Methods in Molecular Biology. (207−217).. Humana Press. (4).
3.1.
2011
Lundin, P.; EL Andaloussi, S.; Langel, Ü. (2011). Toxicity methods for CPPs. In: Langel, Ülo (_EditorsAbbr). Cell-Penetrating Peptides. Methods and Protocols. Methods in Molecular Biology (195−205).. Humana Press. (4).
3.1.
2011
Floren, A.; Mäger, I.; Langel, Ü. (2011). Uptake kinetics of cell-penetrating peptides. In: Langel, Ü. (_EditorsAbbr). Cell-Penetrating Peptides. Methods and Protocols. Methods in Molecular Biology (117−128).. Humana Press. (4).
3.1.
2011
Lindgren, M.; Langel, Ü. (2011). Classes and prediction of cell-penetrating peptides. In: Langel, Ülo (_EditorsAbbr). Cell-Penetrating Peptides. Methods and Protocols. Methods in Molecular Biology (3−19).. Humana Press.
3.1.
2011
Langel, Ü. (2011). Cell-Penetrating Peptides (eessõna). In: Langel, Ü. (_EditorsAbbr). Methods and Protocols. Methods in Molecular Biology (5−6).. Humana Press. (4).
3.1.
2011
Räägel, Helin; Säälik, Pille; Langel, Ülo; Pooga, Margus (2011). Mapping of Protein Transduction Pathways with Fluorescent Microscopy. In: Langel, Ülo (Ed.). Cell-Penetrating Peptides: Methods and Protocols, Methods in Molecular Biology (165−179). . Springer. DOI: 10.1007/978-1-60761-919-2_12.
5.2.
2011
Part, Kristin; Rosenthal-Aizman, Katri; Oskolkov, Nikita; Land, Tiit; Langel, Ülo; Z. Fernaeus, Sandra. (2011). Co-transfection of siRNA and plasmid DNA using the cell-penetrating peptide PepFect6 in cell-culture. Peptide Vectors and Delivery of Therapeutics Tallinn, Estonia, May 19th - 21st 2011. -, 44−44.
1.1.
2010
Langel, K; Lindberg, S; Copolovici, D; Arukuusk, P; Sillard, R; Langel, Ü. (2010). Novel fatty acid modifications of transportan 10. International Journal of Peptide Research and Therapeutics, 16 (4), 247−255.10.1007/s10989-010-9224-x.
1.1.
2010
Jones, S.; Holm, T.; Mäger, I.;, Langel, Ü.; Howl, J. (2010). Characterization of bioactive cell penetrating peptides from human cytochrome c: protein mimicry and the development of a novel apoptogenic agent. Chemistry & Biology, 17 (7), 735−744.
1.1.
2010
Eiriksdottir, E.; Mäger, I.; Lehto, T.; EL Andaloussi, S.; Langel, Ü. (2010). Cellular Internalization Kinetics of Luciferin-Cell-Penetrating Peptide Conjugates. Bioconjugate Chemistry, 21 (9), 1662−1672.10.1021/bc100174y.
1.1.
2010
Runesson, J.; Sollenberg, U.E.; Jurkowski, W.; Yazdi, S.; Eriksson, E.E.; Elofsson, A.; Langel, Ü. (2010). Determining receptor-ligand interaction of human galanin receptor type 3. Neurochemistry International, 57 (7), 804−811.
1.1.
2010
Dobchev, D. A.; Mäger, I.; Tulp, I.; Karelson, G.; Tamm, T.; Tämm, T.; Jänes, J.; Langel, Ü.; Karelson, M. (2010). Prediction of Cell-Penetrating Peptides Using Artificial Neural Networks. Current Computer - Aided Drug Design, 6 (2), 79−89.
1.1.
2010
Sollenberg, U. E.; Runesson, J,: Sillard, R.; Langel, Ü. (2010). Binding of chimeric peptides M617 and M871 to galanin receptor type 3 reveals characteristics of galanin receptor-ligand interaction. International Journal of Peptide Research and Therapeutics, 16 (1), 17−22.10.1007/s10989-009-9197-9.
1.1.
2010
Ezzat, K.; El-Andaloussi, S.; Abdo, R.; Langel, Ü. (2010). Peptide-Based Matrices as Drug Delivery Vehicles. Current Pharmaceutical Design, 16 (9), 1167−1178.
1.1.
2010
Fossat, P.; Dobremez, E.; Bouali-Benazzouz, R.; Favereaux, A.; Bertrand, SS.; Kilk, K.; Léger, C.; Cazalets, JR.; Langel, Ü.; Landry, M.; Nagy, F. (2010). Knockdown of L calcium channel subtypes: differential effects in neuropathic pain. Journal of Neuroscience, 30, 3, 1073−1085.
1.1.
2010
Lehto, Taavi; Abes, Rachida; Oskolkov, Nikita; Suhorutsenko, Julia; Copolovici, Dana-Maria; Mager, Imre; Viola, Joana R.; Simonson, Oscar E.; Ezzat, Kariem; Guterstam, Peter; Eriste, Elo; Smith, C. I. Edvard; Lebleu, Bernard; El Andaloussi, Samir; Langel, Ulo (2010).

Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy

. Journal of Controlled Release, 141 (1), 42−51. DOI: 10.1016/j.jconrel.2009.08.028.
1.1.
2010
Järver, P.; Mäger, I.; Langel, Ü. (2010). In vivo biodistribution and efficacy of peptide mediated delivery. Trends in Pharmacological Sciences, 31 (11), 528−535.10.1016/j.tips.2010.07.006.
1.1.
2010
Mäger, I.; Eiríksdóttir, E.; Langel, K.; Andalouss, S.E.; Langel, Ü. (2010). Assessing the uptake kinetics and internalization mechanisms of cell-penetrating peptides using a quenched fluorescence assay. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1798 (3), 338−343.10.1016/j.bbamem.2009.11.001.
1.2.
2010
Saar, K.; Saar, H.; Hansen, M.; Langel, Ü.; Pooga, M. (2010). Distribution of CPP-Protein Complexes in Freshly Resected Human Tissue Material. Pharmaceuticals, 3 (3), 621−635. DOI: 10.3390/ph3030621.
3.4.
2010
Säälik, P.; Niinep, A.; Pae, J.; Hansen, M.; Langel, Ü.; Pooga, M. (2010). Interaction of cell-penetrating peptides in the model of giant plasma membrane vesicles. Peptides 2010: The 31st European Peptide Symposium; Copenhagen; September 5-9 2010. Ed. Lebl, M.; Meldal, M.; Jensen, K.J.; Hoeg-Jensen, T. European Peptide Society, 410−411.
5.1.
2010
Lorents, A.; Oskolkov, N.; Tõnissoo, T.; Langel, Ü.; Hällbrink, M.; Pooga, M. (2010). Amphipathic CPPs upregulate Ca in cells’ cytosol and induce lysosomal exocytosis. In: (A34). . DOI: 10.1016/j.drudis.2010.09.385.
5.1.
2010
Suhorutsenko, J.; Copolovici, D. M.; Eriste, E.; Oskolkov, N.; Arukuusk, P.; Langel, Ü. (2010). New cell-penetrating peptides induce no inflammatory response in antigen-presenting cell lines. Scandinavian Journal of Immunology, 71, 508−509.
5.1.
2010
Padari, K.; Juks, C.; Oskolkov, N.; Raid, R.; Langel, Ü.; Pooga, M. (2010). Cellular delivery of oligonucleotides by PepFect. In: (1092−1093). . DOI: 10.1016/j.drudis.2010.09.386.
5.1.
2010
Pooga, M.; Säälik, P.; Niinep, A.; Pae, J.; Lubenets, D.; Hansen, M.; Langel, Ü. (2010). Interaction of cell-penetrating peptides with giant plasma membrane vesicles. JOURNAL OF PEPTIDE SCIENCE, 16: The 31st European Peptide Symposium; Copenhagen; September 5-9 2010. , 150. (Suppl 1).
1.1.
2009
Guterstam, P.; Madani, F.; Hirose, H.; Takeuchi, T.; Futaki, S.; El-Andaloussi, S.; Gräslund, A.; Langel, Ü. (2009). Elucidating cell-penetrating peptide mechanisms of action for membrane interaction, cellular uptake, and translocation utilizing the hydrophobic counter-anion pyrenebutyrate. Biochimica et Biophysica Acta, 12 (1788), 2509−2517. DOI: 10.1016/j.bbamem.2009.09.014.
1.1.
2009
Kilk, K.; Mahlapuu, R.; Soomets, U.; Langel, Ü. (2009). Analysis of in vitro toxicity of five cell-penetrating peptides by metabolic profiling. Toxicology, 265 (3), 87−95.
1.1.
2009
Mäe, M.; El-Andaloussi, S.; Lundin, P.; Oskolkov, N.; Johansson, H.J.; Guterstam, P.; Langel, Ü. (2009). A stearylated CPP for delivery of splice correcting oligonucleotides using a noncovalent co-incubation strategy. Journal of Controlled Release, 134 (3), 221−227.
1.1.
2009
Mäe, M.; Myberg, H.; El-Andaloussi, S.; Langel, Ü. (2009). Design at a tumour harving cell-penetrating peptides for drug delivery. International Journal of Peptide Research and Therapeutics, 15, 11−15.
1.1.
2009
Mäe, M.; El-Andaloussi, S.; Lehto, T.; Langel, Ü. (2009). Chemically modified cell-penetrating peptides for the delivery of nucleic acids. Expert Opinion on Drug Delivery, 6 (11), 1195−1205. DOI: 10.1517/17425240903213688.
1.1.
2009
Eiriksdóttir, E.; Langel, Ü.; Rosenthal-Aizman, K. (2009). An improved synthesis of releasable luciferin-CPP conjugates. Tetrahedron Letters, 50, 4731−4733.
1.1.
2009
Räägel, H.; Säälik, P.; Hansen, M., Langel, Ü.; Pooga, M. (2009). Cell-penetrating peptides-protein constructs induce a population of non-acidic vesicles during trafficking through the endolysosomal pathway. Journal of Controlled Release, 139 (2), 108−117. DOI: 10.1016/j.jconrel.2009.06.028.
1.1.
2009
Runesson, J.; Saar, I.; Lundström, L.; Järv, J.; and Langel, Ü. (2009). A novel GalR2-specific peptide agonist. Neuropeptides, 43 (3), 187−192.
1.1.
2009
Säälik, P.; Padari, K.; Niinep, A.; Lorents, A.; Hansen, M.; Jokitalo, E.; Langel, Ü.; Pooga, M. (2009). Protein delivery with transportans is mediated by caveolae rather than flotillin-dependent pathways. Bioconjugate Chemistry, 20 (5), 877−887. DOI: 10.1021/bc800416f.
3.1.
2009
Runesson, J.; Robinson, J.; Sollenberg, U.; Langel, Ü. (2009). Twenty-five years of galanin research. In: J. Howl (_EditorsAbbr). Bioactive peptides (237−260).. Boca Raton: CRC Press Inc.. (CRC Handbook).
3.1.
2009
Langel, Ü.; Cravatt, B.; Gräslund, A.; von Heijne, G.; Land, T.; Niessen, S.; Zorko, M. (2009). Introduction to peptides and proteins. In: Introduction to peptides and proteins (x−x).. London, New York: Taylor & Francis Inc.
3.1.
2009
Hansen, M.; Eriste, E. Langel Ü. (2009). The Internalization mechanisms and Bioactivity of the Cell-Penetrating Peptides. In: Gröner, B. (Ed.). Peptides as Drugs: Discovery and Development, (125−143).. John Wiley & Sons Ltd.
3.4.
2009
Säälik, P.; Räägel, H.; Hansen, M.; Langel, Ü.; Pooga, M. (2009). Protein delivery with transportans avoids recycling endosomal route and is not potentiated by EGF. In: Lankinen, H. (Ed.). Peptides 2008 (390−391). . University of Helsinki.
5.1.
2009
Runesson, J.; Saar, I.; Järv, J.; Langel, Ü. (2009). Novel peptide agonists, favoring galanin receptor type 2 over galanin receptor type 1 and 3. FEBS JOURNAL, 276: 34th Congress of the Federation-of-European-Biochemical-Societies; Prague, CZECH REPUBLIC; JUL 04-09, 2009. 164. (Suppl. 1).
5.2.
2009
Laur, Kristi; Langel, Ülo; Kogerman, Priit; Valkna, Andres (2009). Regulation of transcription factor Gli activity using oligodeoxynucleotide decoy bound to Transportan 10. Spetsai Summer School: Proteins and their Networks - from specific to global analysis; Spetsese saar, Kreeka; 7.09.2009-17.09.2009.
5.2.
2009
Laur, Kristi; Langel, Ülo; Kogerman, Priit; Valkna, Andres. (2009). Regulation of transcription factor GLI activity using oligodeoxynucleotide decoy with Transportan. 3rd Intracellular Delivery of Therapeutic Molecules: From Bench to Bedside. 15 years of cell-penetrating peptides: from molecular mechanisms to the clinic: 3rd Intracellular Delivery of Therapeutic Molecules: From Bench to Bedside; Montpellier, France; 31.08.2009-2.09.2009. 42−42.
6.3.
2009
Pooga, M.; Langel, Ü.; Hansen, M., Soomets, U.; Kilk, K. (2009). Rakusisesed märklauad. Villems, R. (Toim.). Eesti Vabariigi Teaduspreemiad (72−85). . Tallinn: Eesti Teaduste Akadeemia.
1.1.
2008
Järver, P.; Fernaeus, S.; El-Andaloussi, S.; Tjörnhammar, M.-L.; Langel, Ü. (2008). Co-Transduction of Sleeping Beauty Transposase and donor Plasmid via a Cell-penetrating Peptide. A simple one step method. International Journal of Peptide Research and Therapeutics, 14 (1), 58−63. DOI: 10.1007/s10989-007-9114-z.
1.1.
2008
Lundin, P.; Johansson, H.; Guterstam, P.; Holm, T.; Hansen, M.; Langel, Ü.; EL Andaloussi, S. (2008). Distinct Uptake Routes of Cell-Penetrating Peptide Conjugates. Bioconjugate Chemistry, 19 (12), 2535−2542. DOI: 10.1021/bc800212j.
1.1.
2008
Arsov, Z.; Nemec, M.; Schara, M.; Johansson, H.; Langel, Ü.; and Zorko, M. (2008). Cholesterol prevents interaction of the cell-penetrating peptide transportan with model lipid membranes. Journal of Peptide Science, 14 (12), 1303−1308.
1.1.
2008
Arrighi, R.; Ebikeme, C.; Jiang, Y.; Ranford-Cartwright, L.; Barrett, M.; Langel, U.; Faye, I. (2008). Cell-penetrating peptide TP10 shows broad-spectrum activity against both Plasmodium falciparum and Trypanosoma brucei brucei. Antimicrobial Agents and Chemotherapy, 52 (9), 3414−3417.
1.1.
2008
Vukojević, V.; Ming, Y.; D`Addario, C.; Hansen, M.; Langel, Ü.; Schultz, R.,Johansson, B.; Rigler, R.; Terenius, L. (2008). µ-Opioid receptor activation in live cells. The FASEB Journal, 22 (10), 3537−3548. DOI: 10.1096/fj.08-108894.
1.1.
2008
Oglecka, K.; Lundberg, P.; Magzoub, M.; Eriksson, L. E. G.; Langel, Ü.; Gräslund, A. (2008). Relevance of the N-terminal NLS-like Sequence of the Prion Protein for Membrane Perturbation Effects. Biochimica et Biophysica Acta, 1778 (1), 206−213. DOI: 10.1016/j.bbamem.2007.09.034.
1.1.
2008
Myrberg, H.; Zhang, L.; Mäe, M.; Langel, Ü. (2008). Design of a tumor-homing cell-penetrating peptide. Bioconjugate Chemistry, 19 (1), 70−75. DOI: 10.1021/bc0701139.
1.1.
2008
Löfgren, K.; Wahlström, A.; Lundberg, P.; Langel, Ü.; Gräslund, A. (2008). Antiprion properties of prion protein-derived cell-penetrating peptides. The FASEB Journal, 22 (7), 2177−2184. DOI: 10.1096/fj.07-099549.
1.1.
2008
Kuteeva, E.; Wardi, T.; Lundström, L.; Sollenberg, U.; Langel, Ü.; Hökfelt, T.; Ögren, S.- O. (2008). Differential Role of Galanin Receptors in the Regulation of Depression-like Behavior and Monoamine/Stress-Related Genes at the Cell Body Level. Neuropsychopharmacology, 33 (11), 2573−2585. DOI: 10.1038/sj.npp.1301660.
1.1.
2008
Holmström, T.; Mialon, A.; Kallio, M.; Nymalm, Y.; Mannermaa, L.; Holm, T.; Johansson, H.; Black, E.; Gillespie, D.; Salminen, T. A.; Langel, Ü.; Valdez, B.; Westermarck, J. (2008). c-Jun Supports Ribosomal RNA processing and nucleolar localization of RNA Helicase DDX21. Journal of Biological Chemistry, 283 (11), 7046−7053. DOI: 10.1074/jbc.M709613200.
1.1.
2008
Hawes, J. J.; Brunzell, D.; Narasimhaiah, R., Langel, Ü.; Wynick, D.; Picciotto, M. (2008). Galanin protects against behavioral and neurochemical correlates of opiate reward. Neuropsychopharmacology, 33 (8), 1864−1873. DOI: 10.1038/sj.npp.1301579.
1.1.
2008
Guterstam, P.; Lindgren, M.; Johansson, H.; Tederbark, U.; Wengel, J.; El-Andaloussi, S.; Langel, Ü. (2008). Splice switching efficiency and specificity for locked nucleic acids. Biochemical Journal, 412 (2), 307−312.
1.1.
2008
Fuxe, K.; Marcellino, D.; Rivera, A.; Diaz-Cabiale, Z.; Filip, M.; Gago, B.; Roberts, D. C.; Langel, Ü.; Genedani, S.; Ferraro, L.; de la Calle, A.; Narvaez, J.; Tanganelli, S.; Woods, A.; Agnati, L. F. (2008). Receptor- receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Research Reviews, 58, 2, 415−452. DOI: 10.1016/j.brainresrev.2007.11.007.
1.1.
2008
Alier, K. A.; Chen, Y., Sollenberg, U. E.; Langel, Ü.; Smith, P. A. (2008). Selective stimulation of GalR1 and GalR2 in rat in rat substantia gelatinosa reveals a cellular basis for the anti- and pronociceptive actions of galanin. Pain, 137 (1), 138−146. DOI: 10.1016/j.pain.2007.08.030.
1.1.
2008
Hansen, M.; Kilk, K.; Langel, Ü. (2008). Predicting cell-penetrating peptides. Advanced Drug Delivery Reviews, 60, 572−579. DOI: 10.1016/j.addr.2007.09.003.
1.1.
2008
Johansson, H.J.; El-Andaloussi, S.; Holm, T.; Mäe, M.; Jänes, J.; Maimets, T.; Langel, Ü. (2008). Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein. Molecular therapy, 16 (1), 115−123.
1.1.
2007
Yandek, L.E.; Pokorny, A.; Floren, A.; Knoelke, K.; Langel, Ü.; Almeida, P.F.F. (2007). Mechanism Cell-Penetrating Peptide Tp10 Permeation of Lipid Bilayers. Biophysical Journal, 92 (7), 2434−2444.
1.1.
2007
Myrberg, H.; Lindgren, M.; Langel, Ü. (2007). Protein Delivery by the Cell-penetrating Peptide YTA2. Bioconjugate Chemistry, 18 (1), 170−174.
1.1.
2007
Lundström, L.; Sollenberg, U.; Langel, Ü. (2007). Molecular characterization of the ligand binding site of the human galanin receptor type 2, identifying subtype selective interactions. Journal of Neurochemistry, 103 (5), 1774−1784.
1.1.
2007
Fisher, L.; Samuelsson, M.; Jiang, Y., Ramberg, V.; Figuero, R.; Hallberg, E.; Langel, Ü.; Iverfeldt, K. (2007). Targeting cytokine expression in glial cells by cellular delivery of an NF-kB decoy. Journal of Molecular Neuroscience , 31 (3), 209−219.
1.1.
2007
El-Andaloussi, S.; Johansson, H.; Holm, T.; Langel, Ü. (2007). A novel cell-penetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids. Molecular Therapy, 15 (10), 1820−1826. DOI: 10.1038/sj.mt.6300255.
1.1.
2007
El-Andaloussi, S.; Guterstam, P.; Langel, Ü. (2007). Assessing the delivery efficacy and internalization route of cell-penetrating peptides. Nature Protocols, 2 (8), 2043−2047. DOI: 10.1038/nprot.2007.302.
1.1.
2007
Bodor, N.; Toth-Sarudy, É.; Holm, T.; Pallagi, I.; Vass, E. P.; Buchwald, P.T.; Langel, Ü. (2007). Novel, cell-penetrating molecular transporters with flexible backbones and permanently charged side chains. Journal of Pharmacy and Pharmacology, 59 (8), 1065−1076.
1.1.
2007
Blackshear, A.; Yamamoto, M.; Anderson, B.J.; Holmes, P.V.; Lundström, L.; Langel, Ü.; Robinson, J.K. (2007). Intracerebroventricular administration of galanin or galanin receptor subtype 1 agonist M617 induces c-Fos activation in a central amygdala and dorsomedial hypothalamus. Peptides, 28 (5), 1120−1124.
1.1.
2007
Barany-Wallje, E.; Gaur, J.; Lundberg, P.; Langel, Ü.; Gräslund, A. (2007). Cell-penetrating peptides: membrane perturbation effects caused by Tp10 attached to bioactive cargoes. FEBS Letters, 581 (13), 2389−2393.
1.1.
2007
Bavec, A.; Jiang, Y.; Langel, Ü.; Zorko, M. (2007). Role of cysteine 341 and arginine 348 of GLP-1 receptor in G-protein coupling. Molecular Biology Reports, 34 (1), 53−60.
1.1.
2007
El-Andaloussi, S.; Järver, P.; Johansson, H.J.; Langel, Ü. (2007). Cargo dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochemical Journal, 407 (2), 285−292. DOI: 10.1042/BJ20070507.
1.1.
2007
Ehrlich, K.; Viirlaid, S.; Mahlapuu, R.; Saar, K.; Kullisaar, T.; Zilmer, M.; Langel, Ü.; Soomets, U. (2007). Design, synthesis and properties of novel powerful antioxidants, glutathione analogues. Free Radical Research, 41 (7), 779−787.
1.1.
2007
Fuxe, K.; Canals, M.; Torvinen, M.; Marcellino, D.; Terasmaa, A.; Genedani, S.; Leo, G.; Guidolin, G.; Diaz-Cabiale, Z.; Rivera, A.; Lundström, L.; Langel, Ü.; Narvaez, J.; Tanganelli, S.; Lluis, C.; Ferre, S.; Woods, A.; Franco, R.; Agnati, LF. (2007). Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. Journal of Neural Transmission, 114 (1), 49−75. DOI: 10.1007/s00702-006-0589-0.
1.1.
2007
Lundberg, P.; El -Andaloussi, S.; Sütlü, T.; Johansson, H.; Langel, Ü. (2007). Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. The FASEB Journal, 21 (11), 2664−2671. DOI: 10.1096/fj.06-6502com.
1.2.
2007
Järver, P.; Langel, K.; El-Andaloussi, S.; Langel, Ü. (2007). Applications of cell-penetrating peptides in regulation of gene expression. Biochemical Society Transactions, 35 (4), 770−774.
3.1.
2007
Jones, S.; Östlund, P.; Langel, Ü.; Zorko, M.; Nicholl, I.; Howl, J. (2007). A rhegnylogic strategy for the synthesis of signal transduction modulatory, cell penetrating peptides. In: Rolka, K.; Rekovski, P.; Silberring, J. (_EditorsAbbr). Peptides 2006 (430−443).. Kenes International: Geneva University Press.
3.1.
2007
Lundberg, P.; Kilk, K.; Langel, Ü. (2007). Cell-penetrating peptide mediated delivery of peptide nucleic acid oligomers. In: Friedmann, T.; Rossi, J. (Ed.). Gene Transfer. Delivery And Expression of DNA And RNA (581−586).. New York: Cold Spring Harbor Laboratories Press.
5.1.
2007
Lorents, A.; Padari, K.; Hansen, M.; Langel, Ü.; Pooga, M. (2007). Biogenesis of VGF secretory granules in epithelial thyroid cells. FEBS Journal, 274. , 97.
1.1.
2006
Mäe, M.; Langel, Ü. (2006). Cell-penetrating peptides as vectors for peptide protein and oligonucleotide delivery. Current Opinion in Pharmacology, 6 (5), 509−514.
1.1.
2006
Mazarati, A.; Sollenberg, UE.; Lundström, L.; Shin, D.; Langel, Ü.; Sankar, R. (2006). Regulation of kindling epileptogenesis by hippocampal galanin type 1 and type 2 receptors: the effects of subtype selective ligands and the role of G-protein mediated signaling. Journal of Pharmacology and Experimental Therapeutics, 318 (2), 700−708.
1.1.
2006
Jimenez-Andrade, J.M.; Lundström, L.; Sollenberg, U.; Langel, Ü.; Castaneda-Hernandez, G.; Carlton, S.M. (2006). Activation of peripheral galanin receptors: Differential effects on nociception. Pharmacology Biochemistry and Behavior, 85 (1), 273−280.
1.1.
2006
Järver, P.; Langel, Ü. (2006). Cell-penetrating peptides. A brief introduction. Biochimica et Biophysica Acta - Biomembranes, 1758 (3), 260−263.
1.1.
2006
Lundberg, P.; Langel, Ü. (2006). Uptake mechanism of novel cell-penetrating peptides derived from the Alzheimer´s disease associated gamma-secretase complex. International Journal of Peptide Research and Therapeutics, 12 (2), 105−114.
1.1.
2006
EL-Andaloussi, S.; Johansson, H.; Lundberg, P.; Langel, Ü. (2006). Induction of splice correction by cell-penetrating nucleic acids. Journal of Gene Medicine, 8 (10), 1262−1273.
1.1.
2006
Elmquist, A.; Hansen, M.; Langel, Ü. (2006). Structure-activity relationship study of the cell-penetrating peptide pVEC. Biochimica et Biophysica Acta - Biomembranes, 1758 (6), 721−729.
1.1.
2006
Zeng, F.; Peritz, T.; Kannanayakal, TJ.; Kilk, K.; Eiríksdóttir, E.; Langel, Ü.; Eberwine, J. (2006). A protocol for PAIR: PNA-assisted identification of RNA binding proteins in living cells. Nature Protocols, 1 (2), 920−927. DOI: 10.1038/nprot.2006.81.
1.1.
2006
Peritz, T.; Zeng, F.; Kannanayakal, TJ.; Kilk, K.; Eiríksdóttir, E.; Langel, Ü.; Eberwine, J. (2006). Immunoprecipitation of mRNA-protein complexes. Nature Protocols, 1 (2), 577−580. DOI: 10.1038/nprot.2006.82.
1.1.
2006
Zielinski, J.; Kilk, K.; Peritz, T.; Kannanayakal, T.; Miyashiro, KY.; Eiriksdottir, E.; Jochems, J.; Langel, Ü.; Eberwine, J. (2006). In vivo identification of ribonucleoprotein-RNA interactions. Proceedings of the National Academy of Sciences, 5, 1557−1562.
1.1.
2006
Holm, T.; Johansson, H.; Lundberg, P.; Lindgren, M.; Pooga, M.; Langel, Ü. (2006). Studying the uptake of cell-penetrating peptides. Nature Protocols, 1 (2), 1001−1005. DOI: 10.1038/nprot.2006.174.
1.1.
2006
Lindgren, M.; Rosenthal-Aizman, K.; Saar, K.; Eiriksdottir, E.; Jiang, Y.; Sassian, M.; Ostlund, P.; Hällbrink, M.; Langel, U. (2006). Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochemical Pharmacology, 71 (4), 416−425.
1.2.
2006
Robinson, JK.; Bartfai, T.; Langel, Ü. (2006). Galanin/GALP Receptors and CNS Homeostatic Processes. CNS & Neurological Disorders - Drug Targets, 5 (3), 327−334.
1.2.
2006
Sollenberg, U.E.; Lundström, L.; Bartfai, T.; Langel, Ü. (2006). M871 - a novel peptide antagonist selectively recognizing the galanin receptor type 2. International Journal of Peptide Research and Therapeutics, 12 (2), 115−119. DOI: 10.1007/s10989-005-9008-x.
3.1.
2006
Jiang, Y.; Soomets, U.; Langel, Ü. (2006). Design and synthesis of CPPs. In: Langel, Ü (Ed.). Handbook of Cell-Penetrating Peptides, 2nd Edition (537−551).. CRC Press Inc.
3.1.
2006
Hällbrink, M.; Langel, Ü. (2006). Prediction of cell-penetrating peptides and prodrug approach. In: Langel, Ü. (_EditorsAbbr). Handbook of Cell-Penetrating Peptides, 2nd edition (77−85).. CRC Press Inc.
3.1.
2006
Ganyu, A.; Langel, Ü.; Good, L. (2006). Microbial Membrane Penetrating Peptides and Their Applications. In: Langel, Ü (_EditorsAbbr). Handbook of Cell-Penetrating Peptides, 2nd Edition (515−533).. CRC Press Inc.
3.1.
2006
Lindgren, M., Pooga, M., Langel, Ü. (2006). Methods to Study the Translocation of Cell-Penetrating Peptides. In: Langel, Ü. (Ed.). Handbook of Cell-Penetrating Peptides, Second Edition (567−587). . Boca Raton: CRC Press Inc. (CRC Handbook).
3.1.
2006
Pooga, M., Padari, K., Langel, Ü. (2006). Mechanisms of cargo delivery by transportans. In: Langel, Ü. (Ed.). Handbook of Cell-Penetrating Peptides, Second Edition (183−199). . Boca Raton: CRC Press Inc. (CRC Handbook).
3.1.
2006
EL-Andaloussi, S.; Johansson, H.; Lundberg, P.; Langel, Ü. (2006). Cell-penetrating short interfering RNAs and decoy oligonucleotides. In: Langel, Ü. (_EditorsAbbr). Handbook for cell-penetrating peptides (375−386).. CRC Press Inc.
3.1.
2006
Saar, K.; Langel, Ü. (2006). Toxicity methods for cell-penetrating peptides. In: Langel, Ü. (_EditorsAbbr). Handbook of Cell-Penetrating Peptides, Second Edition (553−565).. CRC Press Inc.
3.1.
2006
El-Andaloussi, S.; Johansson, H.; Lundberg, P.; Langel, Ü. (2006). Decoy and siRNA oligonucleotide as cargo. In: Langel, Ü (_EditorsAbbr). Handbook of Cell-Penetrating Peptides, 2nd Edition (375−386).. CRC Press Inc.
3.1.
2006
Langel, Ü. (2006). Classes and prediction of cell-penetrating peptides. In: Langel, Ü (_EditorsAbbr). Handbook of Cell-Penetrating Peptides, 2nd Edition (1−3).. CRC Press Inc.
5.1.
2006
Säälik, P.; Hansen, M.; Langel, Ü.; Pooga, M. (2006). Actin-dependent CPP-mediated protein cellular delivery takes place via induced endocytosis. Journal of Peptide Science, 12, 236.
5.1.
2006
Padari, K.; Koppel, K.; Hansen, M.; Langel, Ü.; Pooga, M. (2006). Endocytic pathways of transportan-mediated protein cellular delivery. Journal of Peptide Science, 12, 236.
6.7.
2006
Langel, Ü. (2006). Preface. In: Langel, Ü. (_EditorsAbbr). Handbook of Cell-Penetrating Peptides, 2nd Edition (1).. CRC Press Inc.
1.1.
2005
Langel, Ü. (2005). Cell-penetrating peptides, mechanisms and applications. Current Pharmaceutical Design, 11 (28), 3595−3596.
1.1.
2005
Magzoub, M.; Sandgren, S.; Lundberg, P.; Oglecka, K.; Lilja, J.; Wittrup, A.; Eriksson, GLE.; Langel, Ü.; Belting, M.; Gräslund, A. (2005). N-terminal peptides from unprocessed prion proteins enter cells by macropinocytosis. Biochemical and Biophysical Research Communications, 348 (2), 379−385.
1.1.
2005
Brever, A.; Langel, Ü.; Robinson, JK. (2005). Intracerebroventricular administration of galanin decreases free water intake and operant water reinforcer efficacy in water-restricted rats. Neuropeptides, 39 (2), 117−124.
1.1.
2005
Brever, A.; Echevarria, DJ.; Langel, Ü.; Robinson, JK. (2005). Assessment of new functional roles for galanin in the CNS. Neuropeptides, 39 (3), 320−323.
1.1.
2005
Marinova, Z.; Vukojevic, V.; Surcheva, S.; Yakovleva, T.; Cebers, G.; Pasikova, N.; Usynin, I.; Hugonin, L.; Fang, W.; Hallberg, M.; Hirschberg, D.; Bergman, T.; Langel, Ü.; Hauser, KF.; Pramanik, A.; Aldrich, JV.; Gräslund, A.; Terenius, L.; Bakalkin, G. (2005). Translocation of dynorphin neuropeptides across the plasma membrane: a putative mechanism of signal transmission. Journal of Biological Chemistry, 280 (28), 26360−26370.
1.1.
2005
Echevarria, D.J.; Brewer, A.; Bushell, G.; Manuzon, H.; Langel, Ü.; Robinson, J.K. (2005). Galanin and perseveration. Brain Research, 1041 (2), 143−148.
1.1.
2005
Zorko, M.; Langel, Ü. (2005). Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Advanced Drug Delivery Reviews, 57 (4), 529−545.
1.1.
2005
Parenteau, J.; Klinck, R.; Good, L.; Langel, Ü.; Wellinger, R.J.; Elela, S.A. (2005). Free uptake of cell-penetrating peptides in fission yeast. FEBS Letters, 579 (21), 4873−4878.
1.1.
2005
Stahl, A.; Nilsson, S.; Lundberg, P.; Bhushan, S.; Biverstahl, H.; Moberg, P.; Morisset, M.; Vener, A.; Mäler, L.; Langel, Ü. (2005). Two novel targeting peptide degrading proteases, PrePs, in mitochondria and chloropast: so similar and still different. Journal of Molecular Biology, 349 (4), 847−860.
1.1.
2005
Sollenberg, U.; Bartfai, T.; Langel, Ü. (2005). Galnon - a low-molecular weight ligand of the galanin receptors. Neuropeptides, 39 (3), 161−163.
1.1.
2005
Sato, M.; Hutchinson, DS.; Bengtsson, T.; Floren, A.; Langel, Ü.; Horinouchi, T.; Evans, B.A:; Summers, R. (2005). Functional domains of the mouse beta3-adrenoceptor associated with differential G protein coupling. Journal of Pharmacology and Experimental Therapeutics, 315 (3), 1354−1361.
1.1.
2005
EL-Andaloussi, S.; Johansson, H.; Magnusdottir, A.; Järver, P.; Lundberg, P.; Langel, Ü. (2005). TP10, a delivery vector for decoy oligonucleotides targeting the Myc protein. Journal of Controlled Release, 110 (1), 189−201.
1.1.
2005
EL-Andaloussi, S.; Holm, T.; Langel, Ü. (2005). Cell-penetrating peptides: Mechanisms and Applications. Current Pharmaceutical Design, 11 (28), 3597−3611.
1.1.
2005
Lundström, L.;Sollenberg, U.; Brewer, A.; Kouya, PF.; Zheng, K.; Xu, XJ.; Xia, S.; Robinson, JK.; Wiesenfeld-Hallin, Z.; Xu, ZQ.; Hökfelt, T.; Bartfai, T.; Langel, Ü. (2005). A Galanin Receptor Subtype 1 Specific Agonist. International Journal of Peptide Research and Therapeutics, 11 (1), 17−27.
1.1.
2005
Lu, X.; Lundström, L.; Langel, Ü.; Bartfai, T. (2005). Galanin Receptor Ligands. Neuropeptides, 39 (3), 165−167.
1.1.
2005
Lundström, L.; Elmquist, A.; Bartfai, T.; Langel, Ü. (2005). Galanin and its receptors in neurological disorders. NeuroMolecular Medicine, 7, 157−180.
1.1.
2005
Lundström, L.; Lu, X.; Langel, Ü.; Bartfai, T. (2005). Important pharmacophores for binding to galanin receptor 2. Neuropeptides, 39 (3), 169−171.
1.1.
2005
Holm, T.; Netzereab, S.; Hansen, M.; Langel, Ü.; Hällbrink, M. (2005). Uptake of cell-penetrating peptides in yeasts. FEBS Letters, 579 (23), 5217−5222.
1.1.
2005
Ostlund, P.; Kilk, K.; Lindgren, M.; Hallbrink, M.; Jiang, Y.; Budihna, M.; Cerne, K.; Bavec, A.; Ostenson, CG.; Zorko, M.; Langel, U. (2005). Cell-penetrating mimics of agonist-activated G-protein coupled receptors. International Journal of Peptide Research and Therapeutics, 11 (4), 237−247.
1.1.
2005
Kilk, K.; El-Andaloussi, S.; Jarver, P.; Meikas, A.; Valkna, A.; Bartfai, T.; Kogerman, P.; Metsis, M.; Langel, U. (2005). Evaluation of transportan 10 in PEI mediated plasmid delivery assay. Journal of Controlled Release, 103 (2), 511−523. DOI: 10.1016/j.jconrel.2004.12.006.
1.1.
2005
Mae, M.; Myrberg, H.; Jiang, Y.; Paves, H.; Valkna, A.; Langel, U. (2005). Internalisation of cell-penetrating peptides into tobacco protoplasts. Biochimica et Biophysica Acta - Biomembranes, 1669 (2), 101−107.
1.1.
2005
Saar, K.; Lindgren, M.; Hansen, M.; Eiriksdottir, E.; Jiang, Y.; Rosenthal-Aizman, K.; Sassian, M.; Langel, U. (2005). Cell-penetrating peptides: A comparative membrane toxicity study. Analytical Biochemistry, 345 (1), 55−65.
1.1.
2005
Hallbrink, M.; Kilk, K.; Elmquist, A.; Lundberg, P.; Lindgren, M.; Jiang, Y.; Pooga, M.; Soomets, U.; Langel, U. (2005). Prediction of cell-penetrating peptides. International Journal of Peptide Research and Therapeutics, 11 (4), 249−259.
1.1.
2005
Floren, A.; Sollenberg, U.; Lundstrom, L.; Zorko, M.; Stojan, J.; Budihna, M.; Wheatley, M.; Martin, NP.; Kilk, K.; Mazarati, A.; Bartfai, T.; Lindgren, M.; Langel, U. (2005). Multiple interaction sites of galnon trigger its biological effects. Neuropeptides, 39 (6), 547−558.
1.1.
2005
Padari, K.; Saalik, P.; Hansen, M.; Koppel, K.; Raid, R.; Langel, Ü.; Pooga, M. (2005). Cell transduction pathways of transportans. Bioconjugate Chemistry, 16 (6), 1399−1410.
1.2.
2005
Zilmer, M.; Soomets, U.; Rehema, A.; Langel, Ü. (2005). The glutathione system as an attractive therapeutic target. Drug Design Reviews - Online, 2 (2), 121−127.
1.2.
2005
Soomets, U.; Zilmer, M.; Langel, Ü. (2005). Manual solid-phase synthesis of glutathione analogs: a laboratory-based short course. Methods in molecular biology, 298, 241−257.
1.2.
2005
Kilk, K.; Langel, U. (2005). Cellular delivery of peptide nucleic acid by cell-penetrating peptides. Methods in molecular biology, 298, 131−141.
3.1.
2005
Pooga, M.; Langel, Ü. (2005). Synthesis of cell penetrating peptides for cargo delivery. In: Howl, John (Ed.). Peptide Synthesis and Applications (77−90). . Totowa, NJ: Humana Press. (Methods in Molecular Biology; 298).
5.1.
2005
Pooga, M., Padari, K., Säälik, P., Koppel, K., Hansen, M., Raid, R., Langel, Ü. (2005). Mechanisms of protein cellular delivery with transportans. FEBS Journal, 272 (Suppl. 1), 525.
5.2.
2005
Ehrlich, K.; Mahlapuu, R.; Viirlaid, S.; Zilmer, M.; Langel, Ü.; Soomets, U. (2005). Antioxidative properties of novel antioxidant UPF1 and its analogues. 1st BBBB Conference on Pharmaceutical Sciences, Siofok, Hungary,September 26-28. 132−133.
1.1.
2004
Nekhotiaeva, N.; Elmquist, A.; Rajarao, GK.; Hällbrink, M.; Langel, Ü.; Good, L. (2004). Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. The FASEB Journal, 18 (2), 394−396.
1.1.
2004
Lindgren, M.; Hällbrink, M.; Elmquist, A.; Langel, Ü. (2004). Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. Biochemical Journal, 377 (1), 69−76.
1.1.
2004
Brever, A.; Langel, Ü.; Robinson, JK. (2004). Intracerebroventricularly administered galanin does not alter operant reaction time of differentially reinforced high rate schedule operant responding in rats. Neuroscience Letters, 369 (3), 245−249.
1.1.
2004
Järver, P.; Langel, Ü. (2004). The use of cell-penetrating peptides in gene regulation. Drug Discovery Today, 9 (9), 395−402.
1.1.
2004
Jiang, Y.; Sassian, M.; Langel, Ü. (2004). Synthesis and applications of cell-penetrating peptide-PNA conjucate. Chimica Oggi-Chemistry Today, 22, 36−39.
1.1.
2004
Poder, P.; Zilmer, M.; Starkopf, J.; Kals, J.; Talonpoika, A.; Pulges, A.; Langel, U.; Kullisaar, T.; Viirlaid, S.; Mahlapuu, R.; Zarkovski, A.; Arend, A.; Soomets, U. (2004). An antioxidant tetrapeptide UPF1 in rats has a neuroprotective effect in transient global brain ischemia. Neuroscience Letters, 370 (1), 45−50.
1.1.
2004
Saalik, P.; Elmquist, A.; Hansen, M.; Padari, K.; Saar, K.; Viht, K.; Langel, V.; Pooga, M. (2004). Protein cargo delivery properties of cell-penetrating peptides. A comparative study. Bioconjugate Chemistry, 15 (6), 1246−1253.
1.1.
2004
Kilk, K.; Elmquist, A.; Saar, K.; Pooga, M.; Land, T.; Bartfai, T.; Soomets, U.; Langel, U. (2004). Targeting of antisense PNA oligomers to human galanin receptor type 1 mRNA. Neuropeptides, 38 (5), 316−324.
1.1.
2004
Fisher, L.; Soomets, U.; Toro, V.C.; Chilton, L.; Jiang, Y.; Langel, U.; Iverfeldt, K. (2004). Cellular delivery of a double-stranded oligonucleotide NF kappa B decoy by hybridization to complementary PNA linked to a cell-penetrating peptide. Gene Therapy, 11 (16), 1264−1272.
1.1.
2004
Mazarati, A.; Lu, X.; Kilk, K.; Langel, U.; Wasterlain, C.; Bartfai, T. (2004). Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. European Journal of Neuroscience, 19 (12), 3235−3244.
1.1.
2004
Hua, X.Y.; Hayes, C.S.; Hofer, A.; Fitzsimmons, B.; Kilk, K.; Langel, U.; Bartfai, T.; Yaksh, T.L. (2004). Galanin acts at GalR1 receptors in spinal antinociception: synergy with morphine and AP-5. Journal of Pharmacology and Experimental Therapeutics, 308 (2), 574−582.
1.2.
2004
Eiríksdottir, E.; Myrberg, H.; Hansen, M.; Langel, Ü. (2004). Cellular Uptake of Cell-Penetrating Peptides. Drug Design Reviews - Online, 1 (2), 161−173.
3.2.
2004
Johansson, H.J.; Järver, P.; Langel, U. (2004). Cell penetrating peptides and their application in gene regulation. In: Epton, R. (_EditorsAbbr). Innovation and Perspectives in Solid Phase Synthesis & Combinatorial Chemical Libraries. Proceedings of the 8th International Symposium (123−128).. London, England, UK: Mayflower Worldwide.
5.1.
2004
Fisher, L.; Samuelsson, M.; Toro, V. C.; Soomets, U.; Yang, J.; Langel, Ü.; Iverfeldt, K. (2004). Downregulation of Abeta-induced cytokine expression in glial cells using NFkappaB decoy. Journal of Neuroimmunology, 154, 31−31.
5.2.
2004
Mahlapuu, R.; Soomets, U.; Bogdanovic, N.; Zilmer, M.; Karelson, E.; Langel, Ü. (2004). Modulating G-proteins and adenylate cyclase activity by amyloid precursor protein carboxy-terminal fragments and amyloid b-peptide. 34th Ann Meeting Soc Neurosci.. San Diego.
6.6.
2004
Mahlapuu, R., Soomets, U., Zilmer, M., Langel, Ü. (2004). Alzheimeri tõve molekulaarsed alused: osalevad valgud ja peptiidid: uued ravistrateegiad. Lege Artis, 8 (32), 10−14.
1.1.
2003
Zachariou, V.; Brunzell, DH.; Hawes, J.; Stedman, DB.; Bartfai, T.; Bartfai, T.; Steiner, R.; Wynick, D.; Langel, Ü. (2003). The neuropeptide galanin modulates behavioral and neurochemical signs of opiate withdrawal. Proceedings of the National Academy of Sciences of the United States of America, 100 (15), 9028−9033.
1.1.
2003
Wu, WP.; Hao, JX.; Lundström, L.; Wiesenfeld-Hallin, ZS.; Langel, Ü.; Bartfai, T.; Xu, XJ. (2003). Systemic galnon, a low-molecular weight galanin agonist, reduces heat hyperalgesia in rats with nerve injury. European Journal of Pharmacology, 482, 133−137.
1.1.
2003
Elmquist, A.; Langel, Ü. (2003). In vitro uptake and stability study of pVEC and its all-D-analoque. Biological Chemistry, 384 (3), 387−393.
1.1.
2003
Bavec, J.; Hällbrink, M.; Olsson, M.; Langel, Ü.; Zorko, M. (2003). Different role of intracellular loops of glucagon-like peptide-1 receptor in G-protein coupling. Regulatory Peptides, 111, 137−144.
1.1.
2003
Lundberg, P.; Langel, Ü. (2003). A brief introduction to cell-penetrating peptides. Journal of Molecular Recognition, 16 (5), 227−233.
1.1.
2003
Howitt, S. G.; Kilk, K.; Wang, Y.; Smith, D. M.; Langel, U.; Poyner, D. R. (2003). The role of the 8-18 helix of CGRP8-37 in mediating high affinity binding to CGRP receptors; coulombic and steric interactions. British Journal of Pharmacology, 138 (2), 325−332.
1.1.
2003
Adlerz, L.; Soomets, U.; Holmlund, L.; Viirlaid, S.; Langel, U.; Iverfeldt, K. (2003). Down-regulation of amyloid precursor protein by peptide nucleic acid oligomer in cultured rat primary neurons and astrocytes. Neuroscience Letters, 336 (1), 55−59.
1.1.
2003
Mahlapuu, R.; Viht, K.; Balaspiri, L.; Bogdanovic, N.; Saar, K.; Soomets, U.; Land, T.; Zilmer, M.; Karelson, E.; Langel, U. (2003). Amyloid precursor protein carboxy-terminal fragments modulate G-proteins and adenylate cyclase activity in Alzheimer's disease brain. Molecular Brain Research, 117 (1), 73−82.
1.1.
2002
Conner, A. C.; Hay, D. L.; Howitt, S. G.; Kilk, K.; Langel, U.; Wheatley, M.; Smith, D. M.; Poyner, D. R. (2002). Interaction of calcitonin-gene-related peptide with its receptors. Biochemical Society Transactions, 30 (4), 451−455.
1.1.
2002
Lundberg, P.; Magzoub, M.; Lindberg, M.; Hällbrink, M.; Jarvet, J.; Eriksson, L.E.G.; Langel, Ü.; Gräslund, A. (2002). Cell membrane translocation of the N-terminal (1–28) part of the prion protein. Biochemical and Biophysical Research Communications, 299 (1), 85−90.
1.1.
2002
Karelson, E.; Mahlapuu, R.; Zilmer, M.; Soomets, U.; Bogdanovic, N.; Langel, U. (2002). Possible signaling by glutathione and its novel analogue through potent stimulation of frontocortical G proteins in normal aging and in Alzheimer's disease. Annals of the New York Academy of Sciences, 973, 537−540.
1.1.
2002
Östenson, CG.; Sandberg-Nordquist, AC.; Chen, J.; Hällbrink, M.; Rotin, D.; Langel, Ü.; Efendic, S. (2002). Overexpression of protein-tyrosine phosphotase PTPo is linked to impaired glucose-induced insulin secretion in hereditary diabetic Goto-Kakizaki rats. Biochemical and Biophysical Research Communications, 291 (4), 945−950.
1.1.
2002
Suzuki, H.; iwanaga, T.; Yoshie, H.; Yamabe, K.; Yanaihara, N., Langel, Ü.; Maeda, T. (2002). Expression of galanin receptor 1 (GALR1) in the rat trigeminal ganglia and molar teeth. Neuroscience Research, 42 (3), 197−207.
1.1.
2002
Farquhar, M.; Soomets, U.; Bates, R.L.; Martin, A.; Langel, Ü.; Howl, J. (2002). Novel mastoparan analogs induce differential secretion from mast cells. Chemistry & Biology, 9 (1), 63−70.
3.1.
2002
Valkna, A.; Soomets, U.; Langel, Ü. (2002). Transport peptides as carriers of oligonucleotides. In: Langel, Ü. (_EditorsAbbr). Cell penetrating peptides: processes an applications (347−363).. Boca Raton, FL: CRC Press Inc. (Pharmacology & Toxicology Series).
3.1.
2002
Pooga, M.; Elmquist, A.; Langel, Ü. (2002). Toxicity and biological effects of CPP. In: Langel, Ü. (Ed.). Cell penetrating peptides : processes and applications (245−262). . Boca Raton, FL: CRC Press Inc.
3.1.
2002
Pooga, M.; Hällbrink, M.; Langel, Ü. (2002). Transportans. In: Langel, Ü. (Ed.). Cell penetrating peptides : processes and applications (53−70). . Boca Raton, FL: CRC Press Inc.
3.1.
2002
Hällbrink, M.; Langel, Ü. (2002). Comparison of gargo delivery efficiency of cell-penetrating peptides. In: Epton, R. (_EditorsAbbr). Innovation and Perspectives in Solid phase Synthesis and Combinatorial Libraries (165−168).. Southampton: Mayflower Worldwide.
3.1.
2002
Kahl, U.; Langel, Ü.; Bartfai, T. (2002). Galanin Receptors. In: Pangalos, MN.; Davies, CH. (_EditorsAbbr). Understanding G-protein receptors and their role in the CNS (286−306).. Oxford Univ Press.
3.1.
2002
Lindgren, M.; Hällbrink, M.; Langel, Ü. (2002). Quantification of cell-penetrating peptides and their cargoes. In: Langel, Ü. (_EditorsAbbr). Cell penetrating Peptides. Processes and Applications (263−275).. CRC Press Inc.
3.1.
2002
Zorko, M.; Hällbrink, M.; Langel, Ü. (2002). Kinetics of uptake of cell-penetrating peptides. In: Langel, Ü (_EditorsAbbr). Cell Penetrating Peptides. Processes and Applications (277−293).. CRC Press Inc.
3.1.
2002
Valkna, A.; Soomets, U.; Langel, Ü. (2002). Cell-penetrating peptides as vectors for delivery of nucleic acids. In: Langel, Ü. (Ed.). Cell Penetrating Peptides. Processes and Applications (347−363).. New York: CRC Press Inc.
3.1.
2002
Pooga, M.; Soomets, U.; Bartfai, T.; Langel, Ü. (2002). Synthesis of cell-Penetrating peptide-PNA constructs. In: Nielsen, P. (Ed.). Peptide nucleic acids: methods and protocols (225−236). . Totowa, NJ: Human Press. (Methods in molecular biology; 208).
3.1.
2002
Langel, Ü. (2002). Preface, in Cell Penetrating Peptides. Processes and Applications. Cell Penetrating Peptides. Processes and Applications (x−x).. CRC Press Inc.
1.1.
2001
Hällbrink, M.; Floren, A.; Elmquist, A.; Pooga, M.; Bartfai, T.; Langel, Ü. (2001). Cargo delivery kinetics of cell-penetrating peptides. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1515 (2), 101−109.
1.1.
2001
Lindberg, M.; Jarvet, J.; Langel, Ü.; Gräslund, A. (2001). Secondary Structure and Position of the Cell-Penetrating Peptide Transportan in SDS Micelles As Determined by NMR. Biochemistry, 40 (10), 3141−3149.
1.1.
2001
Saar, K.; Mahlapuu, R.; Laidmae, E.; Valkna, A.; Kahl, U.; Karelson, E.; Langel, U. (2001). Characterisation of a new chimeric ligand for galanin receptors: galanin(1-13)-[D-Trp(32)]-neuropeptide Y(25-36) amide. Regulatory Peptides, 102 (1), 15−19.
1.1.
2001
Toro, VC.; Tehranian, R.; Zetterström, M.; Eriksson, G.; Langel, Ü.; Bartfai, T.; Iverfeldt, K. (2001). Increased gene expression of interleukin-1alfa and interleukin-6 in rat primary glial cells induced by b-amyloid fragment. Journal of Molecular Neuroscience , 17 (3), 341−350.
1.1.
2001
Hällbrink, M.; Holmqvist, T.; Olsson, M.; Östenson, CG.; Efendic, S.; Langel, Ü. (2001). Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Galfas and Galfai/Galfao activation. Biochimica et Biophysica Acta, 1546 (1), 79−86.
1.1.
2001
Elmquist, A.; Lindgren, M.; Bartfai, T.; Langel, Ü. (2001). VE-cadherin derived cell-penetrating peptide, pVEC, with carrier function. Experimental Cell Research, 269, 237−244.
1.1.
2001
Balaspiri, L.; Langel, Ü. (2001). Synthesis of b-amyloid precursor peptide and presenilin segments. Journal of Peptide Science, 7 (1), 58−60.
1.1.
2001
Mazarati, A.; Langel, Ü.; Bartfai, T. (2001). Galanin: an endogenous anticonvulsant? Neuroscientist, 7 (6), 506−517.
1.1.
2001
Pramanik, A.; Olsson, M.; Langel, Ü.; Bartfai, T. (2001). Fluorescence correlation spectroscopydetects galanin receptor diversity on insulinoma cells. Biochemistry, 40 (36), 10839−10845.
1.1.
2001
Yakovleva, T.; Pramanik, A.; kawasaki, T.; Tan-No, K.; Gileva, I.; Lindegren, H.; Langel, Ü.; Ekström, TJ.; Rigler, R.; Terenius, L.; Bakalkin, G. (2001). p53 Latency: C-terminal domain prevents binding of p53 core to target but not to nonspecific DNA sequence. Journal of Biological Chemistry, 276 (19), 15650−15658.
1.1.
2001
Berglund, M.M; Saar, K.; Lundell, I.; Langel, U.; Larhammar, D. (2001). Binding of chimeric NPY/galanin peptides M32 and M242 to cloned neuropeptide Y receptor subtypes Y1, Y2, Y4 and Y5. Neuropeptides, 35, 148−153.
1.2.
2001
Pooga, M.; Langel, Ü. (2001). Targeting of cancer-related proteins with PNA oligomers. Current Cancer Drug Targets, 1 (3), 231−239.
1.3.
2001
Magzoub, M.; Kilk, K.; Eriksson, G.; Langel, Ü.; Gräslund, A. (2001). Interaction and structure induction of cell-penetrating peptides in the presence of phospholipid vesicles. Biochimica et Biophysica Acta, 1512(1) (2), 77−89.
3.4.
2001
Brown, J.; Howl, J.; Martin, A.; Soomets, U.; Langel, Ü.; Brown, C. (2001). Single amino-acid substitutions in a mimetic tetradecapeptide agonist of the human P2Y2 receptor prevent second messenger activation. Peptides 2000: European Peptide Symposium; Montpellier, France; 10.-15.09.2000. Ed. Martinez, J.; Fehrentz, J.A. Paris: EDK, 913−914.
3.4.
2001
Farquhar, M.; Soomets, U.; Brown, C.; Martin, A.; Bates, R.; Langel, Ü.; Howl, J. (2001). Venomous chimeric secretagogues. Peptides 2000: European Peptide Symposium; Montpellier, France; 10.-15.09.2000. Ed. Martinez, J.; Fehrentz, J.A. Paris: EDK, 633−634.
5.1.
2001
Lindner, AB.; Danon, T.; Sanden, B.; mansson, P.; langel, Ü.; berkovich, E.; Sheradsky, T.; Willner, I.; Eshhar, Z. (2001). High affinity metamphetamine antibodies for sensitive detection of amphetamine type substances. Proceedings, 2001 ONDCP International Technology Symposium: ONDCP International Technology Symposium, San Diego, June 25-28, 2001. San Diego State University Press, 504−510.
1.1.
2000
Lindgren, M.; Hällbrink, M.; Prochiantz, A.; Langel, Ü. (2000). Cell penetrating peptides. Trends in Pharmacological Sciences, 21 (3), 99−103.
1.1.
2000
Floren, A.; Land, T.; Langel, Ü. (2000). Galanin receptor subtypes and ligand binding. Neuropeptides, 34 (6), 331−337.
1.1.
2000
Rezaei, K.; Saar, K.; Soomets, U.; Valkna, A.; Nasman, J.; Zorko, M.; Akerman, K.; Schroeder, T.; Bartfai, T.; Langel, U. (2000). Role of third intracellular loop of galanin receptor type 1 in signal transduction. Neuropeptides, 34 (1), 25−31.
3.1.
2000
Poyner, D.; Howitt, S.; Soomets, U.; Langel, Ü. (2000). Structure activity relationship for CGRP receptor ligands. In: The CGRP family: Calcitonin Gene-related peptide (CGRP) , amylin and adrenomedullin. In: Poyner, D.; Marshall, SD.; Brain, SD. (_EditorsAbbr). Molecular Biology Intelligence Unit 10 (25−32).. Texas, USA: Landes Bioscience.
3.2.
2000
Poyner, D.R.; Howitt, S.; Soomets, U.; Langel, Ü. (2000). Structure activity relationship for CGRP receptor ligands. In: Poyner, D.; Marshall, I.; Brain, S.D. (Ed.). The CGRP family: Calcitonin Gene-Related Peptide (Cgrp), Amylin, & Adrenomedullin (25−32).. Georgetown: Landes Bioscience.
3.2.
2000
Soomets, U.; Kilk, K.; Land, T.; Langel, Ü. (2000). Transportan, its analogues and their applications. Innovation and Perspectives in Solid Phase Synthesis and Combinatorial Libraries: Peptides, Proteins and Nucleic Acids. Proceedings of the 5th International Symposium, London. Ed. Epton, R. Kingswinford, England: Mayflower Worldwide, 131−136.
1.1.
1999
Bavec, B.; Jureus, A.; Cigic, B.; Langel, Ü.; Zorko, M. (1999). Peptitergent PD1 affects the GTPase activity of rat brain cortical membranes. Peptides, 20 (2), 177−184.
1.1.
1999
Hallbrink, M.; Saar, K.; Ostenson, CG.; Soomets, U.; Efendic, S.; Howl, J.; Wheatley, M.; Zorko, M.; Langel, U. (1999). Effects of vasopressin-mastoparan chimeric peptides on insulin release and G-protein activity. Regulatory Peptides, 82, 45−51.
1.1.
1999
Xu, ZQD.; Ma, XS.; Soomets, U.; Langel, U.; Hokfelt, T. (1999). Electrophysiological evidence for a hyperpolarizing, galanin (1-15)-selective receptor on hippocampal CA3 pyramidal neurons. Proceedings of the National Academy of Sciences of the United States of America, 96 (25), 14583−14587.
1.1.
1999
Soomets, U.; Mahlapuu, R.; Tehranian, R.; Jarvet, J.; Karelson, E.; Zilmer, M.; Iverfeldt, K.; Zorko, M.; Graslund, A.; Langel, U. (1999). Regulation of GTPase and adenylate cyclase activity by amyloid beta-peptide and its fragments in rat brain tissue. Brain Research, 850, 179−188.
1.2.
1999
Pramanik, A.; Jureus, A.; Langel, Ü.; Bartfai, T.; Rigler, R. (1999). Galanin receptor binding studies in the membranes of cultured cells measured by florescence correlation spectroscopy. Biomed Chromatogr, 13 (2), 119−120.
1.2.
1999
Soomets, U.; Hälbrink, M; Langel, Ü. (1999). Antisence properties of peptide nucleic acids. Frontiers in Bioscience (FBS), 4, D782−D786.
3.1.
1999
Soomets, U.; Langel, Ü. (1999). Intracellular third loop of galanin receptor as G-protein interaction site. In: Tam, JP.; Kaumaya, PTP (_EditorsAbbr). Frontiers in Peptide Science (662−663).. London: Kluwer Academic Publishers.
3.1.
1999
Soomets, U.; Langel, Ü. (1999). Intracellular third loop of galanin receptor as G-protein interaction site. Peptides. Frontiers of Peptide Science: 15th American Peptide Symposium; Nashville, Tennessee; 14.-19.06.1997. Ed. Tam, J.P.; Kauyama, P.T.P. Dodrecht: Kluwer Academic Publishers, 662−663.
6.2.
1999
Soomets, U.; Zilmer, M.; Starkopf, J.; Karelson, E.-R.; Vihalemm, T.; Zilmer, K.; Sillard, R.; Bourne, J; Langel, Ü. (1999). Selected knowledge for medical biochemistry. Tartu: Tartu Ülikooli Kirjastus.
1.1.
1998
Klimenko, VM.; Lioudyno, VI.; Langel, Ü.; Krasnova, IN.; Abdurasulova, IN. (1998). Contribution of galaninergic structures of the brain to reaction to lipopolysaccharide. Bull Exp Biol Med (Moscow), 125 (4), 380−383.
1.1.
1998
Öhman, A.; Lycksell, PO.; Jureus, A.; Langel, Ü.; Bartfai, T.; Gräslund, A. (1998). NMR study of the conformation and localisation of porcine galanin in SDS micelles. Biochemistry, 37 (25), 9169−9178.
1.1.
1998
Parker, D.; Söderberg, C.; Zotova, E.; Shupliakov, O.; Langel, Ü.; Bartfai, T.; larhammar, D.; Brodin, L.; Grillner, S. (1998). Co-localized neuropeptide Y and GABA have complementary presynaptic effects on sensory synaptic transmission. European Journal of Neuroscience, 10 (9), 2856−2870.
1.1.
1998
Jureus, A.; Lindgren, M.; Langel, Ü.; Bartfai, T. (1998). Purification of a galanin degrading 70 kDa metallopeptidase from bovine spinal cord. Neuropeptides, 32 (5), 453−460.
1.1.
1998
Pooga, M.; Lindgren, M.; Hällbrink, M.; Bråkenhielm, E.; Langel, Ü. (1998). Galanin-Based Peptides, Galparan and Transportan, with Receptor-Dependent and Independent Activities. Annals of New York Academy of Sciences, 863, 450−453.
1.1.
1998
Pooga, M.; Hällbrink, M.; Zorko, M.; Langel, Ü. (1998). Cell penetration by transportan. The FASEB Journal, 12 (1), 67−77.
1.1.
1998
Bavec, A.; Soomets, U.; Langel, U.; Zorko, M. (1998). Structural features of amphipathic peptides required for the activation of G-proteins. Acta Chimica Slovenica, 45 (1), 27−34.
1.1.
1998
Karelson, E.; Langel, U. (1998). Galaninergic signalling and adenylate cyclase. Neuropeptides, 32 (3), 197−210.
1.1.
1998
Mazarati, AM.; Liu, HT.; Soomets, U.; Sankar, R.; Shin, D.; Katsumori, H.; Langel, U.; Wasterlain, CG. (1998). Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. Journal of Neuroscience, 18 (23), 10070−10077.
1.1.
1998
Poyner, DR.; Soomets, U.; Howitt, SG.; Langel, U. (1998). Structural determinants for binding to CGRP receptors expressed by human SK-N-MC and Col 29 cells: studies with chimeric and other peptides. British Journal of Pharmacology, 124 (8), 1659−1666.
1.1.
1998
Pooga, M.; Soomets, U.; Hallbrink, M.; Valkna, A.; Saar, K.; Rezaei, K.; Kahl, U.; Hao, JX.; Xu, XJ.; Wiesenfeld-Hallin, Z.; Hokfelt, T.; Bartfai, A.; Langel, U. (1998). Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nature Biotechnology, 16 (9), 857−861.
1.2.
1998
Soomets, U.; Mahlapuu, R.; Karelson, E.; Zilmer, M.; Zorko, M.; Langel, Ü. (1998). Regulation of activity of GTPase and adenylate cyclase in the rat ventral hippocampus by fragments of b-amyloid. Clinical Neuroscience, 51 (1), 59−60.
1.2.
1998
Soomets, U.; Hällbrink, M.; Zorko, M.; Langel, Ü. (1998). From galanin and mastoparan to galparan and transportan. Current Topics in Peptide and Protein Research, 2, 83−113.
1.2.
1998
Longland, C.; Mezna, M.; Langel, Ü.; Hällbrink, M.; Soomets, U.; Wheatley, M.; Michelangeli, F.; Howl, J. (1998). Biochemical mechanisms of calcium mobilisation induced by mastoparan and chimeric hormone-mastoparan constructs. Cell Calcium, 24 (1), 27−34.
1.2.
1998
Langel, Ü.; Bartfai, T. (1998). Chemistry and molecularbiology of galanin receptor ligands. Annals of New York Academy of Sciences, 863, 86−93.
1.2.
1998
Kask, K.; Berthold, M.; Kahl, U.; Jureus, A.; Nordvall, G.; Langel, Ü.; Bartfai, T. (1998). Mutagenesis study of human galanin receptor GalR1 reveals domains involved in ligand binding. Annals of New York Academy of Sciences, 863, 78−85.
1.2.
1998
Xu, Z.Q.D.; Bartfai, T.; Langel, Ü.; Hökfelt, T. (1998). Effects of three galanin analogues on the outward current evoked by galanin in locus coeruleus. Annals of New York Academy of Sciences, 863, 459−465.
5.2.
1998
Langel, Ü.; Soomets, U.; Mahlapuu, R.; Karelson, E.; Zilmer, M.; Zorko, M. (1998). Regulation of GTPase and adenylate cyclase by amyloid-peptides. The 6th International Conference on Alzheimer's Disease and Related Disorders. Neurobiology of Aging, 19, S48.
6.2.
1998
Soomets, U.; Karlström, A.; Zilmer, M.; Langel, Ü. (1998). Solid phase peptide synthesis of glutathione and its analogs by Fmoc- and tert-Boc-Chemistry (second edition). In: .. Tartu : Tartu University Press.
6.2.
1998
Soomets, U.; Karlström, A.; Zilmer, M.; Langel, Ü. (1998). Solid phase peptide synthesis of glutathione and its analogs by Fmoc- and tert-Boc-chemistry. Manual for laboratory course. Tartu: Tartu University Press.
1.1.
1997
Östenson, CG.; Zaitsev, S.; Berggren, PO.; Efendic, S.; Langel, Ü.; Bartfai, T. (1997). Galparan: a powerfulinsulin releasing chimeric peptide acting at novel site. Endocrinology, 138 (8), 3308−3313.
1.1.
1997
Hianik, T.; Kaatze, U.; Sargent, DF.; Krivanek, R.; Halstenberg, S.; Pieper, W.; Gaburjakova, J.; Gaburjakova, M.; Pooga, M.; Langel, Ü. (1997). A study of interaction of some neuropeptides and their analogs with bilayer lipid membranes and liposomes. Bioelectrochemistry and Bioenergetics, 42 (2), 123−132.
1.1.
1997
Berthold, M.; Kahl, U.; Jureus, A.; kask, K.; Langel, Ü.; Nordvall, G.; Bartfai, T. (1997). Mutagenesis and ligand modification study on galanin binding to its GTP-binding-protein-coupled receptor GalR1. European Journal of Biochemistry, 249 (2), 601−606.
1.1.
1997
Kulinski, T.; Wennerberg, AB.; Rigler, R.; Provencher, SW.; Pooga, M.; Langel, Ü.; Bartfai, T. (1997). Conformational analysis of galanin using end to end distance distribution observed by Forster resonance energy transfer. European Biophysics Journal with Biophysics Letters, 26 (2), 145−154.
1.1.
1997
Jureus, A.; Langel, Ü.; Bartfay, T. (1997). L-Ala substituted rat galanin receptor subtypes. Journal of Peptide Research, 49 (3), 195−200.
1.1.
1997
Howl, J.; Langel, Ü.; Wheatley, M. (1997). Chimeric hormones and neuropeptides. Clinical Science, 93 (6), 605−606.
1.1.
1997
Consolo, S.; Baldi, G.; Nannini, L.; Uboldi, M.C.; Pooga, M.; Langel, Ü.; Bartfai, T. (1997). Galparan induces in vivo acetylcholine release in the frontal cortex. Brain Research, 756, 174−178.
1.1.
1997
Howl, J.; Langel, U.; Hawtin, S.R.; Valkna, A.; Yarwood, N.J.; Saar, K.; Wheatley, M. (1997). Chimeric strategies for the rational design of bioactive analogs of small peptide hormones. The FASEB Journal, 11 (7), 582−590.
1.1.
1997
Soomets, U.; Kairane, C.; Zilmer, M.; Langel, U. (1997). Attempt to solubilize Na+/K+-exchanging ATPase with amphiphilic peptide PD1. Acta Chemica Scandinavica, 51 (3), 403−406.
1.1.
1997
Saar, K.; Valkna, A.; Soomets, U.; Rezaei, K.; Zorko, M.; Zilmer, M.; Langel, U. (1997). Role of the third cytoplasmic loop in signal transduction by galanin receptors. Biochemical Society Transactions, 25 (3), 1036−1040.
1.2.
1997
Soomets, U.; Hällbrink, M.; Zorko, M.; Langel, Ü. (1997). From galanin and mastoparan to galparan and transportan. Current Topics in Peptide and Protein Research, 2, 83−113.
1.2.
1997
Mezna, M.; Langel, Ü.; Hällbrink, M.; Wheatley, M.; Michelangeli, M.; Howl, J. (1997). Calcium-mobilizing actions of chimeric hormone-mastoparan peptides. Biochemical Society Transactions, 25 (2), 450S.
1.1.
1996
Öhman, A.; Davydov, R.; Backlund, BM.; Langel, Ü.; Gräslund, A. (1996). A study of melittin, motilin and galanin in reversed micellar environments, using circular dichroism spectroscopy. Biophysical Chemistry, 59, 185−192.
1.1.
1996
Grundemar, L.; Kahl, U.; Callreus, T.; langel, Ü.; Bienert, M.; Beyermann, M. (1996). Ligand binding and functional effects of systematic double D-amino acid residue substituted neuropeptide Y analogs of Y1 and Y2 receptor types. Regulatory Peptides, 62, 131−136.
1.1.
1996
Carlsson, PO.; Östenson, CG.; Efendic, S.; langel, Ü.; Jansson, L. (1996). Pituitary adenylate cyclase activating polypeptide (PACAP) redistributes the blood within the pancreas of anesthetized rats. Regulatory Peptides, 63, 123−128.
1.1.
1996
Langel, Ü.; Pooga, M.; Kairane, C.; Zilmer, M.; Bartfay, T. (1996). Effects of chimeric galanin-mastoparan analogues on rat cerebral cortical Na+,K+-ATP-ase and galanin receptors. Regulatory Peptides, 62 (1), 47−52.
1.2.
1996
Kairane, C.; Tähepõld, L.; Langel, Ü.; Sillard, R.; Zilmer, M. (1996). Investigation of some natural peptides and their synthetic derivatives using brain Na,K-ATPase. Neurochemistry (Russian), 13 (4), 265−269.
1.2.
1996
Jureus, A.; Langel, Ü. (1996). Galanin and galanin antagonists. Acta Chimica Slovenica, 43 (1), 51−60.
2.2.
1996
Soomets, U; Starkopf, J; Zilmer, Mihkel; Karelson, Ello-Rahel; Vihalemm, Tiiu; Zilmer, K; Valkna, A; Sillard, R; Langel, Ü (1996). Bioorganic chemistry for medical students. Tartu: Tartu University.
1.1.
1995
Valkna, A.; Laidmäe, E.; Karelson, E.; Zilmer, M.; Jureus, A.; Langel, Ü. (1995). Effects of chimeric galanin receptors ligands on basal adenylate cyclase activity in rat ventral hippocampal membranes. Protein and Peptide Letters, 2 (1), 267−274.
1.1.
1995
Kask, K.; Berthold, M.; Bourne, J.; Andell, S.; Langel, Ü.; Bartfai, T. (1995). Binding and agonist/antagonist actions of M35, galanin(1-13)-bradykinin(2-9) amide chimeric peptide, in rin m5F insulinoma cells. Regulatory Peptides, 59 (3), 341−348.
1.1.
1995
Zetterström, M.; Trogen, L.; Hammarström, LG.; Juhlin, L.; Nilsson, B.; Damberg, C.; Bartfai, T.; Langel, Ü. (1995). Synthesis of N-methyl-dehydroalanine containing analogue of misrocystin by combination of solid phase peptide synthesis and b-elimination in solution. Acta Chemica Scandinavica, 49 (9), 696−700.
1.1.
1995
Kask, K.; Langel, Ü.; Bartfay, T. (1995). Galanin - a neuropeptide with inhibitory actions. Cellular and Molecular Neurobiology, 15 (6), 653−673.
1.1.
1995
Xu, X.J.; Wiesenfeldt-Hallin, Z.; Langel, Ü.; Bedecs, K.; Bartfay, T. (1995). New high affinity peptide antagoniosts to the spinal galanin receptor. British Journal of Pharmacology, 116 (3), 2076−2080.
1.1.
1995
Xu, X.J.; Andell, S.; Zhang, X.; Wiesenfeldt-Hallin, Z.; Langel, Ü.; Bedecs, K.; Hökfelt, T.; Bartfay, T. (1995). Peripheral axotomy increases the expression of galanin message associated peptide (GMAP) in dorsal root ganglion cells and alters the effects of intrathecal GMAP on the flexor reflex in the rat. Neuropeptides, 28 (5), 299−307.
1.1.
1995
Bedecs, K.; Langel, Ü.; Bartfay, T. (1995). Metabolism of galanin and galanin(1-16) in isolated cerebrospinal fluid and spinal cord membranes from rat. Neuropeptides, 29 (3), 137−143.
1.1.
1995
Bartfay, T.; Langel, Ü. (1995). Galanin receptor ligands as potential therapeutic agents in depression and neurodegeneration. European Journal of Medical Genetics, 30, 163−174.
1.1.
1995
Valkna, A.; Laidmae, E.; Karelson, E.; Zilmer, M.; Jureus, A.; Langel, Ü. (1995). Effects of chimeric galanin receptor ligands on basal adenylate-cyclase activity in rat ventral hippocampal membranes. Protein and Peptide Letters, 2 (1), 267−274.
1.1.
1995
Heinsoo, A.; Raidaru, G.; Linask, K.; Järv, J.; Zetterstrom, M.; Langel, Ü. (1995). Synthesis of n-protected erythro-phenylalanylepoxides. Tetrahedron-Asymmetry, 6 (9), 2245−2247.
1.1.
1995
Valkna, A.; Jureus, A.; Karelson, E.; Zilmer, M.; Bartfai, T.; Langel, U. (1995). Differential regulation of adenylate-cyclase activity in rat ventral and dorsal hippocampus by rat galanin. Neuroscience Letters, 187 (2), 75−78.
1.2.
1995
Öhman, A.; Lycksell, P.O.; Andell, S.; Langel, Ü.; Bartfai, T.; Gräslund, A. (1995). Solvent stabilized solution structures of galanin and galanin analogs, studied by CD spectroscopy. Biochimica et Biophysica Acta, 1236 (2), 259−265.
1.1.
1994
Wennerberg, ABA.; Jackson, M.; Öhman, A.; Gräslund, A.; Langel, Ü.; Rigler, R.; Mantsch, HH. (1994). The structure of the rodent and porcine neuropeptide galanin and antagonists as determined by FT-IR spectroscopy an CD spectroscopy. Canadian Journal of Chemistry, 72 (6), 1495−1499.
1.1.
1994
Bedecs, K.; langel, Ü.; Xu, XJ.; Wiesenfeld-Hallin, Z.; Bartfai, T. (1994). Biological activities of two endogeneously occuring N-terminally extended forms of galanin in the rat spinal cord. European Journal of Pharmacology, 259 (2), 151−156.
1.1.
1994
Rivera Baeza, C.; Kask, K.; Langel, Ü.; Unden, A.; Bartfai, T. (1994). Analogs of galanin(1-16) modified in positions 1-3 as ligands to rat hypothalamic galanin receptors. Acta Chemica Scandinavica, 48 (5), 434−438.
1.1.
1994
Kahl, U.; Langel, Ü.; Bartfai, T.; Grundemar, L. (1994). Functional effects and ligands binding of chimeric galanin-neuropeptide Y (NPY) peptides on NPY and galanin receptor types. British Journal of Pharmacology, 111 (4), 1129−1134.
1.1.
1994
Gregersen, S.; Langel, Ü.; Bartfai, T.; Ahren, B. (1994). Galanin message-assotiated polypeptide (GMAP) does not affect insulin secretion from isolated islets. European Journal of Pharmacology, 259 (1), 79−82.
1.1.
1994
Arvidsson, K.; Langel, Ü.; Ehrenberg, A. (1994). Comparison of the solution structures of the chimeric peptides galanin(1-12)-Ala-neuropeptide Y(25-36) amide and galanin(1-12) Pro-neuropeptide Y(25-36)amide. European Journal of Biochemistry, 222 (2), 573−581.
1.1.
1994
Gregersen, S.; Langel, Ü.; Bartfay, T.; Ahren, B (1994). N-Terminally elongated fragments of galanin(1-16) inhibit insulin secretion from isolated mouse islets. Regulatory Peptides, 53 (1), 31−38.
1.1.
1994
Gregersen, S.; Langel, Ü.; Bartfay, T.; Ahren, B. (1994). Galanin message-associated polypeptide (GMAP) does not affect insulin secretion from isolated islets. European Journal of Pharmacology, 259 (1), 79−82.
1.1.
1993
Crowley, JM.; Robinson, JK.; Langel, Ü.; Bartfai, T. (1993). Galanin receptor antagonists M40 and C7 block galanin induced feeding. Brain Research, 600 (2), 268−272.
1.1.
1993
Zini, S.; Roisin, MP.; Langel, Ü.; Bartfai, T.; Ben-Ari, Y. (1993). Galanin reduces release of excitatory amino acids but not GABA in the rat hippocampus. European Journal of Pharmacology-Molecular Pharmacology Section, 245 (1), 1−7.
1.1.
1993
Bartfai, T.; Hökfelt, T.; Langel, Ü. (1993). Galanin - a neuro-endocrine peptide. Critical Reviews in Neurobiology, 7, 229−274.
1.1.
1993
Gregersen, S.; Lindskog, S.; Land, T.; Langel, U.; Bartfai, T.; Ahren, B. (1993). Blockade of galanin-induced inhibition of insulin secretion from isolated mouse islets by the nonmethionine containing antagonist M35. European Journal of Pharmacology, 232 (1), 35−39.
1.1.
1993
Girotti, P.; Bertorelli, R.; Fisone, G.; Land, T.; Langel, U.; Consolo, S.; Bartfai, T. (1993). N-terminal galanin fragments inhibit the hippocampal release of acetylcholine in vivo. Brain Research, 612, 258−262.
1.1.
1993
Arvidsson, K.; Land, T.; Langel, U.; Bartfai, T.; Ehrenberg, A. (1993). Solution structure by 2D 1H-NMR of a chimeric peptide recognized by galanin and neuropeptide Y receptors. Biochemistry, 32 (30), 7787−7798.
1.1.
1993
Ogren, S.O.; Pramanik, A.; Land, T.; Langel, U. (1993). Differential effects of the putative galanin receptor antagonists M15 and M35 on striatal acetylcholine release. European Journal of Pharmacology, 242 (1), 59−64.
1.1.
1993
Hulting, A.L.; Land, T.; Berthold, N.; Langel, U.; Hokfelt, T.; Bartfai, T. (1993). Galanin receptors from human pituitary-tumors assayed with human galanin as ligand. Brain Research, 625, 173−176.
1.1.
1993
Bartfai, T.; Langel, U.; Bedecs, K.; Andell, S.; Land, T.; Gregersen, S.; Ahren, B.; Girotti, P.; Consolo, S.; Corwin, R.; Crawley, J.; Xu, X.J.; Wiesenfeld-Hallin, Z.; Hokfelt, T. (1993). Galanin-receptor ligand M40 peptide distinguishes between putative galanin-receptor subtypes. Proceedings of the National Academy of Sciences of the United States of America, 90 (23), 11287−11291.
1.1.
1992
Verge, VMK.; Xu, XJ.; Langel, Ü.; Hökfelt, T.; Wiesenfeld-Hallin, Z.; Bartfai, T. (1992). Evidence for endogenous inhibition of autotomy by galanin in the rat after sciatic nerve section: demonstrated by chronic intrathecal infusion a high affinity galanin receptor antagonist. Neuroscience Letters, 149 (2), 193−197.
1.1.
1992
Hökfelt, T.; Aman, K.; Arvidsson, U.; Bedecs, K.; Ceccatelli, S.; Hulting, AL.; Langel, Ü.; Meister, B.; Pieribone, V.; Bartfai, T. (1992). Galanin message-associated peptide(GMAP) - and galanin-like immunoreactivities: overlapping and differential distributions in the rat. Neuroscience Letters, 142 (2), 139−142.
1.1.
1992
Hökfelt, T.; bartfai, T.; Ceccatelli, S.; Cortes, R.; Fisone, G.; hulting, AL.; Langel, Ü.; Meister, B.; Melander, T.; Pieribone, V.; Schalling, M.; Verge, VMK.; Villar, M.; Wiesenfeld-hallin, Z.; Xu, XJ.; Xu, Z. (1992). Central and Sensory galanin, neurons and functional aspects. Biomedical Research, 13, 311−317.
1.1.
1992
Bedecs, K.; Langel, Ü.; Bartfai, T.; Wiesenfeld-Hallin, Z. (1992). Galanin receptors and their second messengers in the lumbar dorsal spinal cord; the effect of GTP and sciatic nerve transection. Acta Physiologica Scandinavica, 144 (3), 213−220.
1.1.
1992
Bartfai, T.; Fisone, G.; Langel, Ü. (1992). Galanin and galanin antagonists: molecular and biochemical perspectives. Trends in Pharmacological Sciences, 13 (8), 312−317.
1.1.
1992
Wiesenfeld-Hallin, Z.; Xu, XJ.; Langel, Ü.; Bedecs, K.; Hökfelt, T.; Bartfai, T. (1992). Galanin mediated control of pain: enhanced role after nerve injury. Proceedings of the National Academy of Sciences of the United States of America, 89 (8), 3334−3337.
1.1.
1992
Ögren, SO.; Hökfelt, T.; Kask, K.; Langel, Ü.; Bartfai, T. (1992). Evidence for a role of the neuropeptide galanin in spatial learning. Neuroscience, 51 (1), 1−5.
1.1.
1992
Lindskog, S.; Ahren, B.; Land, T.; Langel, U.; Bartfai, T. (1992). The novel high-affinity antagonist, galantide, blocks the galanin-mediated inhibition of glucose-induced insulin secretion. European Journal of Pharmacology, 210 (2), 183−188.
1.1.
1992
Langel, U.; Land, T.; Bartfai, T. (1992). Design of chimeric peptide ligands to galanin receptors and substance-P receptors. International Journal of Peptide and Protein Research, 39, 516−522.
1.1.
1992
Laasik, J.; Sillard, R.; Langel, U.; Zilmer, M. (1992). Lipid-protein interactions in neurotropic na-pump regulation. Acta Physiologica Scandinavica, 146, 249−251.
1.1.
1991
Gregersen, S.; Hermansen, K.; Lindskog, S.; Langel, Ü.; Fisone, G.; Bartfai, T.; Ahren, B. (1991). Galanin-induced inhibition of insulin secretion from rat islets: effects of rat and pig galanin and galanin fragments and analogues. European Journal of Pharmacology, 203 (1), 111−114.
1.1.
1991
Sillard, R.; Langel, Ü.; Jörnvall, H. (1991). Isolation and characterization of galanin from sheep brain. Peptides, 12 (4), 855−859.
1.1.
1991
Land, T.; Langel, U.; Bartfai, T. (1991). Hypothalamic degradation of galanin(1–29) and galanin(1–16): identification and characterization of the peptidolytic products. Brain Research, 558 (2), 245−250.
1.1.
1991
Land, T.; Langel, U.; Low, M.; Berthold, M.; Unden, A.; Bartfai, T. (1991). Linear and cyclic N-terminal galanin fragments and analogs as ligands at the hypothalamic galanin receptor. International Journal of Peptide and Protein Research, 38 (3), 262−272.
1.1.
1991
Bartfai, T.; Bedecs, K.; Land, T.; Langel, U.; Bertorelli, R.; Girotti, P.; Consolo, S.; Xu, X.J.; Wiesenfeld-Hallin, Z.; Nilsson, S.; Pieribone, V.A.; Hokfelt, T. (1991). M-15: High-affinity chimeric peptide that blocks the neuronal actions of galanin in the hippocampus, locus coeruleus, and spinal cord. Proceedings of the National Academy of Sciences of the United States of America, 88, 10961−10965.
3.1.
1991
Fisone, G.; Langel, Ü.; Land, T.; Berthold, M.; Bertorelli, R.; Girotti, P.; Consolo, S.; Crowley, JN.; Hökfelt, T.; Bartfai, T. (1991). Galanin receptor ligands in the hippocampus: galanin, N-terminal galanin fragments and analogues. In: Hokfelt, T.; Bartfai, T.; Jacobowitz, D.; Ottoson, D. (_EditorsAbbr). Galanin: A new multifunctional peptide in the neuro-endocrine system (213−220).. New York: Macmillan Press. (Wenner-Gren International Symposium Series).
3.1.
1991
Land, T.; Langel, Ü.; Fisone, G.; Bedecs, K.; Bartfai, T. (1991). Assay for galanin receptor. In: Methods in Neurosciences (225−234).. Academic Press.
3.1.
1991
Rigler, R.; Wennerberg, A.; Cooke, RM.; Elofsson, A.; Nilsson, L.; Vogel, H.; Holley, LH.; Carlquist, M.; Langel, Ü.; Bartfai, T.; Campell, ID. (1991). On the solution structure of galanin. In: Hökfelt, T.; Bartfai, T.; Jacubowitz, D.; Ottoson, D. (_EditorsAbbr). Galanin: A new multifunctional peptide in the neuro-endicrine system (17−25).. London: Macmillan Press.
1.1.
1990
Crawley, J.; Austin, MC.; Fiske, SM.; Martin, B.; Consolo, S.; Berthold, M.; Langel, Ü.; Bartfai, T. (1990). Activity of centrally administered galanin fragments on stimulation of feeding behaviour and on galanin receptor binding in the rat hypothalamus. Journal of Neuroscience, 10 (11), 3695−3700.
1.1.
1990
Zorko, M.; Langel, Ü.; Palumaa, P. (1990). Simultaneous action of quaternary ammonium ligands and alkanesulfonylchlorides on electric eel acetylcholinesterase. Periodicum Biologorum, 4, 385−391.
5.1.
1990
Langel, Ü.; Land, T.; Bartfai, T. (1990). Synthetic galanin analogs with biochemical activity. Peptides: Twenty-First European peptide Symposium; September 2-8, 1990; Platja d´Aro, Spain. _EditorsAbbr Giralt, E.; Andreu, D. 727−728.
1.1.
1989
Fisone, G.; Langel, Ü.; Carlquist, M.; Bergman, T.; Consolo, S.; Hökfelt, T.; Unden, A.; Andell, S.; Bartfai, T. (1989). Galanin receptor and its ligands in the rat hippocampus. European Journal of Biochemistry, 181 (1), 269−276.
1.1.
1989
Sepp, A.; Palumaa, P.; Langel, U.; Jarv, J.; Zorko, M. (1989). Spatial orientation of normal-alkanesulfonyl chlorides in the active-center of cholinesterases. Bioorganic Chemistry, 17 (1), 79−85.
1.2.
1987
Zharkovski, AM.; Langel, Ü.; Chereshka, KS.; Zharkovsaia, T (1987). Significance of the dopamine-blocking and m-choline-blocking components in the antiapomorphine action of neuroleptics. Biulleten eksperimental'noi biologii i meditsiny, 103 (3), 317−319.
1.2.
1987
Eller, M.; Kõiv, A.; Langel, Ü.; Rinken, A.; Tähepõld, L.; Järv, J. (1987). Quinuclidine benzilate can't be used as a ligand in equilibrium binding studies with muscarinic receptor. Neirokhimiya, 6, 605−609.
1.3.
1987
Rinken, A.; Langel, J.; Järv, J. (1987). Solubilisation of muscarinic cholinoreceptor and its complex with QNB. Biochemistry (Moscow), 52, 263−269.
1.1.
1986
Laasberg, T.; Neuman, T.; Langel, Ü. (1986). Acetylcholine receptors in the gastrulating chick embryo. Experientia, 42 (4), 439−440.
1.1.
1986
Langel, Ü.; Sillard, R.; Järv, J.; Godovikov, N.; Kardanov, N.; Trifonova, S (1986). Interaction of n-alkylcholinbenzilates with cholinesterases. Organic Reactivity, 23 (2, 82), 134−143.
1.1.
1986
Sillard, RG.; Langel, UL.; Jarv, JL.; Godovinkov, NN.; Kardanov, NA.; Trifonova, SA. (1986). Dissociation kinetics of antagonists from complex with rat-brain muscarinic receptor. Organic Reactivity, 23 (3), 370−381.
1.1.
1984
Rinken, AA.; Langel, UL.; Jarv, JL. (1984). Solubilization of muscarinic receptor and receptor-quinuclidinyl benzilate complex with digitonin. Biologicheskie Membrany, 1 (4), 341−348.
1.1.
1984
Rinken, AA.; Langel, YL.; Tyakhepyld, LY.; Yarv, YL. (1984). Kinetics of the inactivation of the muscarine cholinoreceptor, solubilized by digitonin. Biochemistry (Moscow), 49 (11), 1533−1537.
1.2.
1984
Käämbre, T. A.; Langel, Ü. L.; Rinken, A. A.; Tähepõld, L. J.; Järv, J. L. (1984). Action of proteases and phospholipase A2 on the membrane-bound muscarinic acetylcholine receptor from rat brain. Neirokhimiya, 3 (2), 107−115.
1.2.
1982
Langel, Ü.; Rinken, A.; Tähepõld, L.; Järv, J. (1982). Kinetics of the muscarinic receptor inactivation. Neirokhimiya, 1 (4), 343−351.
1.1.
1981
Jarv, JL.; Langel, UL. (1981). Substrate acyl fragment effects in butyrylcholinesterase catalyzed reaction. Bioorganicheskaya Khimiya, 7 (2), 217−227.
1.1.
1980
Langel, Ü.; Speek, M.; Järv, J. (1980). Effect of pH on the cholinesterase reaction with substrates. Biochemistry (Moscow), 45 (12), 2138−2139.
1.1.
1979
Jarv, JL.; Langel, UL. (1979). Substrate leaving group effects in the butyrylcholinesterase catalyzed reactions. Bioorganicheskaya Khimiya, 5 (5), 746−756.
1.1.
1978
Jarv, JL.; Speek, MA.; Langel, UL.; Rotanova, TV. (1978). Interaction of alkylboronic acids with cholinesterases. Bioorganicheskaya Khimiya, 4 (10), 1364−1371.
1.1.
1978
Langel, U.; Jarv, J. (1978). Dissociation-constant of butyrylcholinesterase anionic center. Bioorganicheskaya Khimiya, 4 (10), 1352−1357.
1.1.
1978
Langel, U.; Jarv, J. (1978). Influence of ph on butyrylcholinesterase reaction with organophosphorus inhibitors. Biochimica et Biophysica Acta, 526 (2), 450−456.
1.1.
1978
Langel, U.; Jarv, J. (1978). Leaving group effects in butyrylcholinesterase reaction with organophosphorus inhibitors. Biochimica et Biophysica Acta, 525 (1), 122−133.
1.1.
1978
Langel, U.; Jarv, J. (1978). Influence of ph on naphthalene binding to butyrylcholinesterase active-center. Organic Reactivity, 15 (4), 443−449.
1.1.
1976
Järv, J.; Aaviksaar, A.; Godovikov, N.; Langel, Ü.; Past, U. (1976). Cobra venom acetylcholinesterase active site titration. Biochemistry (Moscow), 41 (5), 827−835.
1.3.
1974
Langel, Ü.; Järv, J.; Aaviksaar, A. (1974). Spectrophotometric determination of the concentration of organophosphorus thioesters. Acta et commentationes Universitatis Tartuensis, 332, 172−178.

Industrial property

20.11.2020